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ABSTRACT 
 
Intensive efforts to control malaria in the past two decades have resulted in substantially 
decreased morbidity and mortality in Indonesia, as in malaria endemic countries elsewhere. 
At present, 70% of malaria endemic regions in Indonesia have achieved low transmission 
status. However, stronger measures are needed to accomplish the national target of 
elimination by 2030. Scaling up on active surveillance using highly sensitive diagnostic tests is 
crucial to allow identification of low-density, asymptomatic infections, strengthened by 
effective treatment with artemisinin-based combination therapy (ACT) to reduce cases and 
halt transmission. Resistance to this drug combination, therefore, poses the greatest threat 
for both malaria control and the elimination goal. The aims of this research project are:  
(1) to investigate the distribution of Plasmodium spp. in three rural areas of North 
Sumatera province, Indonesia, to provide information on malaria risk in the province;  
(2) to identify  drug resistance-associated genetic polymorphisms carried by local 
Plasmodium falciparum parasites;  
(3) to evaluate the efficacy of two ACTs, dihydroartemisinin-piperaquine and artemether-
lumefantrine for treatment of uncomplicated falciparum malaria.  
In this study, molecular diagnostics identified four Plasmodium species (P. vivax 33.9%, P. 
knowlesi 32.0%, P. falciparum 24.8%, and P. malariae 9.3%) among 16.5% of participants 
(614/3731). P. falciparum populations were dominated by amodiaquine-resistant parasites, 
indicated by a high proportion of pfcrt-SVMNT and pfmdr1 86Y/184Y haplotypes. This study is 
the first to our knowledge to test for the presence of mutations in the pfk13-propeller domain 
in western Indonesia, and evidence of polymorphisms in pfk13 was found in a small number 
of individuals. A Thr to Ala mutation at codon 474, was observed in six individuals, and the 
C580Y mutation, previously associated with reduced susceptibility to artemisinin in the 
Greater Mekong subregion , was seen in a single asymptomatic individual that was not part of 
the clinical study. Baseline marker carriage was then tested for association with treatment 
outcomes in the treated cohort study. Dihydroartemisinin-piperaquine and artemether-
lumefantrine were both shown to be highly effective for treatment of P. falciparum malaria, 
INKE LUBIS       ABSTRACT 3 
irrespective of the pfk13 genotypes. Nevertheless, recurrent parasitaemia of all four species 
was observed in both groups at day 42, implying lack of sterilising protection from 
lumefantrine and piperaquine. Further studies are warranted to explore the phenotypic 
impact of pfk13 mutant alleles in this region and regular monitoring of drug efficacy against 
all species present is required.  
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1 INTRODUCTION 
 
1.1 Malaria Worldwide 
Malaria, a preventable and treatable condition, remains as the most important 
parasitic disease globally. In 2016, it was still endemic in 91 countries, and placing 3.8 billion 
people at risk. Significant progress has been made due to aggressive malaria control and 
elimination efforts since 2000 resulting in global reduction of 41% in morbidity and 62% in 
mortality. Nevertheless, the World Health Organization estimates there were still 212 million 
cases in 2015 with 429,000 deaths owing to this disease, most of which occurred in Africa. 
Seventy-one percent of all malaria deaths were in children under 5 years of age. Thus malaria 
continues to be viewed as a highly significant disease of a global public health importance.1 
 
1.1.1 Geographical Distribution 
  Malaria is a vector-borne disease relying on particular conditions determined by 
ecological factors including temperature, rainfall and humidity for the survival of the parasites 
and vectors.2 There are six major Plasmodium species infecting human; Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi, Plasmodium 
ovale wallikeri and Plasmodium knowlesi3; transmitted by 70 of 465 known anopheles 
species.4 P. falciparum and P. vivax are the two main causes of human malaria infections5, with 
the former species accounting for the majority of total malaria cases especially in Africa (Figure 
1.1.A).6-8 Falciparum malaria poses a risk of severe complications and contributes to the 
majority of deaths.5 P. vivax has the widest geographical range of all malaria parasite species, 
being found throughout the temperate climate zones (Figure 1.1.B).2, 9-11 However to cause 
infection, this species relies on Duffy antigen to invade host reticulocytes, therefore Duffy-
negative individuals, which are highly frequent in parts of Africa, are protected from P. vivax 
infection.12, 13 P. vivax contributed 4% of total global cases in 2015, but outside Africa the 
proportion is 41% among all malaria infections.1 Its high burden of disease is maintained in 
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part due to dormant liver stage parasite forms known as hypnozoites which can induce clinical 
relapse episodes.14  
 P. malariae and P. ovale spp. are less common malaria species infecting humans.  
These species are more prevalent in the African region, although these species are also 
regularly reported in Southeast Asia and the Western Pacific.15, 16 The development of species-
specific polymerase chain reaction (PCR) has helped to discriminate human malaria species 
and has enabled more understanding of their global distribution and prevalence. 
Furthermore, it has been used to identify the dimorphic forms of the sympatric P. ovale curtisi 
and P. ovale wallikeri.3, 15 Both P. malariae and P. ovale spp. occur in multi-species endemic 
settings with a prevalence of less than 1% in most settings, but it also has been reported to be 
as high as 22% for malariae.16, 17  
  P. knowlesi is a malaria parasite transmitted by Anopheles leucosphyrus from long-
tailed and pig-tailed macaques to humans.18 The natural hosts and vectors of P. knowlesi are 
widespread throughout Southeast Asia (Figure 1.2.).18-20 Epidemiological studies to define the 
distribution extent of this species in human are still limited and mainly from Malaysian Borneo, 
but small numbers of cases has also been confirmed by molecular diagnostic tests in the rest 
of the Southeast Asia region.20-30  
  Small numbers of cases of other Plasmodium parasites infecting humans have also 
been reported either experimentally or naturally by Plasmodium cynomolgi31-34, Plasmodium 
inui35, Plasmodium brasilianum36, Plasmodium simium37, 38, and Plasmodium schwetzi39.
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Figure 1.1.  The spatial distribution of P. falciparum and P. vivax malaria. (A) P. falciparum malaria 
risk categorized as low risk (light red, where P. falciparum parasite rate in 2-10 year 
olds, PfPR2-10 < 5%), intermediate risk (medium red, where PfPR2-10 > 5% to <40%), 
and high risk (dark red, where PfPR2-10 > 40%). The rest of the land area was defined 
as unstable risk (medium grey areas, where P. falciparum annual parasite incidence, 
PfAPI <0.1 per 1,000 p.a.) or no risk (light grey); (B) P. vivax malaria risk defined by P. 
vivax annual parasite incidence, PvAPI data; transmission was defined as stable (red 
areas, where PvAPI > 0.1 per 1,000 people p.a.), unstable (pink areas, where PvAPI < 
0.1 per 1,000 p.a.) or no risk (grey areas). Predicted Duffy negativity layers are overlaid 
on the P. vivax limits of transmission, areas where Duffy negativity prevalence was 
estimated as > 90.% are hatched. Adapted from reference 2, 7. 
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Figure 1.2.  P. knowlesi infections reported in humans and macaques and the limits of natural distribution of two species of macaques and mosquitoe vectors of the 
Anopheles leucosphyrus group. Adapted from reference 40. 
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1.1.2 Changing Epidemiology 
  In the year 2000, a global commitment was made to fight malaria involving increased 
coverage of insecticide-treated nets (ITNs), indoor residual spraying (IRS) and prompt 
treatment of clinical malaria with effective antimalarial drugs, such as artemisinin-based 
combination therapy (ACT).41 Since then dramatic changes in malaria risk have been seen, 
resulting in a remarkable decrease in prevalence and incidence. P. falciparum as the cause of 
vast majority of infections had a decline in parasite rate in 2 to 10 year olds (PfPR2-10) from 
33% in 2000 to 16% in 2015 in the African region. Moreover, 26 of 43 mainland endemic 
countries in the continent reached > 50% reduction in incidence, resulting in a change in 
transmission status to hypoendemic with PfPR2-10 of 1-10%, as reflected in a six-fold increase 
in the number of countries with low risk compared to in 2000.42, 43 A decline in malaria 
transmission also corresponds to a significant decrease in the prevalence of asymptomatic 
infections in infants and children. A study of 760 participants aged between 2 weeks and 99 
years over a 20-year period (1990-2010) in a high transmission area in Senegal showed the 
proportion of asymptomatic infants and children slide-positive for malaria reduced 
dramatically from 70% and 100% in 1990, respectively, to 1% at the end of the study.44 
However, in low endemic areas, asymptomatic submicroscopic infections also have been 
shown to be important through the use of molecular diagnostics.45 
  The true epidemiology of P. vivax is more difficult to determine. First, many of P. vivax 
cases are asymptomatic with low parasite densities which lead to underdiagnosis.9 The 
hypnozoite forms of P. vivax, which delay the release of merozoites into the blood stream to 
establish detectable erythrocytic infection, also activate after different dormant periods. 
Those with a long latency period allows them to survive the temperate weather, and hence 
sustain the transmission.46 This characteristic makes them more difficult to control using the 
same known measures used to control P. falciparum. Furthermore, it is known that low 
frequency Duffy-positive individuals in the majority Duffy-negative African population are 
sufficient to maintain transmission. Interestingly, recent evidence revealed some P. vivax 
infections among Duffy-negative individuals, historically thought to be resistant.47-49 Given a 
modified estimation of only 50% rather than 100% protection by Duffy negativity from 
acquiring P. vivax, the number of population estimated to be at risk of P. vivax increased from 
2,484,800 to 2,868,900.50 
INKE LUBIS       MALARIA IN INDONESIA 31 
  P. malariae and P. ovale spp. have much lower endemicity than the former two 
species, however despite the control measures in the last few years these species are not yet 
eliminated. There is a gap of knowledge on how these parasites maintain circulation.15 P. 
malariae causes chronic infection that can last for years and the slower life cycle at 72-hour 
rate gives the advantage to avoid drug pressure from antimalarials with shorter half-lives. In 
vivo studies have shown P. malariae parasites survived the 3-day course treatment after being 
exposed with the current recommended ACT.51, 52 P. ovale spp., on the other hand, have the 
advantage of having the dormant stage hypnozoites although there is a lack of evidence on 
the dormancy periods of both species before relapses occur.53 Similar to P. vivax, this unique 
characteristic plays a role in sustaining transmission, as well as hiding the true burden of the 
disease.15, 16  
  In the light of elimination efforts in Southeast Asia, molecular assays have increasingly 
been used to identify low-level infections in surveillance studies. In this region, successful 
malaria control has dramatically reduced both P. falciparum and P. vivax cases.54, 55 The 
numbers of P. malariae cases were increasingly detected by microscopy in Malaysian Borneo, 
and initially thought to be the common malaria infection replacing the former two.18 
Nevertheless, species-specific PCR assay confirmed the presence of P. knowlesi infections 
among these malariae cases including cases retrieved from 1996, implying that P. knowlesi in 
human is not a “new” emerging disease.56, 57 Increased human risk to the surviving, more 
efficient vectors following a combination of deforestation and change in land use might have 
resulted in the apparent rise of confirmed human cases.58, 59 As neighbouring countries are 
now moving towards elimination phase with increased use of molecular tests, a similar pattern 
with a significant proportion of P. knowlesi cases among malaria infected populations has been 
observed.22, 28-30  
 
1.2 Life Cycle of Plasmodium spp. 
 Human Plasmodium spp. share a complex life cycle involving asexual and sexual 
developmental stages in their natural hosts: female Anopheles mosquito vector and human 
host, with macaque hosts limited to P. knowlesi. The transmission cycle among all Plasmodium 
spp. is similar, except the hypnozoite form that is specific in P. vivax and P. ovale spp. It starts 
when the female mosquitoes transmit parasites by inoculating sporozoites from their salivary 
glands into the human bloodstream. Motile sporozoites travel to the liver and invade 
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hepatocytes where a single schizont can produce 10,000 to 30,000 merozoites. This stage is 
referred to as the pre-erythrocytic stage. After about a week, the hepatic schizonts spp. 
rupture and merozoites infect the erythrocytes. This asexual cycle in the erythrocytes differs 
among malaria species. The cycle is 48 hours for P. falciparum, P. vivax and P. ovale spp., 72 
hours for P. malariae, and 24 hours for P. knowlesi, respectively. When infected erythrocytes 
rupture, the release of merozoites results in repeated invasion of other erythrocytes.5, 60 This 
phase is responsible for the clinical manifestations of malaria. Erythrocytes infected with P. 
falciparum have the special ability to sequester by adhesion to the endothelium causing 
microvasculature flow disruption, which often manifests as cerebral malaria, but also can 
cause problems in other organs especially the spleen, liver, kidney and placenta.61-63 Some 
merozoites, following erythrocyte invasion, develop into sexual forms called gametocytes that 
can be transmitted back into the mosquito and continue their life cycle. In the mosquito gut, 
these gametocytes release male and female gametes that undergo fertilization and form a 
zygote. An ookinete later develops from the transient zygote, and then traverses the gut wall 
to become an oocyst. The oocyst ruptures and produces sporozoites which migrate to the 
salivary glands and are inoculated into potential vertebrate hosts during subsequent blood-
feeding. This entire cycle from the inoculation of sporozoites to formation of new sporozoites 
takes a minimum of one month (Figure 1.3.).5, 60 For P. vivax and P. ovale spp., the latent 
periods of the hypnozoites vary. P. vivax relapses depend on the geographical origin, in tropical 
areas it may relapse within 3-4 weeks, but may last longer up to 8-10 months in parasite strains 
adapted to temperate weather.5, 46 
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Figure 1.3.  Life cycle of P. falciparum. Adapted from to reference 5. 
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1.3 Clinical Features 
 The first symptoms of malaria are nonspecific and characterized by headache, fatigue, 
abdominal discomfort, and muscle and joint aches, followed by fever, chills, perspiration, 
anorexia, vomiting and worsening malaise. These features often lead to overdiagnosis of 
malaria in developing countries, where diagnosis is frequently based only on clinical 
judgement with limited resources for parasitological testing.64, 65 In children, conversely, these 
manifestations of uncomplicated malaria can be misinterpreted and attributed to other 
prevalent infections like pneumonia, gastroenteritis, and also sepsis.66 Anaemia is also a 
common manifestation particularly in infants with P. vivax and in children with P. knowlesi 
infection.67-69  
 Severe malaria is not exclusively a disease of children, but also occurs in non-immune 
people across all age groups.70 In low unstable transmission areas in Asia, severe malaria 
develops in all age groups due to lack of protective immunity. Features such as 
hyperparasitaemia, jaundice and renal insufficiency were the most common manifestations 
associated with increasing age.71 In Tanzanian children, a higher density of parasites was found 
in severe cases but was not always linked to severe malaria. They are at the highest risk of 
developing severe malaria in the first 6 months of age and most severe cases present with 
respiratory distress, convulsion or severe anemia.72 Coma and acidosis present equally in both 
older and younger ages, and are predictors for mortality.71  
 Although all  Plasmodium infection other than P. falciparum were thought to be benign, 
some studies have revealed that severe forms of malaria exhibited as cerebral malaria, acute 
respiratory distress syndrome (ARDS), liver dysfunction and renal failure occurred in P. vivax 
cases and included some fatal cases.73-75 More recently, some mortality has also been 
reported in P. knowlesi cases76, with severe cases associated with hyperparasitaemia, 
jaundice, respiratory distress, hypotension and acute kidney injury similar to those features in 
severe falciparum malaria. However, different to severe vivax and falciparum, severe and 
complicated knowlesi is more likely to present in adults. The mechanisms of these parasites 
to cause severe disease are still not well understood. However, the previous reputation of 
both P. vivax and P. knowlesi to cause only uncomplicated manifestations are now dismissed, 
as they have shown their ability to develop to severe diseases.77, 78  
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1.3.1 Asymptomatic and submicroscopic infections 
 In high transmission areas, high and repeated exposure to parasites have an impact on 
the acquisition of immunity resulting in a high proportion of asymptomatic infections 
particularly in older children and adults.79 With the shift of intensity due to effective malaria 
control in many countries, the prevalence of patent parasitaemia has decreased. Molecular 
techniques have been increasingly used to detect parasites and revealed a high burden of 
submicroscopic infections in low-endemic settings.45, 80 The extent of these low-density 
infections still needs to be investigated, but they have been associated with anaemia, and 
premature birth and low birth weight in pregnant women and infants.81-84 These reservoirs, 
more importantly, have shown to be infectious and contribute to sustaining  transmission  
particularly  in low and very  low  transmission  settings.80, 85 
 
1.4 Plasmodium spp. endemicity in Indonesia 
  The focus of this research is P. falciparum, therefore from this section onwards 
discussion will be extensively for this species. Indonesia is an archipelago that lies at the 
southeastern tip of Asia between West Malaysia and Papua New Guinea. It has 17,504 islands 
with a total land area of 1.9 million km2.86 It comprises 34 provinces with 416 
regencies/districts and 98 cities across the country.87 The Wallace Line, named after its 
discoverer, straddles between Kalimantan (Indonesian Borneo) and Sulawasi separating the 
western part of Indonesia from the eastern part, which have distinct biogeographical 
features.88   
  The climate in Indonesia is equatorial, which is typically characterised by high 
temperature and relatively high humidity, with heavy rainfall from October to March. This 
climate favours survival of Anopheles spp. mosquitoes and allows malaria parasites to develop 
in the mosquito more rapidly.89, 90 There are 20 anopheline species documented as malaria 
vectors in Indonesia with overlapping distribution in all the main islands (Figure 1.4.). 
Anopheles balabacensis, A. flavirostris, A. nigerrimus, A. subpictus and A. sundaicus are the 
vectors found circulating in both western and eastern Indonesia.91 
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Figure 1.4.  Map of the distribution of primary Anopheles malaria vectors in Indonesia. Adapted from reference 91.  
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 In Southeast Asia, Indonesia contributed 9% of all malaria cases, and has the second 
highest burden of disease after India.92 WHO estimated that 27% of the 257,563,815 
Indonesian population live in malaria endemic areas.1 This proportion is much lower than the 
estimation made by the national malaria control programmes that 85% of the population are 
at any risk to acquire malaria. This estimation, however, was performed without proper 
stratification and therefore potentially overestimated the proportion to be at risk.92 There are 
difficulties in estimating the real burden of malaria in Indonesia due to changes in diagnostic 
testing and reporting that have occurred over time. In 2015, the country estimated 1.3 million 
malaria cases, a decline from 4 million cases estimated in 2000.1, 93 The scale up of community 
coverage for malaria diagnosis had contributed to the increased trends of cases and deaths 
until 2010, while the decline of malaria cases in the following years was a result of the 
intensified interventions (Figure 1.5.).92  
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Figure 1.5.  Annual malaria incidence in Indonesia, 2000-2010. Based on data from reference 1. 
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 All species of Plasmodium have been documented in Indonesia, including small 
numbers of human P. knowlesi cases in Kalimantan and Sumatera islands.21, 86 P. falciparum is 
slightly more prevalent than P. vivax with proportions of each 55% and 44%, respectively. 
However, in most regions except Papua, P. vivax is the predominant species. P. malariae and 
P. ovale spp. are rarely documented, and almost all cases were recorded in eastern 
Indonesia.86, 92, 94-96  
 Most of the endemic regions in the country are stable transmission zones with low 
transmission risk.1 However, in eastern Indonesia the malaria transmission is more 
concentrated than the rest of the country, and is thus the location of most malaria surveys.86 
The total areas at risk for P. falciparum (87.4% vs 90.5%) and P. vivax (87.6% vs 93.3%) are 
similar between western and eastern Indonesia (Figure 1.6.).88, 97 However, the prevalence of 
infection varies.94, 98-110 The mean prevalence of P. falciparum was higher in eastern Indonesia 
at 8.14% compared to 3.06% in the western region.88 And the mean P. vivax parasite rate in 
1-99 year olds (PvPR1-99) in eastern parts was at 5.6% compared to 1.5% in the western.97 
Nevertheless, the highly density of populations in western Indonesia attributes more people 
to be at risk of the disease (Figure 1.7.).88  
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Figure 1.6.  The risk map of P. falciparum (A) and P. vivax (B) malaria in Indonesia. Adapted from 
reference 88, 97. 
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Figure 1.7.  Population at risk for P. falciparum malaria infection in west and east Indonesia (based 
on data from reference 88). 
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1.5 Malaria elimination and control strategies 
1.5.1 Malaria surveillance system in Indonesia 
 Health care services in Indonesia comprise primary health centres, public hospitals, and 
private sector healthcare facilities. The malaria cases reporting system relies almost entirely 
on passive case detection. Primary health centres are located at sub-district level, with support 
from health posts (a facility run by a nurse) and village delivery posts (a facility run by a 
midwife) to increase community coverage. At primary health centres, subjects with suspected 
malaria infection are examined by microscopy or rapid diagnostic tests (RDTs) for confirmed 
diagnosis. The primary health centres generate monthly malaria reports to be sent to the 
district malaria control officer. The district health office then compiles the data and sends the 
report to the provincial health department and to the Sub-Directorate of Malaria Control at 
the Ministry of Health. Additional malaria data are also collected from laboratories in 
hospitals.86, 92 
 
1.5.2 Elimination and control programmes 
 Malaria control programmes in Indonesia have operated since 1945, however the shift 
to an elimination plan was not started until 2009. The national malaria control programmes 
targets malaria elimination across the country by 2030, and outlined the goal into 4 milestones 
(Figure 1.8.).86, 92 Hay et al developed a recommendation for malaria control strategies to 
guide countries to interrupt malaria transmission and to help transition from malaria control 
to elimination (Figure 1.9.).111 In Indonesia where the level of malaria transmission varies, 
interventions have to be adapted to the local contexts.88 The government’s plans on 
elimination strategies includes the efforts to equip all primary health centres with the capacity 
for malaria diagnosis and treatment by 2010, implementation of active and passive case 
detections with periodic mass surveys, case management with effective drugs, vector control, 
and improvement in surveillance system.86  
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Figure 1.8. The map of Indonesian provincial border with the elimination objectives. Adapted from reference 88. 
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Figure 1.9. Classification for malaria endemicity and the recommended actions.  Adapted from reference 111. 
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  To intensify surveillance for malaria, passive case finding has been strengthened with 
reactive case detection, which is the screening of household members and neighbours within 
certain radius of index cases detected during passive case detection. This strategy is promoted 
with the aim to detect high-risk individuals with asymptomatic infection which could further 
transmit parasites.112 However, studies suggest the magnitude of effort involved in this 
approach is not justified due to its laborious workload, and often yielding only few cases. One 
study suggested targeting hisk risk members of the community (e.g. adult, male, high forest 
exposure) is more efficient than screening all villagers.28 Furthermore, asymptomatic cases 
with positive microscopy results are predominantly in high transmission areas. While in in low 
endemic settings there can be high proportions of subpatent infections, which are undetected 
by microscopy or RDT.80 Therefore, the reactive case detection strategy seems to be 
ineffective to identify parasites reservoirs, unless performed with higher sensitivity tools.  
 A different approach has also been considered to accelerate elimination progress by 
targeting asymptomatic parasite carriers through the implementation of mass drug 
administration (MDA). This strategy depends on several factors like number of rounds, timing, 
and frequency of treatment.113 Studies on MDA are currently being investigated in some 
countries in the Greater Mekong sub-region (GMS), where malaria transmission is low but 
multi-drug resistance P. falciparum parasites are threatening the sustainability of malaria 
control. One study in Zambia performed two rounds of MDA with dihydroartemisinin-
piperaquine (DP) compared to no mass treatment in low and high transmission areas. All 
individuals received standard care when suspected with malaria. The endpoint was parasite 
prevalence after 5 months of follow-up. This study highlighted a large decrease of parasite 
prevalence among MDA and control groups in both low and high transmission areas. The 
authors concluded the dramatic reduction in control group might be a result of high vector 
control coverage, strong surveillance, community diagnosis, and reactive case detection. 
Nevertheless, the long-term effect of this intervention could still not be explained.114 Based 
on different ongoing studies on MDA, a mathematical model predicted a dramatic decrease 
in malaria prevalence after MDA but to be followed by a rebound to pre-intervention status 
in the long-term, if elimination is not being established.115 Until further evidence is available, 
MDA is not the priority for malaria elimination strategies, and vector control supported by 
effective case management, is still the most effective form for malaria control sustainability. 
 Vector control is the mainstay of dramatic reduction in malaria burden in the last two 
decades. Increasing use of ITNs has averted 450 million cases in Africa, and is considered as 
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the most important intervention to control malaria.42 However, this intervention seems to be 
less effective in the GMS where vectors prefer outdoor and early evening biting.116 Therefore, 
ITNs give only limited protection against malaria in this area and are not sufficient to interrupt 
transmission.117 
 To effectively reduce malaria burden, treatment must be with effective drugs. The 
next section focuses on previous and current antimalarials and the development of resistance 
to antimalarials. 
 
1.6 Malaria chemotherapy 
 Despite the considerable progress on malaria control in the past two decades, 
emerging resistance to the only current effective antimalarial ACT poses the greatest threat 
to achieve elimination. P. falciparum has a long history of developing resistance to previous 
antimalarials from chloroquine (CQ), mefloquine (MQ), quinine (QN), amodiaquine (AQ), 
sulfadoxine-pyrimethamine (SP) and recently artemisinin derivates and piperaquine (Figure 
1.10.).64, 118. In the past, resistance emerged in one area or sporadically at various times before 
it spread across countries and continents.119 The failure to contain the spread of parasites’ 
resistance to the previous mainstays of treatment, CQ and SP, resulted in the deaths of 
millions of children, particularly in Africa.120 Therefore, the decline in the efficacy of ACT is 
extremely worrisome. Although there are several new compounds in the antimalarial pipeline, 
the development and licensing of new medicines is very complicated, leading to delays before 
new drugs become available in the market. New chemotherapy should be superior if not 
similar to current treatment against blood stages confirmed by rapid clinical improvement, 
only requires single exposure, provides radical cure for hypnozoites stages of P. vivax and P. 
ovale spp., and blocks the transmission cycle. This ideal new medicine should meet the 
minimal acceptable characteristics of the criteria mentioned above, known as Single Exposure 
Radical Cure and Prophylaxis (SERCaP), and in addition, it should be safe, not contraindicated 
for pregnant or G6PD-deficient patients, convenient and cost-effective. Nevertheless, in areas 
where current treatment already show less efficacy, the priority will be different and is to find 
a drug with activity against resistant strains.121, 122  
 In the absence of effective vaccines and with new drugs not yet licensed, stewardship 
of ACT is critical to prevent current treatment from failing.121 Monitoring and evaluating the 
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current regimen is important to detect early signs of resistance, to identify the spread of 
resistant parasites and to optimize treatment strategies. Here we will review the therapeutic 
efficacies of previous and current antimalarials and their development to resistance but 
concentrating on antimalarial used in Indonesia.
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Figure 1.10. Timeline of several antimalarials development. Adapted from reference 123. 
INKE LUBIS       MALARIA IN INDONESIA 49 
1.6.1 Quinine  
 QN was the first medicine used to treat malaria. It was derived from the bark of 
Cinchona trees, found in high altitudes of South America in the early 17th century.124 It was 
widely used worldwide to treat intermittent fever before the development of synthetic CQ in 
the 1940s.123 Quinine alkaloid acts against blood stages125, but has no antipyretic effect.126  
Despite its early discovery, the active components; QN and cinchonine, were only isolated 
nearly 200 years later by French chemists, Joseph Caventou and Pierre Pelletier.123 During 
colonialism era, the Dutch colony brought Cinchona seeds to Indonesia and established large 
Cinchona plantations in Java at the end of 19th century, which subsequently made Java the 
world’s biggest producer of QN (providing 97% of world’s supply).127 
 In Indonesia, QN is recommended in the national guidelines as the rescue treatment 
for uncomplicated falciparum and vivax malaria and as an alternative treatment for severe 
malaria. For uncomplicated malaria, oral QN is given with additional doxycycline or 
tetracycline for 7 days.128, 129 In vivo studies in North Sumatera between 2006 and 2009 
showed that either combination was very effective for uncomplicated malaria, although a high 
proportion of subjects reported adverse events such as tinnitus.130-132 Treatment with QN in 
combination with clindamycin130, 133, 134 or azythromycin131, 134-136 was similarly efficacious. In 
some other parts of the world, QN is still mainly given for severe malaria especially when 
artemisinin intravenous is not available128 However, very large multinational studies in 
Southeast Asia and Africa have both demonstrated significantly lower mortality among 
children and adults when parenteral artesunatei is given compared to parenteral  quinine. 
Therefore, intravenous artesunate is the first choice of treatment for severe falciparum 
malaria (Figure 1.11).137-139 
 
 
 
                                                             
i  Treatment of severe malaria was given as follows: Artesunate 2.4 mg/kg by intravenous or 
intramuscular injection, followed by 2.4 mg/kg at 12 h and 24 h; continue injection once daily if 
necessary. Quinine dihydrochloride 20 mg salt per kg infused during 4 h, followed by maintenance of 10 
mg salt per kg infused during 2-8 h every 8 h (can also be gven as intramuscular injection when diluted 
to 60-100 mg/mL). Artemether 3.2 mg/kg by immediate intramuscular injection, followed by 1.6 mg/kg 
daily can also be given, when artesunate is not available. 
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Figure 1.11.  Meta-analysis of randomised controlled trials of parenteral artesunate versus parenteral quinine in severe malaria in Asian and African countries. Adapted 
from reference 5. 
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1.6.2 Chloroquine  
  As the Japanese took over Java during World War II, the supply of QN to the rest of 
the world was halted. The urgent demands of effective drugs for malaria had forced American, 
British and Australian scientists to collaborate to develop new synthetic antimalarials. An 
effective but very toxic compound “resochin” discovered few years earlier by Hans Andersag, 
a German scientist, was one of thousands of compounds tested by this group of scientists. 
Using additional data from French Vichy physicians working on a resochin derivate named 
sontochin, a ‘re-discovery’ of a safer and more effective resochin (or later called chloroquine) 
was made in 1944. CQ became the most widely used antimalarial worldwide, and is still 
considered the most successful synthetic antimalarial to date.123, 124, 140 It was cheap, easy to 
administer, better tolerated and effective against all Plasmodium species.125 However, in the 
1960s the first resistance cases emerged in South America and the Thai-Cambodia border. By 
1977, CQ resistance arrived in Africa and in 1989 it already spread widely in South America, 
Asia and Africa with exceptions in some countries (Figure 1.12.).119, 141 
 The first report of P. falciparum-resistance to CQ in Indonesia was documented in East 
Kalimantan in 1974, followed by other reports from various sites in west and east Indonesia. 
As expected, the overall proportion of resistance quickly increased from 25% prior to 1985 to 
54% after 1985, showing a rapid spread of the resistant-parasite (Figure 1.13.).86, 142 In the 
2000s, all studies revealed high level risk of treatment failureii using CQ ranging from 30% to 
95%64, 143-150, consequently the use of CQ as first-line treatment was ended in 2004.146  
 
 
 
                                                             
ii Treatment failure is defined as an inability to clear malarial parasitaemia or resolve clinical symptoms 
despite administration of an antimalarial medicine. Treatment failure is not, however, always due to 
drug resistance, and many factors can contribute, mainly by reducing drug concentrations. These 
factors include incorrect dosage, poor patient compliance in respect of either dose or duration of 
treatment, poor drug quality and drug interactions.  
INKE LUBIS                   MALARIA IN INDONESIA 52 
 
Figure 1.12. The spread of chloroquine resistance. Adapted from reference 141. 
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Figure 1.13. Distribution of chloroquine resistance in Indonesia, 1978 – 2003. Adapted from reference 142. 
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 Today, CQ is widely used as the therapy of choice for P. vivax infection, usually in a 
combination with primaquine. It is still the first-line option after over 60 years where vivax is 
endemic, with exception in some countries in Africa (Algeria, Ethiopia, Mayotte, Somalia, and 
Sudan) and few others in Southeast Asia (Indonesia and Cambodia), and Oceania (Papua New 
Guinea, Solomon island, and Vanuatu).1 Due to the difficulties to define treatment failure in 
vivax complicated by its hypnozoite inducing relapse, diagnosis of CQ resistance is defined by 
recurrent parasitaemia within 28 days after therapy with levels of CQ and desethyl-
chloroquine above 100 ng/mL.14 Early evidence of vivax resistance to CQ appeared in Papua 
New Guinea and eastern Indonesia, with sporadic cases occurred across Malaysia, Myanmar, 
and Vietnam. Eastern Indonesia has the highest level of resistance with treatment failures > 
50%, with lower rates of failure towards western Indonesia.105, 144, 151-154 However, a later study 
from South Sumatera in western Indonesia revealed 43% of failures among patients treated 
with CQ.147 The national policy was subsequently changed in 2007 to replace CQ with ACT for 
the treatment of vivax malaria.128 
 There are few data available on CQ and other antimalarials sensitivity to P. malariae, 
P. ovale spp. and P. knowlesi. Hereafter, there is an assumption of full sensitivity of 
antimalarials to these parasites.95, 139, 154 Only 1 study reported resistance of P. malariae to CQ.  
In South Sumatera, 3 out of 28 individuals with P. malariae had treatment failure with 
chloroquine. Two had persistent parasites until day 8 and one had recurrent parasitaemia at 
day 28, all were showing CQ and desethyl-chloroquine levels > 100 ng/mL at the day of 
failure.155 Ex vivo susceptibility studies against P. knowlesi H strain and P. knowlesi field isolates 
revealed moderate efficacy to CQ with 7-fold higher of IC50 in the H strain over the IC50 in field 
isolates (IC50 values for H strain vs. clinical isolates, 3.2 nM [2.2 to 4.7] vs. 23 nM [+ 4.8]; 
R2=0.86). Surprisingly, in contrast MQ seemed to be ineffective for the laboratory strain and 
field isolates (IC50 values for H strain vs. clinical isolates, 25 nM [7.4 to 81] vs. 26 nM [+ 3.1]; 
R2=0.40).156 Two field studies evaluating the efficacy of CQ in vivo in treating P. knowlesi 
patients in Malaysia demonstrated high efficacy with no treatment failures at the end of 
follow-up (day 28 in Daneshvar study, and day 42 in Grigg study).157, 158 Although the latter 
study showed inferiority of CQ when compared to artesunate-mefloquine (AS-MQ) regarding 
parasite and  fever clearance (P <0.0001 and P <0.034).158 
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1.6.3 Sulfadoxine-Pyrimethamine 
SP was used by many countries as the second-line treatment for P. falciparum 
infection. The two components act synergistically against folate synthesis, inhibiting 
dihydropteroate synthetase and dihydrofolate reductase.159 However, resistance to SP quickly 
emerged, and regional and intercontinental spread followed (Figure 1.14).160, 161 
Observation at day 28 following treatment with SP in Indonesia showed evidence of 
resistance in P. falciparum rose from 0% to 83% in 1998, among the highest seen in 
Indonesia.105, 144, 150, 162, 163 When CQ was added as a combination, the proportion of treatment 
failures decreased146, 149, although in some other studies it remained ubiquitous.144, 150, 154, 164 
SP is now mainly used as intermittent preventive treatment during pregnancy (IPTp), 
intermittent preventive treatment in infants (IPTi), and in combination with artesunate (AS-
SP) for seasonal malaria chemoprevention particularly in sub-Sahel region of Africa139, with 
only a few countries deploying antifolates in AS-SP form as first-line treatment for 
uncomplicated malaria.1  
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Figure 1.14. Spread of sulfadoxine-pyrimethamine resistance. Adapted from reference 165. 
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1.6.4 Artemisinin-based Combination Therapy 
 As the efficacy of QN declined due to the extensive use worldwide, the American army 
research institute (Walter Reed) tried to develop new compounds to protect their soldiers 
from malaria during the war between the United States and Vietnam. The Vietnamese, on the 
other hand, turned to China which then initiated the research programmes that resulted in 
the discovery of artemisinin.166 Artemisinin or qinghaosu, extracted from the leaves of sweet 
wormwood (Artemisia annua), was discovered in the early 1970s. Its derivatives; artesunate, 
artemether and dihydroartermisinin (DHA), were also later developed. DHA is the active 
metabolite, has a greater antimalarial activity than the parent drug.167 Artemisinin acts against 
all Plasmodium species, is effective against asexual and sexual stages, and thus has 
transmission blocking advantage. However, liver stages are not affected. This drug is also very 
potent, it reduces parasite numbers 104 fold within the 48 hours erythrocytic cycle.168, 169  
 The artemisinin component is combined with a partner drug with a longer half-life to 
ensure the clearance of the remaining parasites after rapid reduction by artemisinin, and to 
prevent the development of resistance.64, 167, 170 ACTs are the current recommended treatment 
by WHO for uncomplicated falciparum malaria for all malaria-endemic countries.64 It is highly 
effective with few adverse effects.5 Currently, there are five combinations recommended by 
WHO: artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), dihydroartemisinin-
piperaquine (DP), AS-MQ and AS-SP, given over a period of 3 days (See Box 1).139 
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BOX 1 – TREATMENT RECOMMENDATIONS FOR ACTs 
Body Weight (kg) Dose (mg) 
Artemether-lumefantrine (AL) 
5 to < 15 20 artemether + 120 lumefantrine 
15 to < 25 40 artemether + 240 lumefantrine 
20 to < 35 60 artemether + 360 lumefantrine 
> 35 80 artemether + 480 lumefantrine 
Artesunate-amodiaquine (ASAQ) 
4.5 to < 9 25 artesunate + 67.5 amodiaquine 
9 to < 18 50 artesunate + 135 amodiaquine 
18 to < 36 100 artesunate + 270 amodiaquine 
> 36 200 artesunate + 540 amodiaquine 
Artesunate-mefloquine (AS-MQ) 
5 to < 9 25 artesunate + 55 mefloquine 
9 to < 18 50 artesunate + 110 mefloquine 
18 to 30 100 artesunate + 220 mefloquine 
> 30 200 artesunate + 440 mefloquine 
Artesunate-sulfadoxine-pyrimethamine (AS-SP) 
5 to < 10 25 artesunate + 250 sulfadoxine/12.5 pyrimethamine 
10 to < 25 50 artesunate + 500 sulfadoxine/25 pyrimethamine 
25 to < 50 100 artesunate + 1000 sulfadoxine/50 pyrimethamine 
> 50 200 artesunate + 1500 sulfadoxine/75 pyrimethamine 
Dihydroartemisinin-piperaquine (DP) 
5 to <8 20 dihidroartemisinin + 160 piperaquine 
8 to < 11 30 dihidroartemisinin + 240 piperaquine 
11 to < 17 40 dihidroartemisinin + 320 piperaquine 
17 to < 25 60 dihidroartemisinin + 480 piperaquine 
25 to < 36 80 dihidroartemisinin + 640 piperaquine 
36 to < 60 120 dihidroartemisinin + 960 piperaquine 
60 to < 80 160 dihidroartemisinin + 1280 piperaquine 
> 80 200 dihidroartemisinin + 1600 piperaquine 
All treatment are given once daily for 3 days, except for artemether-lumefantrine twice daily. 
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 ACT was adopted as first-line treatment for uncomplicated P. falciparum infection, 
replacing chloroquine, in 2004. ASAQ was initially recommended for treating uncomplicated 
falciparum malaria across Indonesia.86 But in 2007, two ACTsiii were recommended by the 
Ministry of Health of Indonesia, ASAQ for western Indonesia and DP for eastern Indonesia. 
The change in national policy was also expanded to vivax malaria with ASAQ was being 
recommended to treat this infection replacing CQ.128  However, in 2012 DP became the first-
line therapy throughout the country. Besides the two combinations, AL is also licensed, and is 
available in the private sector. 
  There is regular evaluation and monitoring of ACT efficacy although it is not uniform 
between endemic areas. One of the earliest studies was conducted in Central Java in 2003 
prior to the deployment of ACT. Forty-three patients with uncomplicated P. falciparum 
infection were treated with 3 days of ASAQ, and PCR-corrected adequate clinical and 
parasitological response (ACPR)iv at day 28 revealed low success rate at 80.9%.171, 172 Follow 
up studies revealed high efficacy above 98% in different areas173-175, but two further studies in 
Papua and Sumatera showed treatment failure above 10%.176-178 All but one study 
demonstrated rapid parasite clearance times indicating a good response to artemisinin and 
treatment failure is likely to be due to AQ.179 Treatment failure with AQ might be the result of 
inadequate drug concentration level and cross-resistance with CQ among other factors.179-181 
AQ (a synthetic 4-aminoquinoline) is closely related to chloroquine, but had not previously 
been used as monotherapy in Indonesia.182 However, the widespread clinical resistance to CQ 
has been associated with reduced susceptibility to amodiaquine.183, 184 Today, this 
combination is mainly used in African countries and China.1 
 AL is the first fixed-dose treatment available and the most procured ACT for public 
and private sectors globally8, with 56 countries using it as first- or second-line treatment.185 
Previous studies in Africa and Southeast Asia (including Indonesia) showed excellent efficacy 
> 90% with AL178, 186-194, except in 3 studies from Cambodia and Thailand.195 One study from 
Cambodia later confirmed as having artemisinin resistance, and the treatment failures from 
                                                             
iii Indonesian Ministry of Health recommendation for uncomplicated falciparum malaria: 
Doses for Artesunate-Amodiaquine + Primaquine (3 days + 1 day) 
Amodiaquine base (10 mg/kg/day), artesunate (4 mg/kg/day), primaquine (0.75 mg/kg) 
Doses for Dihydroartemisinin-Piperaquine + Primaquine (3 days + 1 day) 
Dihydroartemisinin (2-4 mg/kg/day), piperaquine (16-32 mg/kg), primaquine (0.75 mg/kg) 
 
iv WHO classification for treatment outcomes in in vivo study, see Methods section 3.15. 
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the two studies in Thailand were associated with slow parasite clearance.195 In Kenya, residual 
submicroscopic parasitaemia at day 3 was detected in 31.8% patients despite high cure rates 
and rapid parasite clearance times after treatment with AL or DP. Day 3 positivity was 
associated with higher risk of reappearance of asexual parasite on day 28 or 42 detected by 
microscopy.196 Moreover, pooled analysis of individuals treated with AL showed an increased 
risk of treatment failure in very young age, high parasitaemia, and low transmission intensity 
area with emerging resistance.195 In Uganda, remarkable changes in parasite polymorphisms 
were seen after increasing use of AL. Within 4 years, there was a reverse trend in the parasites 
populations from high-level CQ-resistant and lumefantrine-sensitive parasites to CQ-sensitive 
parasites with decreased sensitivity to lumefantrine.197 
 MQ monotherapy has a long history of utility to treat malaria in the GMS. However, 
resistance was quickly developed and led to the addition of artesunate to its 3-day regimen.198, 
199 Sadly, resistance to this AS-MQ combination was also soon developed with the first 
evidence reported from western Cambodia185, 200, and subsequently from Thailand185, 201 and 
Myanmar185, 202. Despite the significant failures, the declining efficacy was full responsibility of 
mefloquine resistance and not attributed by the artemisinin component.198  
Dihydroartemisinin-piperaquine (DP) later replaced AS-MQ as the first line treatment in 2008 
for Cambodia and in 2015 for Thailand. Interestingly, repeat studies on AS-MQ in Cambodia 
between 2014 and 2017 revealed 100% efficacy suggesting that AS-MQ has regained its 
efficacy after removal of MQ pressure to parasites.203 
 DP is considered by many to be the best ACT due to the long serum half-life of the 
partner drug, resulting in post-treatment prophylaxis.186 Various studies in Africa and Asia 
have shown superior efficacy of DP compared to the other most used ACTs; ASAQ and AL.179, 
186, 187, 190, 204-208 One study of DP from west Indonesia showed 100% ACPR209, with a small 
proportion of treatment failures (0% to 4.8%) in studies from east Indonesia.176, 193, 210-213 A 
major determinant of treatment failures was plasma concentration of piperaquine below 30 
ng/ml on day 7.211 Prior to 2010, only one study from Rwanda (to our knowledge) reported 
treatment failure exceeding 10% after treatment with DP which necessitated a changes in 
antimalarial policy according to the WHO guidelines.185, 214 In Cambodia, the efficacy of DP has 
declined rapidly. Prior to policy changes to DP in 2008, the efficacy of DP in Pursat was 98.2% 
in 2005215 before falling to 89.3%216 in 2010 and to 54%118 in 2013. Recrudescent parasites 
showed high piperaquine level in the plasma at day 7 and increased piperaquine IC50, implying 
sufficient exposure of partner drug to the parasites and also suggesting that there is an 
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emergence of resistance to artemisinin and also to piperaquine.118 All studies of DP efficacy in 
Indonesia demonstrated excellent efficacy.176, 193, 209-212, 217, 218 WHO recommends to conduct 
therapeutic efficacy studies at least once every 24 months to allow early detection of changes 
in antimalarial efficacy.203 Figure 1.15. and table 1.1. summarised ACTs efficacies for 
uncomplicated P. falciparum malaria in Indonesia. 
  There are limited studies evaluating the efficacy of ACTs to other Plasmodium species. 
Most studies were done on P. vivax showing excellent efficacy with superiority using DP 
compared to AL, ASAQ and AS-SP, but similar efficacy to AS-MQ.219 In Indonesia, studies on P. 
vivax showed high efficacy193, 211, 220-224 except in one study from Papua with 48% recurrences 
after ASAQ.176 Nevertheless, the cause of infection could not distinguish between 
recrudescence, relapse or reinfection.176 ACT was also shown to be effective in limited studies 
on P. malariae and P. ovale.219 In other limited studies on P. knowlesi, AS-MQ, AL and DP were 
successful to treat uncomplicated knowlesi malaria.77, 158, 225-227 
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Figure 1.15. Proportion of treatment failures in various in vivo studies using five different ACTs across Indonesia. (AS-SP, Artesunate-Sulfadoxine-Pyrimethamine; AN, 
Artesunate-Naphtoquine; ASAQ, Artesunate-Amodiaquine; AL, Artemether-Lumefantrine; DP, Dihydroartemisinin-Piperaquine; Treatment failure > 0.1 is 
the cut-off recommended by WHO for new treatment policy).  Based on data from references 162, 171, 173, 174, 176, 193, 194, 211, 212, 228, 86, 177, 178, 209, 210, 217, 218 
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Table 1.1. Summary of in vivo studies on ACTs efficacies for treatment of uncomplicated P. 
falciparum infection across Indonesia 
Year Sites No.of 
samples 
Follow-
up 
Mean 
PCT 
(hours) 
Day-3  
positive* 
(%) 
ACPR 
(%) 
PCR-
corrected 
Ref 
Artesunate-Sulfadoxine-Pyrimethamine (AS-SP) 
1999 Papua 53 28 33.6 0 95.6 Yes 162 
Artesunate-Amodiaquine (ASAQ) 
2003 Cenral Java 43 28 24 13.9 80.9 Yes 171 
2005 Papua 148 42 48 0 84 Yes 176 
2005-6 West Sumba 103 28 48 12.6 97 Yes 174 
2006 North Sumatera 121 28 47 9 100 No 173 
2006 North Sumatera 116 28 48 NA 100 No 228 
2010 South Sumatera 23 28 NA 13 87 No 177 
2010 North Sumatera 140 42 NA NA 86.4 No 178 
2010-11 Central Java 9 28 48 0 100 No 217 
Artemether-Lumefantrine (AL) 
2004 East Sumba 79 42 32.3 0 98.3 Yes 194 
2004-5 Papua 290 42 48 0 95.3 Yes 193 
2010 North Sumatera 140 42 NA NA 90.7 No 178 
Dihydroartemisinin-Piperaquine (DP) 
2004-5 Papua 515 42 48 NA 98.9 Yes 211 
2004-5 Papua 289 42 48 3 95.9 Yes 193 
2005 Papua 151 42 48 0 95.2 Yes 176 
2007-8 Papua 122 42 25.5 NA 97.3 Yes 212 
2008 Lampung 349 42 NA NA 100 Yes 209 
2010-11 Kalimantan & 
Sulawesia 119 28 
38.4 0.84 100 No 210 
2010-11 Central Java 37 42 48 0 100 No 217 
2012 5 provinces  97 42 NA 10.3 91.9 Yes 218 
Artesunate-Naphtoquine (AN) 
2007-8 Papua 121 42 28 NA 96.3 Yes 212 
2012 5 provinces 71 42 NA 1.4 95.1 Yes 218 
* Presence of asexual P. falciparum parasite detected by microscopy 
a Central Kalimantan, West Kalimantan, Central Sulawesi 
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1.6.5 Atovaquone 
 Atovaquone, in a fixed-dose combination with proguanil (Malarone), is used as a 
chemoprevention especially for travelers to malaria-endemic countries229-231. Although the 
extent use of this drug is limited to travelers, several cases of treatment failure have been 
reported.232, 233 Resistance to atovaquone alone, tested in rodent malaria parasite Plasmodium 
berghei, develop quickly, and has been associated with point mutation at codon 268 in 
cytochrome b. Resistant parasites survive drug pressure by atovaquone, however they are 
unable to complete their development in mosquito phase, therefore are not transmissible.  
Further experiments to determine similar phenomenon in P. falciparum infections suggested 
that these human malaria parasites were also unable to transmit atovaquone-resistant 
mutations, and might give some advantage for its use for malaria control.234  
 
1.6.6 Antibiotics 
In vitro and in vivo studies have shown antimalarial activity of several antibiotics 
classes including tetracyclines (tetracycline and doxycycline)235-238, macrolides (erythromycin, 
azythromycin)239-242, and fluoroquinolones (ciprofloxacin)243, 244. These antibiotics are slow 
acting but have potent antimalarial effect against the apicoplast, a phenomenon referred to 
as “delayed death”.245 Therefore, antibiotic is not ideal to be used as monotherapy but should 
be given in conjunction with rapid acting drugs such as artemisinin or quinine.246 Doxycycline 
monotherapy nevertheless has been shown to be effective as malaria prophylaxis, although it 
is not recommended for pregnant women and children < 8 years of age.247  
 
1.6.7 Primaquine 
 Although artemisinin has an impact on gametocyte carriage and thus reduces 
mosquito infectivity248, a single dose of primaquine is still recommended as a gametocytocidal 
in addition to ACT treatment particularly in low transmission areas.5 Primaquine is mainly used 
as radical cure for treatment of P. vivax249, but is also beneficial to block transmission of P. 
falciparum infection.250 Single doses of primaquine either at 0.25 mg/kg or at 0.75 mg/kg 
(WHO recommendation250) have both shown increased in gametocyte clearance in children in 
Uganda with no difference in the risk of developing anemia, a known risk due to primaquine-
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induced haemolysis in individiuals with glucose-6-phosphate dehydrogenase (G6PD) 
deficiency.251 Similar evidence was seen in a study in Indonesia where the addition of 
primaquine to ACT as recommended in national policy contributed to 16.6 times lower in 
gametocyte prevalence at day 14 compared to placebo.209 In the context of radical treatment, 
the optimal dosage of primaquine has long been debated due to its safety concerns.249 It is 
currently recommended to be given at dose 0.25-0.5 mg/kg/day for 14 consecutive days.139 
The efficacy of primaquine in preventing relapse at lower dose (0.25 mg/kg) was comparable 
to higher dose (0.5 mg/kg). In 1 year follow-up, 11.5% and 9.1% of patients had relapse after 
receiving AL and DP plus 14-day of lower dose of primaquine, compared to 6% of relapse in 
patients treated with DP plus 14-day of higher dose primaquine.221 Low prevalence (3.3%) of 
G6PD deficiency with “mild-type“ variant from findings in North Sumatera220 suggested that 
primaquine at certain low dosev can be deployed safely without prior testing for deficiency.250  
 
1.7 The fall of ACTs 
 ACT has been used in Cambodia and Vietnam for over 20 years, and the first report of 
a potential emergence of resistance to artemisinin came from Pailin, western Cambodia in 
2009.252 Noedl and Dondorp expressed their concerns about the declined sensitivity to 
artemisinin reflected by slow parasite clearance. Patients with uncomplicated falciparum were 
treated with artesunate monotherapy (4 mg/kg/day252 or 2 mg/kg/day253 for 7 days) or 
artesunate (4 mg/kg/day for 3 days) plus mefloquine (15 mg/kg at day 3 and 10 mg/kg at day 
4253). A markedly slower parasite clearance time with a small proportion of recrudescences 
were observed, however they were not necessarily associated.253  Artemisinin resistance was 
defined (see Box 2203) and follow-up studies also observed similar evidence in Cambodia254, 255, 
Thailand120, 255, Vietnam255-257, Myanmar255, 258, Laos203 and China259. Proportion of patients 
with day 3 positivity have also been increasingly noted over the years, suggesting a rapid 
spread or a takeover of this resistant parasite in the population.120, 216, 252, 253, 255, 259-261 However, 
slow parasite clearance does not necessarily cause ACT failure. ACT failure unaccompanied by 
slow rate clearing is likely to occur when the partner drug fails to eliminate residual 
parasites.171, 176, 198 As long as the partner drug of ACTS remain effective, ACTs are still the most 
                                                             
v Primaquine was given at dose of 0.25 mg base/kg (or 15 mg for > 40 kg) for 14 days.220 
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effective antimalarial for uncomplicated falciparum malaria despite the delay in parasite 
clearance in some areas of the GMS.203 Nevertheless, reduced sensitivity to artemisinin allows 
pressure on the partner drug, and may facilitate the emergence of partner drug resistance.262 
Unfortunately, as the proportion of patients with artemisinin resistance increases, there is a 
greater pressure on the partner drugs creating de novo resistance which may subsequently 
result in catastrophic ACT failures across the GMS (Figure 1.16.)203  
 However, there is an argument that prolonged parasite clearance should not be used 
solely to define artemisinin resistance. In western Cambodia where proportion of patients 
with day 3 positivity has significantly increased over the years, longer course of treatment with 
7 days of artesunate monotherapy (4 mg/kd/day) still provided 94.7% efficacy.263 As well as in 
a study where 26.9% of patients had day 3 positivity after artemisinin monotherapy later on 
showed 100% adequate clinical and parasitological responses at day 28.258 ACT failures only 
occurred where there is both resistance to artemisinin and the partner drug. Therefore, the 
classical definition of resistance which usually includes treatment failure at days 28 of follow-
up is currently not being applied in the current definition of artemisinin resistance.264 
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  The mechanisms of antimalarial drug resistance are mediated by two processes: drug 
selection of resistant parasites; and the spread of those resistant alleles to other individuals. 
The appearance of de novo mutations is initially only relevant in the individuals harboring 
these mutants and the use of drugs contributes to the selection of resistant parasite strains.265 
In Cambodia, long-term use of artemisinin monotherapies is among other reasons including 
substandard drugs and subtherapeutic doses of treatment that have contributed to the 
increased drug pressure. Strategies to minimize drug pressure, including a ban of 
monotherapy use, have been implemented, yet it remains a challenge.165 Once resistant 
parasites survive the host immune response, which is usually less developed in low-
transmission areas, resistant parasites transfer to a new individual and subsequently spread 
within and between populations.265  
BOX 2 – DEFINITION OF ARTEMISININ RESISTANCE 
There is a long debate whether delay in parasite clearance after treatment with artemisinin should 
be defined as ‘artemisinin resistance’. WHO stated there is no evidence that full resistance have 
emerged, but current clinical evidence with the presence of P. falciparum kelch 13 (pfk13) mutations  
strongly suggests evidence of partial resistance. However, definition below is subject to change 
based on new evidence.  
 
Clinical artemisinin resistance  
It is defined as delayed parasite clearance, it represents a partial/relative resistance that has thus 
far only affected ring-stage parasites. 
 
Suspected endemic artemisinin resistance 
 > 10% of patients with a half-life of the parasite clearance slope > 5 hours after treatment 
with ACT or artesunate monotherapy; or 
 > 5% of patients carrying K13 resistance-confirmed mutations (listed in Table 1.5. – see 
Section 1.8.1.); or 
 > 10% of patients with persistent parasitaemia by microscopy at 72 hours (+ 2 hours; i.e., day 
3). 
 
Confirmed endemic artemisinin resistance 
 > 5% of patients carrying K13 resistance-confirmed mutations, all of whom have been found 
to have either persistent parasitaemia by microscopy on day 3 or a half-life of the parasite 
clearance slope > 5 hours after treatment. 
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Figure 1.16. Regions where ACTs failing have been reported. Adapted from reference 266. 
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1.8 Molecular markers for drug resistance 
 Molecular markers are an important tool to detect and monitor the presence of 
antimalarial resistance. Their significant implication is to geographically map the extent of 
resistant-parasites, thus enabling strategies for their control and elimination to be applied 
before an inevitable increase in the disease burden occurs.267 Different markers have been 
used to identify antimalarial resistance including a molecular marker for artemisinin.268  
  Detection of mutations in the pfcrt gene has been used to identify CQ resistance.269 
There are 15 polymorphisms in the gene linked to the resistance, but KT76 mutation is the 
essential determinant to confer resistance to chloroquine in P. falciparum malaria.270 Codons 
72 – 76 are particularly interesting and contribute to several resistant variants related to their 
geographical origins. The haplotype encoding amino acids CVMNK at that region represents 
wild-type parasites, while the CVIET haplotype is associated with resistant isolates from Africa 
and Southeast Asia, and SVMNT is linked to chloroquine resistant strains in South America and 
some parts of Asia.271 However, the degree of CQ resistance is modulated by additional 
mutations from other P. falciparum genes such as P-glycoprotein homolog (Pgh-1)-encoding 
gene, pfmdr1.181, 272 Mutations at codons 86, 184, 1034, 1042 or 1246 of the pfmdr1 gene 
have been associated with CQ resistance, and a higher risk of CQ treatment failure was 
associated with the presence of parasites harboring the N86Y mutation.272 Pfcrt and pfmdr1 
polymorphisms have also been correlated to AQ resistance.181, 272-274 Level of resistance is 
highly dependent upon the contributions of SVMNT haplotype274, while CVIET alone is not 
sufficient to confer AQ resistance.273 Interestingly, evidence has shown that AQ and AL select 
different alleles at codon 86, 184 and 1246 of pfmdr1 , with amodiaquine positively selects for 
haplotype YYY while AL selects the opposite NFD.273 Molecular surveillance at different time 
points in Uganda confirmed genotypic changes in the parasite population with decreasing 
trends in aminoquinolone-resistant polymorphisms in pfcrt (76T) and pfmdr1 
(86Y/184Y/1246Y) after increasing use of AL in the country.197 Similar trends in the resistance 
markers were also observed in a longitudinal study implementing AL and DP for treatment 
over 5 years with greater changes observed in the AL group.275 Consistent to the polymorphic 
changes, the impact on clinical efficacy was shown in a study on ASAQ versus AL showing less 
risk of recurrence (P<0.001) and recrudescence (P<0.006) in the ASAQ group.276 Mutation at 
N1042D of pfmdr1 has shown a strong association with quinine, mefloquine and 
artemisinin.181 Treatment failure with mefloquine and artemether-lumefantrine has also been 
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demonstrated with increased copy number of pfmdr1 in studies from Asia, although clinical 
failure has not been seen in Africa.199, 261, 277 In contrast, deamplification of pfmdr1 has been 
associated with reduced response to piperaquine.216 
 Various investigations in west and east Indonesia identified wide distribution of 
mutant alleles of pfcrt and pfmdr1 genes (Figure 1.17.), with high prevalence of K76T mutation 
of pfcrt but more heterogeneity in the proportion of 86Y and 1042D mutant alleles of pfmdr1 
(Table 1.2.). The high frequency of mutant alleles is consistent with the high treatment failure 
of chloroquine observed in in vivo studies.278 Studies from east Indonesia also revealed 
parasites carrying SVMNT and CVIET haplotypes, although the latter was in a much smaller 
proportion.279-282 The SVMNT haplotype is similar to that found in Papua New Guinea and East 
Timor where chloroquine and amodiaquine were both widely used, and aminoquinolone 
resistance has previously been described.283-286
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Figure 1.17. Sampling sites across Indonesia for studies of drug resistance markers of P. falciparum  
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Table 1.2. Frequency distribution of mutant alleles of pfcrt and pfmdr1 genes from P. falciparum 
isolates in various sites in Indonesia after 2000 
Year Area 
No. of 
samples 
Proportion with mutant alleles, % (n) 
Ref Pfcrt Pfmdr1 
76T 86Y 1034C 1042D 1246Y 
2000 Purworejo 111 99  
(111) 
92  
(111) 
0  
(111) 
4.5  
(111) 
0  
(111) 
278 
2002 Batulayar 48 97.9  
(48) 
35.4  
(48) 
NA NA NA 279 
2003 Kokap 35 94.7  
(19) 
100  
(32) 
0  
(32) 
0  
(32) 
0  
(24) 
278 
2003 Hanura 48 100  
(25) 
100  
(33) 
0  
(33) 
0  
(33) 
0  
(33) 
278 
2003 Nias 20 100  
(19) 
100  
(19) 
0  
(19) 
0  
(20)  
0  
(19) 
278 
2003 Kutai 28 100  
(19) 
100  
(28) 
0  
(19) 
5.2 
(19) 
0  
(19) 
278 
2003 Mamuju 25 100  
(16) 
62.5  
(16) 
0  
(22) 
13.6  
(22) 
0  
(24) 
278 
2003 Minahasa 41 94.7 
(19) 
94.7  
(19) 
0  
(24) 
13  
(3) 
0  
(24) 
278 
2003 Armopa 21 88.2  
(17) 
26.6  
(15) 
0  
(17) 
0  
(15) 
0  
(17) 
278 
2003 Genyem 93 89.1  
(93) 
27.3  
(93) 
0  
(93) 
19.3  
(93) 
0  
(93) 
278 
2003 Flores 21 100  
(19) 
16.6  
(19) 
0  
(19) 
89.4  
(9) 
0  
(19) 
278 
2004 Nias 106 99  
(101) 
31.4 
(102) 
NA 2  
(102) 
0  
(102) 
107 
2005 Sumba 103 97.1  
(103) 
20.4 
(103) 
NA 16.5 
(103) 
0  
(103) 
174 
2007 Sumba* 213 92.9  
(213) 
41.9 
(131) 
0  
(191) 
72.8 
(191) 
0  
(191) 
106 
2007 Sumba** 231 84.9  
(174) 
42.8  
(63) 
0  
(191) 
53.3 
(180) 
0  
(191) 
106 
2010 Minahasa 44 
 
100 
(44/44) 
88.2 
(45/51) 
NA NA NA 282 
Legend: *wet season; **dry season 
 
  Mutations in the dihydrofolate reductase (dhfr) gene are known to be responsible for 
pyrimethamine resistance with a point mutation at codon 108 to be sufficient enough to 
confer resistance.287 This point mutation can arise spontaneously and frequently in a rapid 
manner after only short exposure to pyrimethamine.161 In Southeast Asia where a high level 
of pyrimethamine resistance has been documented, four amino acid changes have been 
commonly identified, while only one to three mutations have been observed in Africa.288 
Double mutations in Pfdhfr gene encompassing 108N mutant with either 51I or 59R allele 
confer greater levels of pyrimethamine resistance287 which usually manifests in slower 
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parasite clearance times. Triple-mutation at codons 108, 51 and 59 results in high treatment 
failure and four mutations with additional mutation at codon 164 leave the parasite 
untreatable.272, 288, 289 Genetic studies revealed despite multiple origins of low-level resistance, 
three point mutations of dhfr which confer full resistance to SP appeared to only have two 
origins, in South America and Southeast Asia.288, 290, 291 SP resistance seems to originated in 
these two regions and the spread followed the pattern of chloroquine-resistant parasites.161 
  Five amino acid changes have been described in sulfonamide resistance: 436A/F, 
437G, 540, 581G, and 613T/S.292 A single mutation in the dihydropteroate synthetase (pfdhps) 
gene can confer a level of sulfonamide resistance, however double mutations at 436F and 
613S/T or point mutation at 581G contribute much higher levels of resistance.287 Triple mutant 
alleles in the pfdhps conferring resistance involving codons 437, 540, and 436 or 581 are 
prevalent in Southeast Asia, while in West and Central Africa parasites harboring a single 
mutation at codon 437 or in combination with mutant allele 436A/F are the most common. In 
East Africa, wild type parasites and combinations of 437 and 540 mutations are well 
established.292 
  The prevalence of polymorphisms in the pfdhfr and pfdhps genes (Table 1.3. and 1.4.) 
in Indonesia is less frequent compared to that observed in the pfcrt and pfmdr1 genes. Double 
mutations in the pfdhfr gene were observed with the most common pair identified being 108N 
and 59R, which accounted for approximately 30% of all samples.106, 108, 174 Mutation in the the 
pfdhps gene is less common with a single mutation at 437G as the most common, followed by 
mutation at 540E. Triple mutations reported in Southeast Asian countries were not seen in 
the studies in Indonesia.292 
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Table 1.3. Frequency distribution of mutant alleles of pfdhfr gene from P. falciparum isolates in various sites in Indonesia after 2000 
Year Area No. of 
samples 
Proportion with Pfdhfr mutant alleles, % (n) Ref 
16V 50R 51I 59R 108N 108T 164L  
2000 Purworejo 111 29 (111) 0 (111) 0 (111) 46 (111) 51 (111) 27 
(111) 
0 (111) 278 
2003 Kokap 35 33 (27) 0 (27) 0 (27) 33 (27) 41 (27) 67 (27) 0 (27) 278 
2003 Hanura 48 0 (32) 0 (32) 0 (32) 63 (32) 78 (32) 34 (32) 0 (32) 278 
2003 Nias 20 0 (17) 0 (17) 0 (17) 75 (16) 94 (17) 0 (17) 0 (17) 278 
2003 Kutai 28 0 (18) 0 (18) 0 (18) 0 (18) 56 (18) 5 (18) 0 (18) 278 
2003 Mamuju 25 9 (22) 0 (22) 0 (22) 27 (22) 27 (22) 73 (22) 0 (22) 278 
2003 Minahasa 41 0 (20) 0 (20) 0 (20) 10 (20) 55 (20) 75 (20) 0 (20) 278 
2003 Armopa 21 0 (19) 0 (19) 0 (19) 68 (19) 68 (19) 0 (19) 0 (19) 278 
2003 Genyem 93 0 (93) 0 (93) 0 (93) 58 (93) 79 (93) 0 (93) 0 (93) 278 
2003 Flores 20 10 (20) 0 (20) 0 (20) 35 (17) 0 (20) 90 (20) 0 (20) 109 
2004 Nias 109 0 (69) 0 (69) 0 (69) 52.2 (69) 82.5 (69) 0 (69) 0 (69) 107 
2005 Sumba 103 0 (103) 0 (103) 0 (103) 37.8(103) 87.4(103) 0 (103) NA 174 
2007 Sumba* 213 0 (99) 0 (99) 0 (99) 25.6 (99) 31.5 (99) 0 (99) 0 (99) 106 
2007 Sumba** 231 0 (73) 0 (73) 0 (73) 25.4 (73) 24.7 (73) 0 (73) 0 (73) 106 
   Legend: *wet season; **dry season 
 
 
INKE LUBIS                   MALARIA IN INDONESIA 75 
Table 1.4. Frequency distribution of mutant alleles of pfdhps gene from P. falciparum isolates in various sites in Indonesia after 2000 
Year Area 
No. of 
samples 
Proportion with Pfdhps mutant alleles, % (n) Ref 
436F/A 437G 540E 581G 613S/T  
2000 Purworejo 111 0 (111) 35.3 (111) 26.5 (111) 0 (111) 0 (111) 278 
2003 Kokap 35 0 (28) 3.57 (28) 3.57 (28) 0 (28) NA 278 
2003 Hanura 48 0 (48) 20.8 (48) 0 (48) 0 (48) 0 (48) 278 
2003 Nias 20 0 (20) 0 (20) 0 (20) 0 (20) 0 (20) 278 
2003 Kutai 28 0 (28) 17.8 (28) 0 (28) 0 (28) 0 (28) 278 
2003 Mamuju 25 0 (25) 4 (25) 0 (25) 0 (25) 0 (25) 278 
2003 Minahasa 41 0 (40) 22.5 (40) 2.5 (40) 0 (40) 0 (40) 278 
2003 Armopa 21 0 (21) 23.8 (21) 4.7 (21) 0 (21) 0 (21) 278 
2003 Genyem 93 0 (93) 25 (93) 21.7 (93) 0 (93) 0 (93) 278 
2003 Flores 20 0 (20) 0 (20) 0 (20) 0 (20) 0 (20) 109 
2004 Nias 109 0 (69) 1.18 (69) 1.18 (69) 0 (69) 0 (69) 107 
2005 Sumba 103 0 (103) 3.9 (103) 0.9 (103) 0 (103) 0 (103) 174 
2007 Sumba* 213 0 (92) 0 (92) 0 (92) 0 (92) 0 (92) 106 
2007 Sumba** 231 0 (92) 2.2 (92) 0 (92) 0 (92) 0 (92) 106 
    Legend: *wet season; **dry season 
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 Although single copy number of pfmdr1 has been associated with decreased 
piperaquine susceptibility, there was no validated marker to identify piperaquine resistance 
specifically.216 Initial work to predict treatment failure after DP was the development of 
piperaquine survival assay (PSA). Culture-adapted and fresh P. falciparum isolates were 
exposed to 200 nM piperaquine for 48 hours and then monitored for 24 hours. PSA survival 
rates > 10% was associated with higher risk of recrudescence.293 In search of the markers for 
piperaquine resistance, two studies were further done on patients from areas where DP is 
failing. Amato et al.294 used a genome-wide association study (GWAS) platform with increased 
piperaquine IC50 as the basis294, while Witkowski et al.295 used PSA survival rates and whole-
genome sequencing to identify single-nucleotide polymorphisms (SNPs) and copy number 
variations. GWAS identified exo-E415G in chromosome 13 as the best candidate for increased 
piperaquine IC50294, and amplification of plasmepsin 2 and plasmepsin 3 copy numbers in 
chromosome 14 was strongly correlated with increased piperaquine IC50294 and PSA survival 
rates295. In addition, proportion of exo-E415G294 and multicopy plasmepsin 2-3 in those 
population increased over time. Further to validate these novel markers, both studies 
investigated the association between the markers and DP treatment outcomes. Recrudescent 
patients were associated with increased piperaquine IC50, PSA survival rates and DP failures. 
Interestingly, Amato found single copy pfmdr1 was equally distributed in recrudescent and 
non-recrudescent samples294, while Witkowski showed a higher risk to fail treatment if 
harboring a single copy mdr1 (RR 3.0 [95% CI 1.4-6.3], p=0.003)295. Multicopy plasmepsin 2 
was a strong predictor for DP failures294, with copy numbers of three or more are more 
frequent in recrudescent patients (Figure 1.18.)295. Analysis on archived samples revealed 
amplified plasmepsin 2 gene has occurred in western Cambodia since 2008 and later in 
Thailand in 2014-2015 with no amplification in isolates from Laos and Myanmar. The presence 
of multicopy plasmepsin 2 only in the back of artemisinin-resistant parasite (harbouring pfk13 
C580Y) implied that this amplification occurred after the selection of artemisinin-resistant 
genotypes.296  
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Figure 1.18. Cumulative proportion of non-recrudescent patients treated with full-course DP. (A) 
Pfplasmepsin2 gene copy number at enrollment before treatment; (B) Pfplasmepsin2 
copy number and K13 genotype at enrollment before treatment. Adapted from 
reference 295. 
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1.8.1 Molecular marker for artemisinin 
  There have been several candidates for molecular markers for P. falciparum 
resistance to artemisinin including pfatp6, G7, pfmrp1, pfubp1, and pfap2-mu. However, there 
is not enough evidence yet to link the mutations in these genes with clinical artemisinin 
resistance.170 In ACT-treated children in Kenya, persistent submicroscopic infections were 
present on day 3 and polymorphisms in pfap2-mu S160N/T and Pfubp1 E1528D were 
significantly higher than pre-treatment. However, the variant genotypes in both genes are not 
associated with Southeast Asian resistant-parasites where reduced efficacy of artemisinin 
associated to slow-clearance has been established.297 
  One study performed a targeted association analysis to identify the genome region 
underlying artemisinin resistance using 91 isolates from Cambodia, Thailand and Laos. This 
study identified 33 genome regions, 10 of which accounted for previously known antimalarial 
resistance genes. Chromosome 13 showed a strong association with slow clearance rates, and 
several candidate genes were selected from that region.298 Further work to discover molecular 
markers for artemisinin resistance used laboratory-adapted parasite clones that survive high 
doses of artemisinin in vitro.268 Mutations acquired in this parasite were analysed and used as 
a guide to analyse polymorphisms in clinical parasite isolates from Cambodia. While no 
mutations at pfcrt, pftctp, pfmdr1, pfmrp1, ABC transporters, pfatp6 and pfubp1 were seen, 
mutations at K13-propeller domain were identified. Four-mutant alleles (Y493H, R539T, I543T 
or C580Y) were associated with parasite phenotypes determined by the ring-stage assay0-3 h 
(RSA0-3 h) survival rates. Subsequently, K13 polymorphisms analysis was performed on in vivo 
study on artemisinin efficacy. Forty-two percents (72/150) harbored wild-type allele and the 
remaining (58%) carried single non-synonymous SNP in the pfk13-propeller: C580Y, R539T, or 
Y493H. Patients with any of the three K13 propeller mutant-alleles showed significantly slower 
clearance.268 Further Straimer et al. studied whether K13-propeller mutations mediate 
artemisinin resistance and explored the contribution of the mutations to the levels of 
resistance by genetic modification using zinc-finger nucleases (ZFNs) method. Removal of K13 
mutations from culture-adapted Cambodian isolates showed to reverse the response in the 
RSA0-3h survival rates, while introduction of K13 mutations into Dd2 parasites correspond to 
increased RSA0-3h in varying level depending on which point mutation was present (Y493H < 
C580Y < M476I < R539T < I 543T). Thus, these findings suggested K13 mutations confer 
different levels of resistance to artemisinin and strengthened the importance to track the 
presence of K13 mutations in a large-scale surveillance.299 
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 To further investigate the association of this resistance marker with phenotypic profile 
of slow clearing infections, randomised controlled trials on the efficacy of ACTs were done 
involving 10 countries (Cambodia, Thailand Laso, Vietnam, Myanmar, Bangladesh, India, 
Nigeria, Kenya, and the Democratic Republic of Congo). Prolonged parasite clearance (parasite 
clearance half-life > 5 hoursvi)300 were predominantly observed in patients from Cambodia and 
Thailand (49 to 73%), with a higher chance to occur in the presence of point mutation after 
position 440 in the propeller domain of K13 (OR 94.7, 95% CI 54.6 to 164.0, P<0.001) (Figure 
1.19.).255 Mutations in pfk13 were shown to be determinants of the half-life of parasite 
clearance.255, 301 
                                                             
vi Parasite clearance half-life is estimated by measuring parasite density from serial microscopic parasite 
count data to assess to which extent ring-stage parasites are killed and removed from the circulation, 
with time relationship between log-transformed parasite density and time generally linear. A tool to 
measure this rate is developed by WorldWide Antimalarial Resistance Network. 
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Figure 1.19. (A) Proportion of patients with clinical and K13 profiles according to study sites; (B) Parasites clearance half-lives according to study sites; (C) Polymorphisms 
in the propeller domain of K13 gene in relation to the parasites clearance half-life. One circle represent one pasient. Polymorphisms in the pfk13 are 
indicated by blue circles (wild-type or mutation before position 441), red circles (mutation after position 440), or black circles (at least part of K13 sequence 
is missing or heterozygous). Adapted from reference 255. 
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 Increasing concerns that artemisinin-resistant parasites might disseminate from its 
epicenter in Cambodia have led to the efforts to map the geographical extent of the pfk13 
mutants. Early detection of mutations will allow understanding whether resistance have 
spread or emerged independently and to implement strategies to contain the parasites. 
Menard et al. sequenced 14,037 samples from 59 countries to identify the pfk13 
polymorphisms linked to the geographical origins. 108 nonsynonymous K13 mutations were 
identified with 9 had frequency > 1%; C580Y, F446I, R539T, A578S, Y493H, P574L, P553L, 
N458Y, and R561H (Table 1.5.).302 Most mutations were distributed in two regions in 
Southeast Asia exhibiting distinctive profiles: Cambodia, Vietnam, Laos were prevalent for 
C580Y, R539T, Y493H, I543T; while Thailand, Myanmar, China were prevalent for F446I, 
N458Y, P574L, R561H (Figure 1.20.).296, 302, 303 Three mutations (493H, 574L, and 580Y) 
occurred in both populations. However, subsequent haplotype analysis based on linkage 
disequilibrium in flanking areas of K13 suggested 493H to originate from Cambodia and spread 
to Vietnam, and 574H and 580Y arose focally in Vietnam or Vietnam/Cambodia and Myanmar 
(Figure 1.21.). There was no evidence that resistant-parasites have spread from Cambodia to 
Myanmar, and K13 mutations emerged independently in the two regions.301, 304 In Africa, K13 
mutations have also been documented, however different to those (580Y, 539T, 493H) 
associated with artemisinin resistance in Southeast Asia. Novel mutations have been observed 
with mutation at A578S appeared in several countries with yet unknown phenotypic 
impact.305-307 In high transmission settings, patients’ immunity usually clears parasite residuals, 
therefore measuring the parasite clearance times is probably not the best indicator to detect 
resistance in this region. A case report of patient from Equatorial Guinea with day-3 positivity 
after full course of DP identified mutation at M579I in the propeller domain of K13.308 
However, this single case is not sufficient to correlate K13-propeller mutations with 
artemisinin resistance in Africa. Limited evidence on the association of clinical resistance with 
K13 mutations in African isolates, suggesting there is a different mechanism mediating 
artemisinin resistance in this region.305, 306, 309 
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Table 1.5. List of K13 point mutations and their association with clinical resistance and 
validation by in vivo and in vitro data. Adapted from reference 203. 
K13 mutation Classification 
E252Q Not associated 
P441L Candidate 
F446I Candidate 
G449A Candidate 
N458Y Validated 
Y493H Validated 
G538H Candidate 
R539T Validated 
I543T Validated 
P553L Candidate 
R561H Validated 
V568G Candidate 
P574L Candidate 
A578S Not associated 
C580Y Validated 
A675V Candidate 
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Figure 1.20. (A) Frequency distribution of the wild-type pfk13 allele worldwide; (B) Frequency 
distribution of the wild-type pfk13 allele in Asia; (C) Distribution of the common 
mutant alleles of pfk13 in Southeast Asia. Colored boxes and hatches boxes 
correspond to shared haplotypes and the presence of additional country-specific 
haplotypes, respectively. Adapted from reference 302. 
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Figure 1.21. P. falciparum K13 mutations within linkage disequilibrium of the K13 gene. Prevalence 
of haplotype is proportional to size of the circle. Red color indicate Cambodia origin, 
purple color indicate Myanmar origin, green color indicate Vietnam origin. Adapted 
from reference 301. 
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1.9 Actions to ACTs resistance 
 Declining efficacy of ACTs in Southeast Asia is highly concerning and a real threat for 
malaria-endemic countries. WHO launched a Global Plan on Artemisinin Resistance 
Containment in 2013 with detailed actions to contain resistant parasites from spreading to 
high endemic regions. Nevertheless, K13-propeller mutations associated with artemisinin 
resistance have emerged independently in at least two sites in the GMS, and resistance to 
partner drug (e.g. piperaquine) may also have emerged independently. Efforts to control 
malaria and to achieve elimination require new strategies to prevent increased morbidity and 
mortality. Several proposed strategies including:310, 311 
 Extending current ACT course from 3 days to either 5 or 7 days 
 Re-ACT or administration of two different 3-day ACT in sequence 
 Rotating two ACTs  
 Deployment of multiple first-line therapies 
 Triple ACTs (combination of artemisinin with two partner drugs) 
 As Indonesia progresses towards elimination, the threat of spread or emergence of P. 
falciparum resistance to current recommended treatment into this corner of Southeast Asia 
is alarming. There is a need to establish a strong surveillance system to evaluate the progress 
made to achieve elimination, to monitor the efficacy of the recommended ACT in this region, 
thus treatment failures due to drug resistance can be avoided and malaria elimination goal 
can be achieved. 
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2 AIMS 
 
The work described in this thesis aims to improve our understanding on malaria distribution 
in North Sumatera, Indonesia during the malaria elimination era and to investigate the efficacy 
of current ACTs where emergence of multi-drug resistance parasites is prevalent in the 
neighboring countries. The research has two major aims described below. 
 
Aim 1. To investigate malaria distribution in a low transmission setting in North Sumatera 
province, Indonesia. 
Specific objectives: 
1. To identify the presence of all Plasmodium species and to determine the proportion 
of each species  
2. To determine the contribution of subpatent infections to the overall malaria burden 
3. To provide genetic profiles associated with polymorphisms in drug resistance markers 
to current recommended antimalarial treatment among P. falciparum infections 
These objectives are addressed by work described in chapters 4 and 5. 
 
Aim 2. To evaluate the efficacy of dihydroartemisinin-piperaquine and artemether-
lumefantrine for the treatment of uncomplicated P. falciparum malaria and as post-treatment 
prophylaxis. 
 
Specific objectives: 
1. To determine the proportion of treated patients showing adequate clinical and 
parasitological response (ACPR) at day 42, for each of the two ACTs 
2. To measure the P. falciparum clearance dynamics in the 72 hours after treatment  
3. To investigate the association between genetic polymorphisms and treatment 
outcomes , using the established WHO definition of ACPR 
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4. To determine the proportion of subpatent recurrent infection at day 28 and day 42 
after treatment using molecular assays, and relate this to genetic variation in parasite 
genes implicated in ACT susceptibility 
These objectives are addressed by work described in chapters 6 and 7.
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3 MATERIALS AND METHODS 
 
3.1 Study design 
This study consisted of two study designs. The first study is a parasitological survey in 
three study sites in North Sumatera province, Indonesia. The second study is a prospective, 
open label, randomised controlled trial to assess the safety and efficacy of dihydroartemisinin-
piperaquine (DP) and artemether-lumefantrine (AL) in children and adults with uncomplicated 
P. falciparum  malaria infection. 
 
3.2 Study sites 
The study was conducted in three regencies in North Sumatera province, Indonesia. 
North Sumatera province is located at 200’N 9900’E (Figure 3.1.) with a total land area of 
71,680.68 km2. The total population in 2014 was 13,766,851 with equal ratio between male 
and female. There are 8 cities and 25 regencies, with Medan as the capital city. Productive age 
(15-64 years of age) accounted for the most proportion in this population.312  
There are two seasons occurring in this area with a transition period in between. Dry 
season starts from June to September and rainy season begins in November to March. The 
temperature ranges from 13.4 C to 33.9C.312 The transmission intensity for P. falciparum 
infection is stable in approximately half of the region but stands at low risk. In 2010, Elyazar et 
al. estimated a quarter of population in this region were exposed to P. falciparum infection.88. 
A total of 44,403 malaria cases was suspected in 2015, and 99% underwent diagnostic tests 
by microscopy or rapid diagnostic test resulted in 3,503 positive cases. From 2008 to 2013, 
there were an increasing trends in annual parasite incidence before declining in the following 
year (Figure 3.2.).93, 313 
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Figure 3.1.  Map of North Sumatera province, Indonesia with the three studied regencies indicated. Adapted from reference 29.
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Figure 3.2. Annual parasite incidence in North Sumatera province and Indonesia, 2000 - 2016. Based on data from reference 87, 93, 314. 
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Three study sites: Batubara, Langkat and South Nias regencies were selected based 
on published malaria endemicity.315 Batubara is located on the east coast of Sumatera facing 
peninsular Malaysia with a size of 904.96 km2. It comprises semiforested and plantation areas, 
with 37.31% of productive age population was working in agriculture, plantation, forestry or 
fishery. There were 2 public hospitals, 14 primary health centres and 60 health posts in 
addition to 1 private hospital and 127 private clinics/pharmacies to cover the 396,479 
population. Primary health centre runs 6 days a week from 8 am to noon. We also established 
a 24-hour 7-day clinic to capture more patients with fever. We conducted health promotion 
and education on malaria at 47 primary health centres, health posts, schools and head village 
offices (Figure 4.1.) during 8-week period of screening. Primary health centres also referred 
patients with positive slide or RDT to our clinic. Bahasa Indonesia and/or local dialect Malay 
with the help of a translator were used to communicate with patients. There had been a 
significant increase of annual malaria incidence (AMI) in this regency between 2010 and 2014 
from 8.52 to 24.34 per 1,000 population due to increased funding for malaria diagnostic 
tests.316 
Langkat regency is a forested highland area with a size of 6,263.29 km2 located 105-
530 m above sea level. There were 967,535 population in Langkat with over 50% of population 
over 15 years of age was also working in agriculture, plantation, forestry or fishery. There were 
1 public hospital, 30 primary health centres and 171 health posts supported by 5 private 
hospital and 127 private clinics. Nevertheless, villages we visited in this regency were isolated 
with very poor access to health facilities (Figure 4.2.). We visited 10 villages and malaria 
screening by active case detection was done for 2-3 days in each village.312, 317 In this study 
site, Bahasa Indonesia and/or local dialect Karo with the help of a translator were used to 
communicate with patients. 
South Nias regency is cluster of islands in Indian ocean. Main part of the regency is 
situated in Nias island, with the rest of the region scattered in 101 small islands named Batu 
islands (islands of rocks). There were 289,708 population in 1,625.91 km2 of its total area. We 
set up a-24 hour 7-day clinic in Tello island which functioned also as a diagnostic laboratory. 
We visited 32 villages and schools spread across 7 islands: Tello, Tanahmasa, Balogia, Sipika, 
Pono, Sibaranun, and Marit (Figure 4.3.), however most villages were not connected by land. 
Malaria screening involved daily sea journeys to conduct malaria sensitization in the 
community, followed-up by screening of individuals with fever and healthy individuals who 
INKE LUBIS              MATERIALS AND METHODS 94 
requested for a malaria test.312 The local dialect Nias was used to communicate with patients 
in this study site. 
 
3.3 Study duration 
Samples were collected between January and June 2015. 
 
3.4 Sampling 
We performed passive and reactive case detections at each regency. Passive case 
detections were done for groups of patients who visited primary health centres or our 24-
hour clinic with fever (axillary temperature > 37.5 °C) or a history of fever in the preceding 48 
hours. Reactive case detections were conducted on household members and neighbours of 
index case detected during passive surveillance. Individuals who appeared with fever or 
history of fever, and healthy volunteers during community/school sensitization were also 
tested for malaria as part of active case detection. 
 
3.5 Enrollment to drug efficacy study 
Patients aged > 6 months of age with fever or history of fever in the preceding 48 
hours and confirmed by microscopy for uncomplicated P. falciparum infection. 
 
3.5.1 Sample size calculation 
In vivo therapeutic efficacy studies on DP in Indonesia showed high efficacies at day 
42.176, 193, 209 We used the efficacy result from previous study in South Sumatera with 100% 
ACPR.209 With the estimation of the efficacy for artemether-lumefantrine of 95%, we 
calculated the sample size for comparing two proportions.318 
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n1 = n2 = f (,P) (p1 (1 – p1) + p2 (1 – p2)) 
    (p1 – p2)2 
 
 n1 = n2  :   number of subjects in one group 
   :   statistical significance 
 P  :   power 
 p1  :   Proportion of subjects with ACPR in group 1 
 p2  :   Proportion of subjects with ACPR in group 2 
 
Based on the calculation above, using a power of 80% and a significance level of 0.05, 
a total of 300 subjects in the study will provide us with a statistical significant difference in 
treatment outcomes between dihydroartemisinin-piperaquine and artemether-lumefantrine.  
 
3.6 Ethical clearance 
The study was approved by the ethic committees of the London School of Hygiene 
and Tropical Medicine, United Kingdom (identifier 8504-01, Appendix 1) and the University of 
Sumatera Utara, Indonesia (identifier 401/KOMET/FK USU/2014, Appendix 2). 
 
3.7 Randomisation 
Randomisation list was generated using excel software. Pre-assigned treatment was 
printed on numbered case record form for 300 participants.  
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3.8 Study protocol flow diagram 
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3.9 Study procedures 
Table 3.1. describes lists of assessments conducted during the study, all information 
was recorded in the case screening forms  (Appendix 3) and case record forms (CRF, Appendix 
4)). 
 
Table 3.1. List of evaluation tasks during study period 
Evaluation Enrollment Treatment 
 
Follow-Up 
Days 0 1 2 3 7 14 21 28 35 42 
Hours  0 8 24 36 48 60 72       
Demographic data               
Medical history               
Concomittant 
treatment 
              
Vital signs and body 
weight  
              
Physical examination               
Blood smear               
Gametocyte count               
Rapid diagnostic test               
Hematology and 
biochemistry tests 
              
Pregnancy test               
Drug administration               
PCR sampling               
Adverse events               
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3.10 Recruitment 
During the recruitment period, the following activities were performed including basic 
screening, evaluation for enrollment, and informed consent. 
 
3.10.1 Basic screening 
We performed blood smears, rapid diagnostic tests (RDTs), when available, and filter 
paper blood spots sampling on patients presenting at the study clinic with fever (axillary 
temperature > 37.5 C) or history of fever in preceding 48 hours, and also on healthy 
individuals who volunteered to have malaria tests. Baseline information including age, sex, 
body weight and height were recorded as part of the initial screening. Giemsa stained thick 
(and thin) blood films were prepared to screen asexual parasites and gametocytes at 1000x 
magnification microscopy examination. Thin films were used to identify Plasmodium species. 
Thick films were used to determine parasite density by counting the number of asexual forms 
of P. falciparum parasites per 200 WBCs, with an assumption that white blood cell density is 
8000 per L.  
 
 Parasite density / L  =            Number of parasites counted x 8000 
             Number of leukocytes counted (200) 
 
A blood smear was considered to be negative after examination in 100 microscopic 
fields. To detect sexual forms of parasite, the presence of gametocytes was screened against 
1000 leukocytes. All information was recorded in the case screening form (Appendix 4). 
Repeated blood films were done for enrolled participants as scheduled above and until the 
parasite was cleared from the slides.  
In addition to microscopy examination, we also performed RDT as a comparison. RDTs 
examination is the standard diagnosis for malaria in the local health clinics especially when 
trained microscopist is not available. CareStartTM Malaria HRP2/pLDH (Pf/Pan) Combo, SD 
Bioline Malaria Ag Pf/Pan, Parascreen-Rapid Test for Malaria Pan/Pf, FalciVaxTM-Rapid Test 
for Malaria Pv/Pf, and Paracheck Pf-Rapid Test for P. falciparum malaria device were 
provided by the Provincial Department of Health and the LSHTM, and it was used based on 
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availability. For this procedure, during the finger prick blood sampling for blood films 
preparation, a full drop of blood (±5 L) was taken using the loop supplied by the 
manufacturer RDT package and placed onto the filter paper in the RDT device. Six drops of 
buffer were added to the well. Results were interpreted after 15 minutes and positive result 
was confirmed by identifying two lines (control and test) on the device. The microscopists 
were blinded from the RDT results. Patients must have positive blood slides to be enrolled to 
the study. Patients with positive RDT results but negative blood slides were treated for malaria 
but were not eligible for the study. 
 Three drops of blood were spotted onto 3MM Whatman filter paper to be examined 
by nested PCR at LSHTM for quality control. The filter papers were left to dry overnight and 
attached to a labeled cardboard cover on the following day. A set of 30-40 covers with 
attached filter papers were kept in a plastic bag containing silica gel. Hemoglobin level was 
determined using HemoCue® to exclude severe anemia. 
 
3.10.2 Evaluation for enrollment 
Study doctors evaluated patients who fulfilled the basic criteria for enrollment. 
Participants were assessed for inclusion and exclusion criteria. A case screening form 
(Appendix 3) was used to document participant’s information. Doctors carefully evaluated the 
presence of danger signs, severe malaria, severe anemia and also other febrile causes to 
exclude participants from the study.  
 
3.10.2.1 Inclusion criteria 
 Male or female; 
 All patients over 6 months of age; 
 Fever as defined by axillary temperature > 37.5 C or history of fever 
during the 48 hours before recruitment; 
 Infection with P. falciparum detected by microscopy; 
 Parasitaemia >250 /l blood; 
 Ability to swallow oral medication; 
 Ability and willingness to comply with the protocol for the duration of 
the study and to comply with the study visit schedule; 
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 Informed consent from the patient of from a parent or guardian in the 
case of children; 
 Absence of history to hypersensitivity reactions or contraindication to 
antimalarial drugs; 
 Not currently consuming antibiotic with antimalarial activity (such as 
cotrimoxazole, macrolides, tetracycline or doxycycline) (Appendix 5) 
 
3.10.2.2 Exclusion criteria 
 Presence of P. vivax infection detected by microscopy; 
 Presence of general danger signs in children under 5 years or signs of 
severe falciparum malaria according to the definitions of WHO (2000) 
(Appendix 6); 
 Presence of severe malnutrition according to WHO child growth 
standards (Appendix 7); 
 Presence of febrile conditions caused by diseases other than malaria; 
 Presence of severe anemia (Hemoglobin < 7 gr/dl); 
 Received any of the study drugs within the past 4 weeks; 
 Received any antimalarial within the last 2 weeks; 
 Recurrent vomiting (necessitating more than a single repeat dose); 
 Pregnant (demonstrated by positive result of -HCG in women of 
childbearing age); 
 Lactating mother 
 
3.10.2.3 Criteria for withdrawal from the study 
 Withdrawal of consent; 
 Persistent vomiting; 
 In need of parenteral treatment; 
 Severe adverse events related to study drug; 
 Hypersensitivity or allergy to study drug; 
 Received any antimalarial or antibiotic with antimalarial activity during 
study period; 
 Move out from study area; 
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 Failure to complete the treatment 
 
3.10.2.4 Amendments to the protocol 
After the protocol has been accepted, amendment on exclusion criteria was made 
with agreement of the principal investigator and the LSHTM and University of Sumatera Utara 
ethic committees. Amendments were made in the exclusion criteria where the first point of 
the criteria “Presence of P. vivax infection detected by microscopy” was omitted. 
 
3.10.3 Informed consent 
Participants received full information about the study including the purpose of the 
study, procedures, compensations, disadvantages or risks from taking part, benefits, 
confidentiality, discontinuation, and duration of study according to the rules of international 
and local guidelines for research relating human subjects (Appendix 11 and Appendix 13). 
Information was given in either Bahasa Indonesia or local dialect Malay, Karo or Nias 
translated by a local translator. Participants were given time to ask questions and to consider 
whether they agree to be enrolled to the study. Signed informed consents (Appendix 12 and 
Appendix 14) were sought from participants or guardians of children (age < 15 years). 
 
3.11 Enrollment 
Participants who met all selection criteria and signed gave written informed consent 
were further interviewed for demography and medical history recording, and also had physical 
and laboratory examinations. 
 
3.11.1 Demography and medical history recording 
Participant’s name, address, occupation as well as medical history were recorded. The 
address was particularly important to reach patients at their home when they failed to appear 
on follow-up days. Patients’ identification (name and address) was not entered to digital 
documents. 
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3.11.2 Physical examinations 
Physical examination was done thoroughly at every scheduled visit. Physical 
examinations comprised examinations on general appearance, skin, ear, throat, respiratory, 
cardiology, abdominal, genito-urinary and extremities. All abnormalities were documented in 
the CRF (Appendix 8) and the examiners assessed the need for any concomitant medications. 
 
3.11.3 Laboratory examinations 
 Hemoglobin level was determined using HemoCue® at enrollment and day 28. 
 Pregnancy test from urine was done for childbearing age women at initial 
screening. 
 Thin and thick films were examined on day 1, 2, and 3 or until patients cleared the 
parasites, as well as at the following scheduled visits (day 7, 14, 21, 28, 35 and 42) 
or at any day patients showed up at the clinic, and blood film examination was 
requested by the study staff.  
 Filter paper blood sampling was performed for post hoc PCR analysis to determine 
Plasmodium species, to measure parasite clearance times and to detect molecular 
markers.  
 
3.12 Treatment 
3.12.1 Treatment  
 Treatment with dihydroartemisinin-piperaquine (Duo-Cotecxin, Zhejian Holley 
Nanhu, Guangzhou, China) 
One tablet of DP consists of 40 mg of dihydroartemisinin and 320 mg of 
piperaquine. DP was administered once daily for 3 days (at enrollment, hour 24, 
and hour 48). Dosing was given based on body weight. Daily dose for 
dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 
mg/kg (total 54 mg/kg). DP is the first line treatment in Indonesia. 
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 Treatment with artemether-lumefantrine (Coartem, Beijing Novartis Pharma Ltd, 
Beijing, China) 
AL was administered as 6-dose regimens given twice daily for 3 days (at 
enrollment, hour 8, hour 24, hour 36, hour 48, and hour 60). Half a tablet 
consisting of 20 mg of artemether and 120 mg of lumefantrine was given per 5 kg 
body weight.  
 
3.12.2 Treatment administration 
 Administration of the drugs for DP was supervised at the study center or during home 
visit at enrollment, day 1 and day 2. Administration of the first dose of AL for each day was 
given at the study center and for the second daily dose, study staff visited the patient at home 
if feasible to observe drug administration. Subjects in DP group were visited in the afternoon 
to ensure equal monitoring between two groups. AL was given with drinking water on a full 
stomach, and food was provided for participants with an empty stomach. While DP was given 
in an empty stomach, patients were instructed to fast for 2 hours after drug administration. 
For paediatric participants, the tablet was crushed to meet the correct dosage and then 
dissolved in drinking water in a small cup. After drinking the water, 10 ml of drinking water 
was added to the cup to be administered to the patients again. Hereafter, study staff observed 
participants for 1 hour after drugs administration, if a participant vomited within 30 minutes 
then a full dose was  repeated and if between 30 minutes and 1 hour a half dose was given. 
Recurrent vomiting would withdraw participants from the study and receive rescue 
medication.  
 Antimalarial and other medicines were provided to participants, non-recruited 
patients and withdrawn patients. Medicines for participants are listed as non-allowed 
concomitant medicines, allowed concomitant medicines and rescue medicine. Non-allowed 
concomitant treatment includes any antimalarial drugs and antibiotic with antimalarial action 
such as cotrimoxazole, macrolides, tetracycline or doxycycline. Allowed concomitant 
medicines are anthelminthics, analgesics, other antibiotics without antimalarial action such as 
penicillins, cephalosporins, hematinics. The use of antipyretic was allowed (if necessary). Any 
concomitant medicine was recorded in the CRF (Appendix 4). Rescue medication was given to 
participants who develop signs of treatment failure within 42 days according to WHO 
definitions (Table 3.2.). Participants were withdrawn from the study and received second-line 
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treatment according to the national treatment protocol. Current recommendation is quinine 
(10 mg of salt/kg three times a day for 7 days), with additional doxycycline (100 mg twice a 
day for 7 days) for children > 8 years of age and non-pregnant women. Non-recruited 
participants received treatment according to the standard of care in the national guidelines. 
 
3.13 Follow-up 
Follow-up schedule comprised of visits on day 3, day 7 and then weekly after day 7. 
However, participants were also asked to return on any day the symptoms reappear. Follow-
up observations included assessment on safety and tolerability of treatment throughout the 
study. Safety evaluation consisted of monitoring of adverse events, measurement of vital sign 
and body weight, physical examination, hemoglobin evaluation, and thin and thick blood films 
to verify presence of parasites. Parasite density were measured at each reading. Presence of 
gametocytes was recorded on follow up days 3, 7, 14, 21, 28, 35 and 42. Microscopists 
remained unaware of treatment allocation until the end of the study. Filter paper blood 
sampling was done at each visit as scheduled and also at any day participants felt unwell. All 
results were recorded on the CRF (Appendix 4) and adverse events form (Appendix 9). 
Adverse events were assessed by direct interview. Adverse events were defined as a 
condition of any unfavourable, unintended sign, symptom, syndrome or disease that develops 
or worsens concomitant with the use of study medicines, regardless of whether it is related 
to the study medicines. Occurrence of an adverse event was classified based on the severity, 
its relationship with the study drugs, duration of adverse events, which actions taken, the 
outcomes, and the person who has identified the adverse event according to established 
clinical trial practise (Appendix 9).172  
A serious adverse event is defined as any untoward medical occurrence that at any 
dose results in death, is life threatening; requires hospitalization or prolongation of 
hospitalization; results in persistent or significant disability or incapacity; or is a congenital 
anomaly or birth defect; or is medically significant that jeopardizes the participant or requires 
intervention to prevent one of the previously mentioned outcomes. If a serious adverse event 
was identified, a report was made immediately within 24 hours to trial monitor (Appendix 
10).172 
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3.14 Laboratory analysis 
All samples collected at enrollment were screened for any Plasmodium infection for 
confirmation using nested PCR following the protocol by Snounou et al.319 Extraction of 
parasite DNA from filter paper was performed using the Chelex-based method.320 Parasite 
clearance times for enrolled patients were determined using qPCR.321 
Polymorphisms in genes associated with drug resistance markers for antimalarial used 
in the study including pfcrt gene, pfmdr1 gene and pfk13, encoding the kelch13 propeller 
domain protein, were determined using published methods.270, 273, 322 Samples from day of 
treatment failure were investigated by msp1 (merozoite specific protein), msp2 and glurp 
(glutamate-rich protein) genotyping according to the WHO protocols. The genotypic profiles 
of pre-treatment and day of failure strains were compared to distinguish a recrudescence 
from a reinfection.323, 324 For assessment of parasite persistence in follow-up, quantitative 
polymerase chain reaction (qPCR) targeting PgMET and nested polymerase chain reaction 
(PCR) targeting pfmdr1 were also used to screen all samples from day 28 and day 42.273, 321 
 
3.15 Outcome measurements  
All identified Plasmodium species-infecting human from symptomatic and 
asymptomatic patients were documented. A comparison of microscopy and PCR detection 
was made. Treatment outcomes from enrolled participants are classified as early treatment 
failure, late clinical failure, late parasitological failure or adequate clinical and parasitological 
response (Table 3.2.) according to the latest WHO guidelines.64 
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Table 3.2. Treatment outcomes according to WHO guidelines64 
Treatment outcomes 
Early treatment failure: 
 Danger signs or severe on day 1, 2 or 3 in the presence of parasitaemia 
 Parasitaemia on day 2 higher than on day 0, irrespective of axillary 
temperature 
 Parasitaemia on day 3 with axillary temperature > 37.5 ⁰C 
 Parasitaemia on day 3 > 25% of count on day 0 
 
Late treatment failure: 
   Late clinical failure: 
 Danger signs or severe malaria in the presence of parasitaemia on any 
day between day 4 and day 28 (day 42) in patients who did not 
previously meet any of the criteria of early treatment failure 
 Presence of parasitaemia on any day between day 4 and day 28 (day 42) 
with axillary temperature > 37.5 ⁰C (or history of fever) in patients who 
did not previously meet any of the criteria of early treatment failure 
 
Late parasitological failure:  
 Presence of parasitaemia on any day between day 7 and 28 (day 42)  and 
axillary temperature < 37.5 ⁰C in patients who did not previously meet 
any of the criteria of early treatment failure or late clinical failure 
 
Adequate clinical and parasitological response  
 Absence of parasitaemia on day 28 (day 42), irrespective of axillary 
temperature, in patients who did not previously meet any of the criteria 
of early treatment failure, late clinical failure or late parasitological 
failure 
 
 
Parasite clearance was assessed daily by microscopy at 24-hours intervals following 
study drug administration until parasites were cleared from blood films. Parasite density was 
measured at each examination and qPCR was performed as quality control and to determine 
the proportion of patients remaining parasitaemic at day 1, 2, and 3. Gametocyte prevalence 
was assessed at enrollment, day 3, day 7, day 14, day 21, day 28, day 35 and day 42. Fever 
clearance times were determined by measuring axillary temperature on daily visit and as 
scheduled. Parasite carriage at days 28 and 42 was identified by PCR. 
 Polymorphisms in pfcrt gene, pfmdr1 gene and pfk13 propeller on pre-treatment day 
were evaluated as a predictor tool for therapeutic responses. Molecular data from parasites 
isolated on follow-up days were also assessed and associated with resistance genotypes. 
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3.16 Data management 
All data collected (clinical notes, laboratory records, supporting data) were recorded 
in case record forms and could only be accessed by study field manager. Data were 
subsequently entered into a database with a password protected by a data entry officer and 
were then reviewed and validated by the investigator. Any missing data were communicated 
to the site for resolution. The principle investigator was responsible for keeping subject 
identification code list in a secure location. Access to the database was only available to the 
study investigator and principle investigator.  
 
3.17 Monitoring and quality assurance 
This trial is registered to ClinicalTrials.gov number NCT02325180 and complies with 
international guidelines for clinical trial reporting. Experienced staff including senior 
physicians were recruited to perform the study, to monitor participants closely and to ensure 
that the rights, safety and the wellbeing of the human subjects in the study are in accordance 
with the study protocol, national protocol, ICH and GCP guidelines. Training session related to 
study protocol was conducted for all study staff to ensure the expected tasks were performed 
consistent with the protocols and guidelines. 
The study investigator frequently and closely monitored the study site. Trial monitor 
was appointed to monitor the progress of the study with the objectives of: 
 Maintaining the performance of the staff 
 Facilitating required work 
 Checking the availability of signed informed consents 
 Comparing individual records (CRFs) to the source documents 
 Ensuring protection of study subjects, compliance with the protocol, and accuracy and 
completeness of records 
 The monitoring schedule were planned prior the start of the study and study 
investigator and the staff were available at the study site to allow discussion about 
study progress. 
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3.18 Reporting and publication of results 
At the end of the study, the investigator prepared a final report of the study to be 
reviewed by advisors and later to be shared with the National Malaria Control Programmes 
and to the Ministry of Health of Indonesia. Initial results from the study have been presented 
in several conferences, and was published in a scientific journal. A full report of the clinical 
study will also be published. 
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4 RESULTS      
Molecular detection of Plasmodium spp. 
in three rural areas of North Sumatera 
Some parts of this chapter have been published in a research manuscript (Lubis IND, Wijaya H, Lubis 
M,Lubis CP, Beshir KB, Sutherland CJ. Contribution of Plasmodium knowlesi to Multispecies Human 
Malaria Infections in North Sumatera, Indonesia. The Journal of Infectious Diseases. 2017;215(7):1148-
1155). Additional material is added here to explain the whole work.  
 
4.1 Introduction 
Malaria remains widespread across Southeast Asia. In Indonesia, 2 million cases of 
malaria are reported each year, with Plasmodium falciparum and P. vivax the two major cause 
of illness.88 Human cases of P. knowlesi, a parasite that previously known to infect long-tailed 
and pig-tailed macaques, have been documented on the islands of Kalimantan and 
Sumatera21, 28 but not as a major cause of human malaria as reported in Borneo, Malaysia.56 
The morphological features of this species in the blood stage are similar to P. falciparum and 
P. malariae which in routine practice has led to frequent misdiagnosis.28, 56, 325 Its capability to 
cause high parasitaemia has also been reported to cause fatal disease.76 Despite this, a 
proportion of P. knowlesi infections are asymptomatic and submicroscopic across all age 
groups.326  
The Ministry of Health of Indonesia has implemented malaria control and elimination 
efforts since 2009 with 4 distinct stages aiming for the national elimination goal by 2030. 
Malaria surveillance performed at primary health centres relies on passive case detection by 
microscopic examination and rapid diagnostic tests (RDTs).102 These tests are sufficient to 
detect clinical malaria infection caused by major species.327 However, identification of less 
common species is often difficult and low density parasitaemia can lead to underdiagnosis.328 
Modelling of data from low endemicity areas predicts that submicroscopic parasites may 
contribute 70 to 80% of all malaria infections.80 Other studies have also shown that these 
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submicroscopic parasites are infectious to mosquitoes and contribute to ongoing malaria 
transmission.196 Hence, the use of routine microscopy and RDT in malaria surveillance fails to 
detect a substantial proportion of the human reservoir of infection and so may compromise 
malaria elimination strategies. Deployment of molecular assays, providing excellent sensitivity 
and specificity, may therefore solve these issues.51, 329-331 
In this study, we performed intensive malaria screening in 3 regencies of the Province 
of North Sumatera, western Indonesia. This region is aimed for malaria elimination by 2020. 
In addition to microscopy, we used established polymerase chain reaction (PCR) assays for 
detection of Plasmodium parasites.332 However, these tests have limitations for the 
identification of P. knowlesi infection, because the target region of the 18S ribosomal RNA 
(rRNA) can cross-hybridise with P. vivax.333 Therefore, we developed a novel assay with high 
sensitivity and highly specific for P. knowlesi identification to ensure reliable determination of 
all Plasmodium species, including submicroscopic infection. 
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4.2 Methods 
4.2.1 Study sites and samples collection 
A parasitological survey was conducted between January and June 2015 in three 
selected regencies in North Sumatera province, Indonesia. A total of 47, 10 and 32 temporary 
clinics were set up in each of Batubara (Figure 4.1.), Langkat (Figure 4.2.) and South Nias 
(Figure 4.3.) regencies, respectively. Sampling sites were adjusted to the accessibility of 
community to the local health clinics. There was a good access to healthcare in Batubara, 
therefore sampling was mainly conducted in the local health clinics with few additional visits 
in villages and schools (Figure 4.1.). In Langkat and South Nias, geographical locations restraint 
community access to healthcare, therefore screening of patients was heavily relied on visits 
to the villages and schools (for South Nias only, Figure 4.2. and 4.3.). Screened individuals were 
classified into sick individuals visiting the health clinics, household contacts and healthy 
volunteers, nevertheless this information was not recorded during the survey. Patients with 
fever or history of fever visiting the outpatients clinics were screened for malaria infection. 
Healthy individuals visiting the health clinics and in the visited villages who volunteered to be 
tested and household members of malaria-positive individuals were also included in the 
malaria testing. During sensitization visits at schools in Batubara and South Nias, parents were 
asked to fill in questionnaires containing information on history of fever in the past 48 hours 
of the children. Children with history of fever and healthy children who volunteered were then 
tested for malaria. Local health clinics were asked to refer patients diagnosed with 
uncomplicated malaria to our clinics. Finger-prick blood sampling was done to make thick and 
thin blood films for microscopy examination, RDTs examination (when available), and blood 
was also spotted on 3MM Whatman filter paper for molecular analysis. Patients confirmed 
with P. falciparum infection by microscopy were subsequently enrolled in a prospective drug 
efficacy study (Chapter 6) if they fulfilled the inclusion and exclusion criteria (Section 3.10.2.1 
and 3.10.2.2). Patients with slide-positive for other Plasmodium species were clinically 
assessed and treated according to national guidelines, but not followed-up. Febrile status in 
slide-negative individuals were not recorded. Due to the limited numbers of individuals tested 
with RDTs, only microscopy and PCR results will be presented. 
The study was approved by the Ethics committee of the London School of Hygiene 
and Tropical Medicine (London, United Kingdom; 8504-01), and the Ethics committee of 
University of Sumatera Utara (Medan, Indonesia; 401/KOMET/FKUSU/2014). Written 
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informed consent (Appendix 11 to 14) was obtained from adult patients and parents or 
guardians of enrolled children.  
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Figure 4.1. Study sites in Batubara regency, North Sumatera province, Indonesia. 
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Figure 4.2. Study sites in Langkat regency, North Sumatera province, Indonesia. 
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Figure 4.3. Study sites in South Nias regency, North Sumatera province, Indonesia. 
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4.2.2 DNA extraction 
Extraction of parasite DNA from 3MM Whatman filter paper was performed using the 
Chelex-based method.320 A dried blood spot of 3 mm in diameter was punched into a well in a 
96-deep well plate. The puncher was cleaned with 70% alcohol and flamed before used for the 
next dried blood spot. One well from each row was left empty as control measure for cross 
contamination. Dried blood spots were then soaked in 1 ml of 0.5% Saponin overnight. Saponin 
was dissolved in distilled water and phosphate-buffered saline (PBS) using a magnetic stirrer. 
After centrifugation, saponin was aspirated from each well and 1 ml of PBS was added to wash 
the dried blood spots. Samples were incubated for 15 to 30 minutes. During this time, 6% 
Chelex-100 (BioRad, Richmond, CA) was prepared by adding 6 gr of Chelex-100 to 100 ml of 
water. Following aspiration of the PBS, 100 µL of 6% Chelex-100 was added into the well and 
boiled to 100 °C in water block for 10 minutes. After incubation, samples were centrifuged at 
10,000 X g for 2 minutes. The supernatant was recovered and placed into a new 96-well plate.  
 
4.2.3 Parasite species identification by rRNA gene amplification 
A nested PCR assay targeting the genes encoding Plasmodium 18S rRNA was performed 
on all samples for species determination and detection of additional submicroscopic infection 
(limit of detection of 1 parasite per µL).56, 332, 334-336 The primers for nest 1 and nest 2 
amplifications are provided in Table 4.1. Reaction mixture for nest 1 included 5 µL of DNA 
template, NH4 buffer, 2 mM MgCl2, 200 µM of deoxynucleotides (dNTPs), 250 nM of each 
primer, and 1 unit of BIOTAQ (Bioline, UK). Cycling conditions for nest 1 amplification were as 
follows: denaturation at 95 °C for 5 minutes, 25 cycles of 94 °C for 1 minute, 58 °C for 2 minutes 
and 72 °C for 2 minutes, followed by final extension of 5 minutes at 72 °C. Reaction mixture for 
nest 2 contained 1 µL of nest 1 product, NH4 buffer, 2 mM MgCl2, 200 µM of dNTPs, 250 nM of 
each primer, and 1 unit of BIOTAQ (Bioline, UK). Cycling conditions for nest 2 were as follows: 
denaturation at 95 °C for 5 minutes, 30 cycles of 94 °C for 1 minute, 58 °C for 2 minutes and 72 
°C for 2 minutes, followed by final extension of 5 minutes at 72 °C. Positive controls for P. 
falciparum, P. vivax, P. malariae, P. ovale spp. and P. knowlesi, along with no template control 
were included in all nested-PCR assays. 8 µL of PCR products from nest 2 amplifications were 
stained with ethidium bromide and analysed by gel electrophoresis. In the case of no template 
control yielding positive results, repeat on experiments was performed until negative controls 
were negative. 
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Table 4.1. Genus and species-specific primers for nested PCR malaria detection assay56, 334-336 
PCR Species  Primer Sequence Size 
(bp) 
1st Plasmodium 
genus 
Forward 
Reverse 
rPLU6 
rPLU5new 
5’- CYTGTTGTTGCCTTAAACTTC -3’ 
5’- TTAAAATTGTTGCAGTTAAAACG -3’ 
 
2nd P. falciparum Forward rFAL1 5’- TTAAACTGGTTTGGGAAAACCAAATATATT -3’ 205 
  Reverse rFAL2 5’- ACACAATGAACTCAATCATGACTACCCGTC -3’  
 P. vivax Forward rVIV1 5’-CGCTTCTAGCTTAATCCACATAACTGATAC-3’ 120 
  Reverse rVIV2 5’-ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA-3’  
 P. malariae Forward rMAL1 5’- ATAACATAGTTGTACGTTAAGAATAACCGC-3’ 144 
  Reverse rMAL2 5’- AAAATTCCCATGCATAAAAAATTATACAAA-3’  
 P. ovale  
(classic) 
Forward 
Reverse 
rOVA1 
rOVA2 
5’- ATCTCTTTTGCTATTTTTTAGTATTGGAGA-3’ 
5’- GGAAAAGGACACATTAATTGTATCCTAGTG-3’ 
800 
 P. ovale  
(classic & 
variant) 
Forward 
Reverse 
PadPo 
rOVA2_2v 
5’- CTGTTCTTTGCATTCCTTATGC-3’ 
5’- GGAAAAGGACACTATAATGTATCCTAATA-3’ 
800 
 P. knowlesi Forward Pmk8 5’- GTTAGCGAGAGCCACAAAAAAGCGAAT-3’ 153 
  Reverse Pmkr9 5’- ACTCAAAGTAACAAAATCTTCCGTA-3’  
 
4.2.4 Development of malaria detection PCR assay 
To overcome the cross-reactivity between P. vivax and P. knowlesi commonly reported 
in PCR assay targeting the 18S rRNA, we designed new molecular assay primarily for detection 
of all human malaria species targeting a region in mitochondrial cytochrome b (cytb) gene. The 
aim of this development is to confirm novel findings of other species than P. falciparum and P. 
vivax in this study. Cytb has good conservation intraspecies with sequence variation between 
species.30 Primers are provided in Table 4.2. PCR mixture for nest 1 contained 5 µl of template 
DNA, NH4 buffer, 2 mM MgCl2, 250 µM of dNTPs, 200 nM of each primer, and 1 unit of BIOTAQ 
(Bioline, UK). For the nested PCR, reaction mixture contained 1 µl of nest 1 product, NH4 buffer, 
2 mM MgCl2, 250 µM of dNTPs, 200 nM of each primer, and 1 unit of BIOTAQ (Bioline, UK). 
Nest 1 and nest 2 amplifications were run under following conditions: denaturation at 94 °C for 
3 minutes, 30 cycles of 94 °C for 30 seconds, 48 °C for 30 seconds and 72 °C for 1 minutes, 
followed by final extension of 5 minutes at 72 °C. DNA from human Plasmodium species 
including P. falciparum, P. vivax, P. malariae, P. ovale curtisi, P. ovale wallikeri, P. knowlesi and 
simian Plasmodium species including P. cynomolgi, P. coatneyi, P. inui and P. fieldi were tested 
using this assay. Standard 2% agarose gel electrophoresis stained with ethidium bromide was 
used to detect PCR products. Direct sequencing was then performed on PCR products to allow 
species identification. Geneious (version 8.0.5) and BLAST software were used to identify 
sequences. A subset of samples were tested using this assay as comparison for the findings by 
standard PCR assay targeting 18S rRNA. 
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Table 4.2. Nest 1 and nest 2 primers for cytochrome b PCR amplification30 
PCR  Primer Sequence Size 
(bp) 
1st Forward PgCytbF1 5’- GAATTATG GAGTGGATGGTG-3  
 Reverse PgCytbR1 5’- CATCCAATCCATAATAAAGC-3’  
2nd Forward 
Reverse 
PgCytbF1 
PgCytbR2 
5’- GAATTATG GAGTGGATGGTG-3 
5’-TTTTAACATTGCATAAAATGG-3’ 
618 
 
4.2.5 Development and validation of a novel highly specific P. knowlesi PCR 
assay 
To further validate our findings on P. knowlesi isolates, we further designed a new set 
of primers for a hemi-nested PCR assay based on a conserved region in the gene-family 
encoding the P. knowlesi-specific schizont-infected cell agglutination variant antigens (sicavar). 
The primers used for nest 1 and nest 2 are described in Table 4.3. These newly developed 
primers generated final amplicons of 228-249 base pairs, encoding 76 – 83 amino acids. 
Reaction mixture for nest 1 amplification contained 5 µL of DNA template, NH4 buffer, 2 mM 
MgCl2, 200 µM of deoxynucleotides (dNTPs), 200 nM of each primer, and 1 unit of BIOTAQ 
(Bioline, UK). Amplifications for nest 1 was performed under the following conditions: 
denaturation at 95 °C for 3 minutes, 30 cycles of 94 °C for 30 seconds, 55 °C for 30 seconds and 
65 °C for 1 minutes, followed by final extension of 5 minutes at 65 °C. 0.2 µL of nest 1 product 
was used as a template for the 25 µL reaction mixture of the nest 2 PCR containing NH4 buffer, 
2 mM MgCl2, 200 µM of deoxynucleotides (dNTPs), 200 nM of each primer, and 1 unit of 
BIOTAQ (Bioline, UK). Cycling conditions for nest 2 amplifications were similar to nest 1 
amplifications. 
All Plasmodium species used to validate the sicavar assay was tested using cytb PCR 
assay to confirm the presence of DNA. The sicavar assay was then tested against all human 
malaria parasites (P. falciparum, P. vivax, P. malariae, P. ovale curtisi and P. ovale wallikeri 
obtained from Malaria Reference Lab and P. falciparum culture parasites at LSHTM), simian 
malaria parasites (P. knowlesi, P. inui, P. cynomolgi, P. coatneyi and P. fieldi), clinical P. knowlesi 
isolates obtained from Kapit of Malaysian Borneo and human DNA to assess its specificity. We 
also determined the limit of detection by using P. knowlesi culture of known parasitaemia which 
was serially diluted in whole human blood and spotted on filter paper to mimic a variety of 
parasitaemia obtained from field isolates. Initially, 2% parasitaemia was prepared in 50% 
haematocrit and then diluted accordingly. A total of 40 µL of blood from the series of dilution 
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was then spotted on filter papers. DNA from these blood spots were extracted with a 
QIAsymphony automated DNA extraction system resulted in a final volume of 100 µL of DNA, 
and a total of 5 µL of DNA was used in the experiments. All field isolates were tested for P. 
knowlesi infection using this novel PCR assay. DNA from a subset of positive samples by sicavar 
were validated by direct sequencing using BigDye Terminator v3.1 cycle sequencing kits and 
analysis on an ABI 3730 Sequencer (Applied Biosystems). Results were aligned and compared 
to P. knowlesi H strain reference using Geneious (version 8.0.5) and BLAST (Basic Local 
Alignment Search Tool) software. 
 
Table 4.3. Nest 1 and nest 2 primers for sicavar PCR amplification 
PCR  Primer Sequence Size (bp) 
1st Forward SICAf1 5’-GGTCCTCTTGGTAAAGGAGG-3  
 Reverse SICAr1 5’- CCCTTTTTGACATTCGTCC-3’  
2nd Forward SICAf2 5’-CTTGGTAAAGGAGGACCACG-3’ 228-249 
 Reverse SICAr1 5’- CCCTTTTTGACATTCGTCC-3’  
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4.3 Results 
4.3.1 Validation of cytb assay for malaria detection   
The cytb assay amplified DNA from all human and simian malaria parasites. The 
products of cytb test were sequenced to identify and differentiate Plasmodium species. BLAST 
software was used for species confirmation. Sequences of each species are shown in Figure 
4.4. After confirmation of malaria detection using this assay, we tested 11 of our field isolates 
for comparison with the standard PCR assay for malaria diagnosis (Table 4.4.). Cytb gave 
positive amplifications in all 18S rRNA-positive isolates, but it was only able to identify one of 
the species present in multiple infections, giving unconvincing diagnosis of mixed P. vivax and 
P. knowlesi cases. Interestingly, this test identified 2 additional positive cases missed by the 
standard PCR test. However, the limited performance of cytb to identify multiple species in a 
single sample led to the development of novel specific assay for detection of P. knowlesi. We 
designed new primers with a target gene of sicavar, specific only for P. knowlesi. We then used 
cytb assay to confirm the presence of Plasmodium species for the validation of sicavar assay. 
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Figure 4.4. Sequences of a portion of cytochrome b gene in human and simian Plasmodium species.  
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Table 4.4. Comparison of microscopy and various PCR assays for malaria diagnosis in 11 
Plasmodium infected individuals from Batubara 
ID Microscopy 
PCR assays* 
18S rRNA Cytb SICAvar 
BB20001 P. falciparum P. falciparum P. falciparum P. knowlesi 
BB20002 P. vivax P. falciparum, P. vivax, P. 
knowlesi 
P. vivax Negative 
BB20003 Negative P. vivax P. vivax Negative 
BB20004 Negative Negative P. vivax Negative 
BB20005 P. vivax P. vivax, P. knowlesi P. vivax Negative 
BB20008 Negative Negative P. vivax Negative 
BB20010 P. vivax P. vivax P. vivax Negative 
BB20011 P. falciparum, 
P. vivax 
P. vivax, P. knowlesi P. vivax Negative 
BB20012 P. vivax P. vivax P. vivax Negative 
BB20013 P. falciparum, 
P. vivax 
P. vivax, P. malariae, P. 
knowlesi 
P. vivax Negative 
BB20019 Negative P. vivax P. vivax Negative 
*For details of PCR assays see Section 4.2. 
 
4.3.2 Sicavar assay for P. knowlesi-specific identification 
The novel sicavar assay was found to be specific for P. knowlesi and did not amplify 
other Plasmodium species other than P. knowlesi (Figure 4.5.). After confirmation of the 
sicavar assay, we determined the limit of detection using a series of dilution of P. knowlesi 
DNA extracted from dried blood spots to mimic samples collected in the field. The limit of 
detection was estimated as 0.1 parasite per µL of whole blood (Figure 4.6.). 
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Figure 4.5. Validation of P. knowlesi primers targeting sicavar against human and simian malaria parasites reported from Southeast Asia. Control DNA of human malaria 
Plasmodium species were from imported cases in the United Kingdom (courtesy of the Public Health England Malaria Reference laboratory); 2 isolates each 
are shown for P. falciparum, P. vivax and P. malariae. P. knowlesi DNA were obtained from clinical P. knowlesi patients from Kapit of Malaysian Borneo. 
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Figure 4.6. Limit of detection of sicavar test against series of dilution of P. knowlesi DNA. Each DNA sample was tested in triplicates. DNA was obtained from P. knowlesi 
H strain adapted in human blood, DNA was serially diluted in whole human blood and spotted on filter paper. QIAsymphony automated extraction system 
was used to extract DNA from filter papers.
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The sicavar targeted primers detected 377 P. knowlesi cases, whereas the standard 
assay targeting 18S rRNA identified only 76 P. knowlesi cases, revealing a significantly higher 
sensitivity compared to the standard assay. Using the two tests, a total of 443 cases were 
detected but only 10 cases (2.3%) had a positive result in both assays (Table 4.5.). With the 
sicavar results as the definitive diagnosis for P. knowlesi, our findings suggested that 66 
individuals positive by rRNA nested PCR alone had cross-reactivity with P. vivax DNA. Nearly 
half of all sicavar -positive P. knowlesi infections were also rRNA amplicon positive for > 1 other 
species, and P. vivax being the most common co-infection.  
To further confirm our results, we directly sequenced products from 7 P. knowlesi 
isolates detected by SICAvar. The sequences showed high variability (Figure 4.7.), and 2 of the 
7 sequences harbored an insert encoding an additional 7 amino acids which was used to probe 
the current P. knowlesi reference genome (http://www.sanger.ac.uk/resources/down-
loads/protozoa/plasmodium-knowlesi.html). 
 
Table 4.5. Comparison of sicavar assay and standard rRNA assay for P. knowlesi case detection 
Infection detected Cases, No. (%) 
18S rRNA assay SICAvar assay Any assay Both assays 
Total P. knowlesi cases 76 (100) 377 (100) 443 (100) 10 (100) 
P. knowlesi monoinfection 42 (55.3) 215 (57.0) 254 (57.3) 3 (30) 
P. knowlesi plus P. vivax 16 (21.1) 65 (17.2) 77 (17.4) 4 (40) 
P. knowlesi plus other  
   Plasmodium spp.  
   infections 
18 (23.7) 97 (25.7) 112 (25.3) 3 (30) 
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BB20002  TCAGTACAGGAACAACTCCTCGATCATGTGGATGAAGGTGCTTCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACAAAACGTTCTGGTCGCGATCCTGCTGGTGGTGGTCGCGTGAAT 
NS14046  TCAGTACAGGAACAACTCCTCGATCATGTGGATGAAGGTGCTTCACATGAATATCGATTAGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACGAAACGTTCTGGTCGCGATCCTGCTGGCGGTGGCCGCGTAAAT 
BB12001  TCAGTACAAGAACAAGTCCTCGGTCATGTGGATGAAGGTGCTGCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGTTCCAACGAGAACAAAACGTTCTGGT---------------------CCCGTGAAT 
LK01077  TCAGTACAGGAACAACTCCTCGATCATGTGGAAGAAGCTGGTCCACATGAATATCGATTGGTGAAGGAACGAAAACCTCGTTCTGTTCCAGCGAGAACGAAACGTTCTGGT---------------------CCCGTGAAT 
LK01037  TCGGTACAGGAACAAGTCCTTGATCATGTGCAACAAGATGGTTCACATGAATATCAATTGGTGAAAGAACGAAAACCTCCATCTGCTCCAACGAGAACAAAACGTTCTGGT---------------------CGCGTGAAT 
BB06012  TCGATACAGGAACAAGTCCTCGATCATGTGCAGCCAGATAGTTCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACGAAACGTTCTGGT---------------------TCCGTGAAT 
BB02019  TCCGTACAAGAACAAGTCCTTGATCATGTGCAGCAAGATGGTCCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACGAAACGTTCTGGT---------------------CCCGTGAAT 
NS14039  TCAGTACAGGAACAAGTCCTCGATCATGTGCAACAAGATAGTTCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACGAAACGTTCTGGT---------------------CCCGTGAAT 
 
0932000  TCAGTACAGGAACAACTCCTCGATCATGTGGATGAAGGTGCTTCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACAAAACGTTCTGGTCGCGATCCTGCTGGTGGTGGTCGCGTGAAT   
0118500  TCAGTACAGGAACAAGTCCTCGATCATGTGCAGCAAGATAGTTCACATGAATATCAATTGGTGAAGGAACGAAAACCTCGTTCTGCTCCAACGAGAACGAAACGTTCTGGT---------------------CGCGTGAAT  
 
 
Figure 4.7. Sequence alignment of representative 120 and 141 nucleotide sequences of sicavar amplicons from the peripheral blood DNA of four participants from 
Batubara (BB), and two each from Langkat (LK) and South Nias (NS). Amplicons were produced by hemi-nested PCR as described in Materials and Methods. 
Representative amplification products were chosen for this sample, and sequenced directly using amplification primers to prime forward and reverse 
sequencing reactions. Sequences shown were confirmed in both directions. Two loci from the P. knowlesi H strain reference genome (0932000, 0118500) 
are shown for comparison. Double-peaking was seen in most samples – only the peak with highest amplitude was read for this analysis.
INKE LUBIS                                        MALARIA EPIDEMIOLOGY IN NORTH SUMATERA 128 
Following this validation, we estimated the contribution of each species to malaria 
infection in each study sites. To our surprise, we found P. falciparum, P. vivax, P. malariae and 
P. knowlesi to be co-endemic in all the three study sites. P. falciparum and/or P. vivax are the 
most abundant species in Langkat and South Nias, as expected. While in Batubara, P. knowlesi 
was the most prevalent (Figure 4.8.).  
 
4.3.3 Parasite carriage 
A total of 3731 individuals from Batubara (n=1270), Langkat (n=544), and South Nias 
(n=1917) were included in the malaria screening. At each regency, 117 (9.2%), 98 (18.0%) and 
397 (21.3%) were positive for Plasmodium infections by microscopy examination. Three species 
(P. falciparum, P. vivax and P. malariae) were identified. However, the numbers of confirmed 
malaria infections decreased with the failure by PCR tests to amplify DNA from stored blood 
spots from individuals deemed positive by microscopy in the field. Thus, the total numbers of 
malaria positive cases became 93 (8.1%), 74 (13.6%) and 169 (9.1%). Poor specificity of 
microscopy was particularly observed in South Nias (Table 4.6.) Nevertheless, the successful 
detection of submicroscopic infection meant PCR-confirmed parasite carriage was estimated 
as 25.2%, 33.5% and 35.3% of all tested individuals (Table 4.7.). All Plasmodium species with 
the exception of P. ovale spp. were detected by a combination of the rRNA gene and sicavar 
PCR assays. 
 
Table 4.6. Odds ratio for PCR negative microscopy positive results according to study sites and 
parasite density 
 Odds Ratio 95% Confidence Interval P Value 
Study Site    
   Batubara Reference   
   Langkat 1.16 0.90 – 1.50 0.24 
   South Nias 1.62 1.36 – 1.93 0.001 
Parasite density (p/µL)    
   < 100 Reference   
   101 – 250 1   
   251 – 500 0.95 0.13 – 6.83 0.96 
   501 – 1000 1.29 0.12 – 14.53 0.84 
   > 1000 1   
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Figure 4.8.  Proportion of Plasmodium species and multiplicity of infections by regency. Numbers on the left of the bar represent the numbers of individual tested, and 
numbers above the bar represent the total numbers of positive cases. Abbreviation: Pf=P. falciparum, Pv=P. vivax, Pm=P. malariae, Pk=P. knowlesi. 
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Table 4.7. Submicroscopic infections in 1169 participants with positive PCR results for 
Plasmodium spp. 
Infection type 
Participants, No. (%) 
All PCR* positive 
PCR* positive and microscopy 
negative 
All Plasmodium infections 1169 (31.3) 833 (71.3) 
Plasmodium falciparum 247 (6.6) 165 (14.1) 
Plasmodium vivax 335 (8.9) 227 (19.4) 
Plasmodium malariae 40 (1.1) 35 (2.9) 
Plasmodium knowlesi 254 (6.8) 220 (18.8) 
Mixed infections 293 (7.9) 186 (15.9) 
No. of species by PCR 
   1 
   2 
   3 
   4 
 
876 (74.9) 
256 (21.9) 
35 (2.9) 
2 (0.2) 
 
647 (77.7) 
163 (19.6) 
21 (2.5) 
2 (0.2) 
PCR positive by regency 
   Batubara 
   Langkat 
   South Nias 
 
320/1270 (25.2) 
182/544 (33.5) 
667/1917 (34.8) 
 
227/320 (70.9) 
108/182 (59.3) 
498/667 (74.7) 
*For details of PCR assays see Section 4.2. 
 
With the increased numbers of infection detected by molecular tests, we found that 
living in South Nias increased the risk of infection to P. vivax (OR 1.49, 95% CI 1.23-.179, 
P=0.001), P. malariae (OR 5.05, 95% CI 3.12-8.52, P=0.001), and P. knowlesi (OR 1.43, 95% CI 
1.17-1.76, P=0.001). While risk of acquiring P. falciparum infection only increased in residents 
of Langkat (OR 1.81, 95% CI 1.39-2.35, P=0.001). We found there was no increased risk of 
infection with age. Our particular interest was the increased risk of P. knowlesi, as to our 
knowledge this is the first study outside Malaysian Borneo to report a high burden of P. 
knowlesi infection in humans. Thus, we tried to map geographically the contribution of this 
species at the village-level (Table 4.8). In this effort, we decided to focus on Batubara regency 
due to less population movement in this area (Figure 4.9.A.). We found that incidence of P. 
knowlesi infections among individuals residing in urban areas (Figure 4.9.C) was similar to those 
living in the rural settlements (Figure 4.9.B) 
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Table 4.8.  Proportion of P. knowlesi infection among all tested individuals according to sampling 
sites in Batubara regency 
Site ID District Site Proportion of P. knowlesi, n (%) 
1 Lima Puluh Puskesmas Kedai Sianam 5/19 (26.3) 
2  Guntung 12/159 (7.5) 
3  Dusun 1 Perupuk 8/80 (9.1) 
4  Balai Desa Titi Putih 5/39 (11.4) 
5  Titi Putih 2/77 (2.5) 
6  Perupuk 18/153 (10.5) 
7  Pasir Permit 0/8 (0) 
8  SMPN 4 Lima Puluh 2/51 (3.8) 
9  SDN 016517 Guntung 6/38 (13.6) 
10 Talawi Indrayaman 6/29 (20.7) 
11  Puskesmas Labuhan Ruku 2/21 (9.5) 
12  Dahari Selebar 13/175 (7.4) 
13  Mesjid Lama 0/11 (0) 
14 Tanjung Tiram Puskesmas Tanjung Tiram 47/192 (24.5) 
15  Bagan Dalam 4/31 (12.9) 
16  Sentang 3/24 (12.5) 
17  Posko Tanjung Tiram 10/47 (21.3) 
18  Pustu Bagan Baru 0/10 (0) 
19  Tali Air 1/14 (7.1) 
20  Puskesmas Ujung Kubu 3/27 (11.1) 
21 Medang Deras Pagurawan 0/1 (0) 
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Figure 4.9. (A) Sampling sites in Batubara regency; (B) Proportion of P. knowlesi infection among tested individuals according to sampling sites in Lima Puluh and 
Talawi sub-districts; (C) Proportion of P. knowlesi infection among tested individuals according to sampling sites in Tanjung Tiram sub-district. 
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4.3.4 Carriage of submicroscopic infection 
PCR analysis of 1169 infected individuals revealed the vast majority of the infections 
(71.3%) were submicroscopic (Table 4.7.). Among these submicroscopic infections, 77.7% 
(647 of 833) were single infection predominated by P. vivax (27.3%, n=227) and P. knowlesi 
(26.4%, n=220) (Table 4.7.). We found adults to be more likely to carry submicroscopic 
infection compared to older children (OR 1.81, 95% CI: 1.38-2.38) and younger children (OR 
1.75, 95% CI: 1.15-2.64). While mean age of individuals with patent infection was 18.0 years 
(95% CI, 16.2 – 19.7 years; P<0.001, 2-sided t-test). Submicroscopic cases were also more likely 
to occur in Batubara (OR 1.67, 95% CI: 1.14 – 2.45) and South Nias (OR 2.02, 95% CI: 1.43-
2.85) than in Langkat. However, infection with multiple species was not significantly 
associated with increased age among malaria positive individuals (P=0.66, 2-sided t test). 
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Table 4.9. Detection of Plasmodium species by microscopy and nested PCR* 
 
Microscopy Detection by Nested PCR 
 
 
Pf Pv Pm Pk Pf  
Pv 
Pf 
Pm 
Pf  
Pk 
Pf  
Pv 
Pm 
Pf  
Pv 
Pk 
Pf 
Pm 
Pk 
Pf 
Pv 
Pm 
Pk 
Pv 
Pm 
Pv 
Pk 
Pv 
Pm 
Pk 
Pm 
Pk 
Neg Total 
B
at
u
b
ar
a 
R
eg
en
cy
 
Pf 18 - - - 3 - 5 - - - - - - - - 8 34 
Pv 1 37 - 4 3 - - - 3 - - - 11 - - 15 74 
Pf Pv 1 3 - - 2 - - - - - - - 1 1 - 1 9 
Pm - - - - - - - - - - - - - - - - - 
Neg 34 53 10 110 4 - 5 - - - - 3 7 - 1 926 1153  
Total 54 93 10 114 12 - 10 - 3 - - 3 19 1 1 950 1270 
La
ng
ka
t 
R
eg
en
cy
 
Pf 18 3 - 3 2 - - - - - - - - - - 15 41 
Pv 3 24 - 1 5 - - - - - - - 5 - - 7 45 
Pf Pv 4 1 - - 1 - - - - - - - 3 - - 2 11 
Pm - - 1 - - - - - - - - - - - - - 1 
Neg 45 34 2 16 5 2 1 - 1 - - - 1 - 1 338 446 
Total 70 62 3 20 13 2 1 - 1 - - - 9 - 1 362 544 
So
u
th
 N
ia
s 
R
eg
en
cy
 
Pf 26 22 3 18 7 2 14 1 1 2 - 2 12 2 2 154 268 
Pv 8 16 - 7 2 1 1 - 2 - - 1 1 1 1 64 105 
Pf Pv 3 2 1 1 2 - - - - 1 - 2 2 - - 12 26 
Pm - - - - - - - - - - - - - - - - - 
Neg 86 140 23 94 25 4 26 - 8 3 2 25 34 9 19 1020 1518 
Total 123 180 27 120 36 7 41 1 11 6 2 30 49 12 22 1250 1917 
 
Pf=P. falciparum, Pv=P.vivax, Pm=P.malariae, Pk=P.knowlesi 
*Nested PCR targeting the 18 ssu rRNA gene (plus sicavar gene for P.knowlesi infection) 
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Table 4.10. Age and sex of participants with positive PCR results for Plasmodium spp. 
Age and sex by Plasmodium species PCR positive, No. (%) 
Parasite carriage by age group, y  
   P. falciparum 
       <5 
       5-14 
       >15 
 
24 (9.7) 
91 (36.8) 
132 (53.4) 
   P. vivax 
       <5 
       5-14 
       >15 
 
41 (12.2) 
143 (42.7) 
151 (45.1) 
   P. malariae 
       <5 
       5-14 
       >15 
 
4 (10.0) 
18 (45.0) 
18 (45.0) 
   P. knowlesi 
       <5 
       5-14 
       >15 
 
28 (11.0) 
96 (37.8) 
130 (51.2) 
Parasite carriage among female participants 
     P. falciparum 
     P. vivax 
     P. malariae 
     P. knowlesi 
 
137 (55.5) 
171 (51.0) 
15 (37.5) 
129 (50.8) 
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4.4 Discussion 
In this study, we reported contribution of malaria infections in 3 regencies in North 
Sumatera province. This study combined microscopy and PCR for detection of Plasmodium 
parasites among febrile and nonfebrile residents. PCR identified 1169 individuals harboring 
Plasmodium species, much higher compared to 612 cases identified by microscopy. P. 
falciparum and P. vivax are the two major contributors for malaria infection as reported in 
regional malaria reports.312 However, using molecular tests we detected 4 species to be 
circulating: P. falciparum, P. vivax, P. malariae and P. knowlesi.  
In Indonesia, the national malaria control programmes focus on case management 
through passive surveillance at primary health centres, deploying microscopy or RDTs to 
detect malaria cases to be treated.102 Microscopy is the gold standard to measure parasite 
infection and often used as the point-of care diagnostic.337 However, the quality of 
examination depends highly on the microscope, staining reagents and the skills of the 
technician.338 When performed by an experienced microscopist, the limit of detection is 
around 50 parasites per microliter and sensitivity and specificity of 95% and 98% can be 
achieved.338 In our study, microscopy identified many Plasmodium spp. infections but lacked 
accuracy in distinguishing among the 4 species, as previously reported in Malaysia.339 Although 
personnel differed between sites, identification of non-major species was still problematic in 
all sites. Microscopy only identified 1 case of P. malariae, while P. knowlesi was left 
unrecognized. Poor specificity of microscopy was particularly common in South Nias, leading 
to a number of false-positives, whereas specificity was better at the other two sites. Samples 
collection in South Nias involved sea journeys therefore transfer of samples and storage 
conditions were not optimal and might have resulted in a loss of PCR sensitivity.340 
Innovation of RDTs has also advanced the methods for malaria diagnosis and provides 
new techniques for detection of uncomplicated symptomatic malaria and severe malaria.341 
These tests have detection limit ranging from 100 to 200 parasites per microliter337, and are 
based on P. falciparum histidine-rich protein 2 and/or Plasmodium parasite lactate 
dehydrogenase (pLDH) monoclonal antibodies.328 Thus, these tests are limited for detection 
of P. falciparum and P. vivax only, although high sensitivity of pLDH-based RDTs has been 
reported in severe cases caused by P. knowlesi, these tests have limited capacity for 
distinguishing the non-falciparum species.328, 341 In this study, only 28.7% of the infections 
detected by PCR were also identified by either one or both of the conventional tests, 
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suggesting the presence of many subpatent and asymptomatic infections. Therefore, both 
conventional methods were satisfactory for detection of symptomatic cases requiring 
treatment, but provide limited sensitivity to detect submicroscopic infections. Because these 
submicroscopic Plasmodium carriage is associated with subsequent transmission to 
mosquitoes, these tests therefore are not adequate tools for malaria elimination and control 
activities.196 
Molecular tests are highly sensitive and specific, and provide a greater sensitivity to 
detect low density infections missed by microscopy or RDT. Molecular techniques for 
detection of human malaria infections are well established342, however the current test used 
to identify P. knowlesi infection is not yet optimal due to cross-amplification of P. vivax with 
ribosomal gene PCR.56, 333 In this study, we initially developed a PCR-sequencing approach to 
detect human malaria infection aiming for confirmation of P. knowlesi cytb DNA. This test 
provides us with satisfactory sensitivity.30 But, in Indonesia where mixed infections are 
frequent, this test is limited with the capacity to only detect one species. In order to meet this 
challenge we developed a novel assay targeting sicavar gene, which gives a greater sensitivity 
for P. knowlesi identification and detected an unexpectedly large number of P. knowlesi 
infection in our study. Sicavar genes encode an antigen family unique to P. knowlesi with 
estimated > 100 members, including both multiexon and truncated forms, randomly 
distributed across all 14 chromosomes.343 Sicavar proteins undergo antigenic variation in the 
course of single infection344, 345 and are likely to play a key role in maintaining chronic 
parasitaemia in semi-immune hosts. Sequencing of a handful of sicavar amplicons from our 
samples confirmed nucleotide diversity in our short target sequence, double peaking 
indicative of multiple loci being amplified in some cases, and distinguished a variant form with 
a 7-amino acid insert. Probing the P. knowlesi reference genome with these 2 forms generated 
many hits with both length variants, including both types 1 and 2. Therefore, despite moderate 
numbers of P. knowlesi coinfections with P. vivax in the present study, we can confidently 
report our assay is performing as hoped and is a useful tool for identifying P. knowlesi 
infections among complex mixtures of Plasmodium species. 
P. knowlesi infection has been widely recorded in Southeast Asian countries, but the 
largest number of cases were reported from Malaysian Borneo.325 In Indonesia, it was initially 
reported in a handful of cases among gold miners in Kalimantan, eastern Borneo.21, 226 More 
recently, more cases were identified in Aceh province, on the northwest of Sumatera.28 This 
latter study used loop-mediated isothermal amplification (LAMP) in a passive and reactive 
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case detection to detect malaria cases and identified a total of 20 P. knowlesi,, 15 P. vivax, and 
8 P. falciparum among 1532 tested individuals, mostly symptomatic.28 This contrasts to our 
findings of higher parasite burden in the population, and of a significant proportion of 
subpatent and asymptomatic infections, suggesting inter-province differences. 
Aceh is a neighboring province of North Sumatera, however has much lower malaria 
transmission intensity and is aimed for the elimination goal by 2015.88 This pattern however 
is similar to those found in Malaysian Borneo where Plasmodium species other than P. 
knowlesi have decreased and P. knowlesi is now the most common infecting species.55, 325 In 
North Sumatera, P. falciparum and P. vivax are still widely distributed, as shown in our data. 
Thus, acquired immunity to these human parasites may protect individuals subsequently 
infected with P. knowlesi346, although asymptomatic infections have also been reported in 
Sabah Malaysia.326 North Sumatera’s natural forests have been affected by deforestation in 
the last few years. Residents of rural districts may live in close proximity to semiforested, 
forested and plantation areas, with a high likelihood of forest exposure, but may not have 
adequate access to health facilities and antimalarial medication. Our data shows that there is 
no difference in P. knowlesi incidence between sampling sites in Batubara. 
Despite the aim to achieve malaria elimination by 2020 in Sumatera, our findings 
demonstrate that our study sites still pose the risk of malaria infection to humans especially 
in South Nias. P. falciparum still contributes to one-fifth of all malaria cases, while P. vivax is 
slightly more prevalent. Interestingly, our findings also demonstrate a substantial number of 
P. knowlesi infections suggesting that P. knowlesi was just as common as the other two main 
Plasmodium species. Macaques were present at all sites, and communities shared established 
risk factors for malaria transmission. Many P. knowlesi infected individuals carried multiple 
Plasmodium infections, in contrast to areas in Malaysian Borneo where P. falciparum and P. 
vivax are now very scarce.325, 326 Nevertheless, sampling was not done appropriately to assess 
transmission intensity (lack of randomisation strategies and limited records of febrile status in 
tested individuals), therefore our results do not represent the true prevalence of each malaria 
species but to show the distribution of four Plasmodium species in North Sumatera. Multiple-
species infections in our study were equally distributed across all age groups with both female 
and male subjects exposed to a similar risk of infection, whereas submicroscopic infections 
were more common in older individuals, suggesting a role for acquired immunity.346 The 
observation of asymptomatic P. knowlesi infections in our study is consistent with recent 
findings in Malaysia326 but does not necessarily support the occurrence of human-mosquito 
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transmission of P. knowlesi. Our data also suggest cross-protection among the 4 human 
Plasmodium species that maintain overall parasite density at low levels.346 
Our study demonstrated the presence of 4 Plasmodium species in North Sumatera 
including P. knowlesi. The latter species is widely circulating in all three study sites, and 
contributes to this in a high proportion as submicroscopic infections. There is a need to 
investigate human risk to this infection, and for the national malaria programmes to include 
in malaria guidelines the recommendation that microscopist are trained to identify P. knowlesi 
infections in Indonesian clinics. Molecular detection of infection is also needed, to strengthen 
control and elimination programmes by accurately defining the true extent of the malaria 
reservoir, so as to achieve the current goal of elimination by 2020.85 
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5  RESULTS        
Markers of antimalarial drug resistance in 
Plasmodium falciparum parasites  
in North Sumatera 
 
5.1 Introduction 
 Successful malaria elimination strategies depend heavily on the effectiveness of the 
first-line antimalarials drugs. Failures with previously recommended therapies; chloroquine 
and sulfadoxine-pyrimethamine, had compromised malaria control strategies in many malaria 
endemic countries and contributed to a significant increase in morbidity and mortality.160 
Today, artemisinin combination therapies (ACTs) are the mainstay of treatment for 
uncomplicated Plasmodium falciparum infection, relying on the combination of fast-acting 
artemisinin and long protection by its partner drug to delay the development of resistance to 
this combination.347 Nevertheless, artemisinin resistance, characterised by slow parasite 
clearance has been reported in Cambodia, Thailand, Vietnam, Myanmar, Laos and China.120, 
203, 252-259 These artemisinin-resistant parasites have been postulated to facilitate the 
development of resistance to the partner drugs leading to a substantial decreased of ACT 
efficacy.118, 348 
 The progression to clinical resistance or the spread of resistance parasites may be 
prevented by the implementation of regular monitoring on drug resistance markers of P. 
falciparum parasites. Resistance to aminoquinolines is known to be mediated by the putative 
transporter pfcrt 269, with mutation at codon 76T is associated with resistance to chloroquine 
and amodiaquine.349 However, the degree of resistance to these drugs is modulated by 
additional mutations from other genes including the gene encoding P-glycoprotein H1, 
pfmdr1. Mutation of N86Y of pfmdr1 has been associated with greater resistance to 
chloroquine and amodiaquine, but in contrast linked to an increased sensitivity to artemisinin, 
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lumefantrine and mefloquine.273, 350 Furthermore, some polymorphisms in the P. falciparum 
K13-propeller domain have also been associated with slow-clearing infections and become 
the marker for artemisinin resistance.268 Resistance markers for partner drugs of ACT such as 
piperaquine have also been established, with amplifications in plasmepsin gene 2-3 copy 
numbers and reduced copy numbers in pfmdr1 were shown to be associated with reduced 
susceptibility to this drug.295, 351 Given the availability of these molecular markers today, the 
use of these tools in epidemiological studies is essential for monitoring antimalarial sensitivity 
and more importantly allowing real-time measurement of the parasite genetic changes before 
treatment starts failing. 
 ACT has been used in Indonesia since 2004 after failures using the previous first-line 
antimalarial, chloroquine. Artesunate-amodiaquine (ASAQ) was initially deployed, but in 2007 
two ACTs were recommended, ASAQ continued to be used for western Indonesia and 
dihydroartemisinin-piperaquine (DP) was deployed for eastern Indonesia.86 However, 
treatment failures with ASAQ were frequently documented which led to another drug policy 
change in 2012 to the wide deployment of DHP across the country. In vivo studies using  ASAQ 
for falciparum malaria demonstrated poor clinical efficacies in Central Java, Papua and 
Sumatera171, 176-178, with one study showed PCR-corrected efficacy as low as 80% even prior to 
the adoption of ASAQ to the national recommendation.171 The lack of information on parasite 
polymorphisms in these studies nevertheless hindered the efforts to design the accurate 
strategy for alternative treatment. Of great concern is that artemisinin-mutant parasites are 
now spreading across Southeast Asia, and with the history of less responsive to previous ACT 
treatment in this region, there is an urgent need to further investigate the genetic resistance 
of P. falciparum parasites in western Indonesia. 
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5.2 Methods 
5.2.1 Study sites and samples collection 
Samples were from a parasitological survey in Batubara, Langkat and South Nias 
regency in North Sumatera province, collected between January and June 2015. Description 
of the study sites and methods for sampling are described in details in Chapter 3 and 4. A total 
of 3731 participants were screened for P. falciparum infection by microscopy and nested 
polymerase chain reaction (PCR). Individuals with Plasmodium parasites identified by 
microscopy were treated with the standard 3-dose regimen of dihydroartemisinin-
piperaquine (DP) or 6-dose regimen of artemether-lumefantrine (AL) plus primaquine, given 
according to their body weight. The study was approved by the ethics committee of the 
London School of Hygiene and Tropical Medicine (London, United Kingdom; 8504-01) and the 
ethics committee of the University of Sumatera Utara (Medan, Indonesia; 401/KOMET/FK 
USU/2014). Written informed consent (Appendix 11 to 14) was obtained from adult patients 
and parents or guardians of enrolled children. 
 
5.2.2 Characterisation of parasite polymorphisms 
Parasite DNA was isolated from dried blood spots using the Chelex-based method.320 
All samples were screened by nested PCR assays targeting the 18S ribosomal RNA (rRNA) and 
pfmdr1 gene.273, 332 P. falciparum isolates detected by polymerase chain reaction (PCR) were 
subsequently genotyped for all loci of interest in the pfcrt gene, pfmdr1 gene and pfk13 
propeller domain.  
Polymorphisms in the pfcrt gene, encoding the P. falciparum chloroquine resistance 
transporter, were determined using multiplex qualitative PCR (qPCR) Rotor-gene® Q 
thermocycler (Corbett Research, Australia) to detect the most common haplotypes at codons 
72 to 76, as previously described.270, 352 Samples were initially run in nest 1 PCR to enable 
detection of low density parasites. Reaction mixture for nest 1 contained 5 µL of DNA 
template, NH4 buffer, 2 mM MgCl2, 200 µM of deoxynucleotides (dNTPs), 400 nM of each 
forward and reverse primer (Table 5.1.) and 1 unit of BIOTAQ (Bioline UK). PCR was performed 
with an initial denaturation step at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 30 
seconds, 56 °C for 30 seconds, 62 °C for 1 minute, and final extension of 62 °C for 5 minutes. 
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Nest 1 product were subsequently used as template for qPCR for pfcrt genotype identification. 
Double-labelled probes designated for haplotypes CVMNK, CVIET and SVMNT with a reported 
dye at the 5’ end and a quencher moiety at the 3’ end were used (Table 5.1.). The wild-type 
pfcrt haplotype encoding CVMNK at codons 72-76, and the mutant haplotypes encoding 
variants of pfcrt, CVIET and SVMNT.270 Primer sets used in this assay are provided in Table 5.1. 
Reaction mixture for this qPCR assay contained 5 µL of nest 1 product, NH4 reaction buffer, 
5.5 mM MgCl2, 600 µM of dNTPs, 600 nM of each primer, 200 nM of each probe and 1 unit of 
BIOTAQ (Bioline, UK). Cycling conditions were as follows: denaturation at 95 °C for 6 minutes, 
45 cycles of 95 °C for 15 seconds, 55 °C for 1 minute. DNA from 3D7, Dd2 and 7G8 clones were 
used to represent pfcrt haplotypes CVMNK, CVIET and SVMNT, respectively. A single reaction 
was prepared for each field isolate for qualitative measurement. Thresholds for each probe 
were set manually using the positive and negative controls. Genotypes of each sample were 
determined according to which of the reported dye signals accumulated.  
 
Table 5.1. Primers and probes for pfcrt genotyping269, 270 
Assay Primer 5’ 
Fluorophore 
Sequence 3’ 
Quencher 
PCR Nest 1 P1  5'-CCG TTA ATA ATA AAT ACA CGC AG-3'     
 P2  5'-CGG ATG TTA CAA AAC TAT AGT TAC C-3'  
qPCR D1  5’-TGT GCT CAT GTG TTT AAA CTT-3’  
 D2  5'-CAA AAC TAT AGT TAC CAA TTT TG-3'     
 Crt76_CVMNK  FAM 5’-TGT GTA ATG AAT AAA ATT TTT GCT AA-3’ BHQ1 
 Crt76_CVIET JOE 5’-TGT GTA ATT GAA ACA ATT TTT GCT AA-3’ BHQ1 
 Crt76_SVMNT ROX 5’-AGT GTA ATG AAT ACA ATT TTT GCT AA-3’ BHQ2 
 
 Polymorphisms in the loci of interest of pfmdr1 gene were identified by direct 
sequencing of PCR products, as described.273 PCR amplifications and direct sequencing were 
performed on four different fragments of pfmdr1 encompassing codons of interest 86 and 
184 (fragment 1), codons 1034, 1042 and 1246 (fragment 2), codons 1034 and 1042 (fragment 
3), and codon 1246 (fragment 4). Amplification on fragment 3 and fragment 4 were performed 
when PCR failed to amplify fragment 2 of pfmdr1. Nest 1 reaction mixture contained 5 µL of 
DNA, NH4 reaction buffer, 2 mM MgCl2, 1 mM of dNTPs, 200 nM of each primer, and 1 unit of 
BIOTAQ (Bioline, UK). The nest 2 reaction contained 1 µL of nest 1 product, NH4 reaction 
buffer, 2 mM MgCl2, 1 mM of dNTPs, 200 nM of each primer, and 1 unit of BIOTAQ (Bioline, 
UK). Primers and cycling conditions for each fragment are described in Table 5.2. PCR products 
of nest 2 amplifications were detected using 2% agarose gel electrophoresis and ethidium 
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bromide staining. PCR products were subsequently sequenced using BigDye Terminator v3.1 
cycle sequencing kits and analysis on an ABI 3730 sequencer (Applied Biosystems). The 
sequences were analysed using Geneious software (Version 8.0.5, Biomatters, New Zealand). 
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Table 5.2. Primers and cycling conditions for pfmdr1 PCR amplifications273 
Gene Primers Sequence PCR product size PCR conditions 
Pfmdr1 
Fragment 1 
Fwd1-FN1/1 
Rev1-REV/C1 
 
Fwd2-MDR2/1 
Rev2-NEWREV1 
5'‐AGGTTGAAAAAGAGTTGAAC‐3' 
5'‐ATGACACCACAAACATAAAT‐3' 
 
5'‐ACAAAAAGAGTACCGCTGAAT‐3' 
5'‐AAACGCAAGTAATACATAAAGTC‐3' 
578 bp 
 
 
534 bp 
94°C 3 mins/30x (94°C 30 secs, 55°C 30 secs, 
65°C 1 min)/ 65°C 5 mins 
 
94°C 3 mins/30x (94°C 30 secs, 60°C 30 secs, 
65°C 1 min)/ 65°C 5 mins 
 
Pfmdr1 
Fragment 2 
 
 
 
Fwd1-MDRFR2F1 
Rev1-MDRFR2R1 
 
Fwd2-MDRFR2F2 
Rev2-MDR2FR2R2 
 
5’‐GTGTATTTGCTGTAAGAGCT-3’ 
5’‐GACATATTAAATAACATGGGTTC-3’ 
 
5’ CAGATGATGAAATGTTTAAAGATC-3’ 
5’‐TAAATAACATGGGTTCTTGACT-3’ 
958 bp 
 
 
864 bp 
94°C 3 mins/34x (94°C 30 secs, 55°C 1 min, 
65°C 1 min)/ 65°C 5 mins 
 
94°C 3 mins/29x (94°C 30 secs, 60°C 30 secs, 
65°C 1 min)/ 65°C 5 mins 
 
Pfmdr1 
Fragment 3 
Fwd1-MDRF3N1 
Rev1-MDRF3R1 
 
Fwd2-MDRF3N2 
Rev2-MDRF3R1 
 
5’‐GCA TTT TAT AAT ATG CAT ACT G‐3’ 
5’‐GGA TTT CAT AAA GTC ATC AAC‐3’ 
 
5’‐GGT TTA GAA GAT TAT TTC TGT A‐3’ 
5’‐GGA TTT CAT AAA GTC ATC AAC‐3’ 
 
 
 
234 bp 
94°C 3 mins/30x (94°C 30 secs, 56°C 60 secs, 
65°C 50 secs)/ 65°C 5 mins 
 
Same as primary PCR above 
 
Pfmdr1 
Fragment 4 
Fwd1-MDRF4N1 
Rev1-MDRF4R1 
 
Fwd2-MDRF4N2 
Rev2-MDRF4R1 
5’‐CAA ACC AAT CTG GAT CTG CAG‐3’ 
5’‐CAA TGT TGC ATC TTC TCT TCC‐3’ 
 
5’‐GAT CTG CAG AAG ATT ATA CTG‐3’ 
5’‐CAA TGT TGC ATC TTC TCT TCC‐3’ 
 
 
 
 
194 bp 
94°C 3 mins/30x (94°C 30 secs, 55°C 60 secs, 
65°C 40 secs)/ 65°C 5 mins 
 
Same as primary PCR above 
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 Amplifications of pfk13 propeller domain were performed by nested PCR 
amplification.268 PCR master mix for nest 1 were performed in 25 µL reaction mixture 
containing 5 µL of DNA template, 0.25 µM of each primer and 1X HOT FirePol Master Mix (Solis 
Biodyne), with cycling conditions as follow: initial denaturation at 95 °C for 15 minutes, 
followed by 30 cycles of 95 °C for 30 seconds, 58 °C for 2 minutes, and 72 °C for 2 minutes, 
followed by final extension at 72 °C for 10 minutes. For nest 2 amplification, a 50 µL of reaction 
mixture was prepared containing 5 µL of nest 1 product, 0.25 µM of each primer and 1X HOT 
FirePol Master Mix (Solis Biodyne). Cycling conditions for nested PCR were as follows: initial 
denaturation at 95 °C for 15 minutes, followed by 40 cycles of 95 °C for 30 seconds, 60 °C for 1 
minutes, and 72 °C for 1 minutes, followed by final extension at 72 °C for 10 minutes. Primer 
sets for both PCR assays are provided in Table 5.3.268 Nested PCR products were then 
sequenced using BigDye Terminator v3.1 cycle sequencing kits and analysis on an ABI 3730 
sequencer (Applied Biosystems). Polymorphisms were analysed using Geneious software 
(Version 8.0.5, Biomatters, New Zealand).  
 
Table 5.3. Primers for pfk13 gene amplifications268 
Reaction Primer Sequence 
1st K13-1 5′-CGG AGT GAC CAA ATC TGG GA-3′ 
 K13-4 5′-GGG AAT CTG GTG GTA ACA GC-3′ 
2nd K13-2 5′-GCC AAG CTG CCA TTC ATT TG -3 
 K13-3 5′-GCC TTG TTG AAA GAA GCA GA -3′ 
 
5.2.3 Statistical analysis 
Statistical analyses were performed using Stata IC (version 15, StataCorp, TX, USA). 
Binary variables were used to compare across pairs of categories. Odds ratios (ORs) with 95% 
confidence intervals (CIs) were estimated, and significance was determined using X2 
distribution.   
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5.3 Results 
PCR detected 404 (10.8%) individuals with P. falciparum infections (additional pfmdr1 
genotyping detected 11 P. falciparum cases to the total numbers presented in Chapter 4), of 
which 65% were subpatent (Table 5.4.). Batubara, Langkat and South Nias each provided 81 
(20.0%), 90 (22.3%) and 233 (57.7%) P. falciparum isolates, respectively.  
 
Table 5.4. Prevalence of P. falciparum infection detected by microscopy and PCR 
Pf* microscopy 
Pf* PCR 
Total 
Positive Negative 
Batubara 
   Positive 36 57 93 
   Negative 45 1132 1234 
Sub-total 81 1189 1270 
Langkat 
   Positive 33 41 74 
   Negative 57 413 470 
Sub-total 90 454 544 
South Nias 
   Positive 75 96 171 
   Negative 158 1588 1746 
Sub-total 233 1684 1917 
Total 404 3327 3731 
*Pf=P. falciparum 
5.3.1 Polymorphisms in pfcrt gene 
Pfcrt genotyping at codons 72 to 76 was successful only in 183 (45.3%) samples. Low 
PCR success rate observed here may be due to high proportion of submicroscopic infections 
among our samples, in addition to lesser sensitivity of qPCR assay compared to the nested PCR 
assay used to identify P. falciparum infections.353 For this analysis, mutant 76T was present in 
91.8% (168 of 183, 95% CI 86.9-94.9) of samples. The pfcrt-SVMNT was confirmed to be the 
predominant haplotype as observed in 76.5% (140 of 183; 95% CI 69.9-82.1) of samples, 
presented either alone (68.6%) or mixed with other genotypes (31.4%). Parasites carrying 
SVMNT were also the most prevalent in all three sites with 85.7% (42 of 49; 95% CI 73.3-92.9) 
in Batubara, 84.6% (33 of 39; 95% CI 70.3-92.8) in Langkat, and 68.4% (65 of 95; 95% CI 58.5-
76.9) in South Nias. The remaining haplotypes, calculated by combining isolates with single and 
mixed genotypes, were less common being detected at 34.9% (64/183; 95% CI 28.4%-42.1%) 
for wild-type CVMNK and 20.2% (37/183; 95% CI 15.0%-26.6%) for mutant-CVIET haplotypes 
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(Figure 5.1.). Although overall proportion of CVIET-parasites was low, but in South Nias this 
mutant genotype was relatively more common (34/95; 35.8%, OR 3.67, 95% CI 1.54-9.42, 
P=0.001) (Table 5.5.).   
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Figure 5.1. Proportion of pfcrt polymorphisms in three study sites in North Sumatera province 
(n=49 for Batubara, n=39 for Langkat, and n=95 for South Nias). 
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Table 5.5. Proportion of pfcrt polymorphisms according to sites 
Pfcrt 72-76  
haplotype 
Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall, 
n (%) Patent Subpatent Patent Subpatent Patent Subpatent 
CVMNK 2/49  
(4.0) 
3/49 
(6.0) 
1/39  
(2.6) 
1/39  
(2.6) 
3/95  
(3.2) 
5/95  
(5.3) 
15/183 
(8.2) 
CVIET 0/49 
(0) 
1/49  
(2.0) 
0/39  
(0) 
1/39  
(2.6) 
4/95  
(10.3) 
14/95  
(14.7) 
20/183 
(10.9) 
SVMNT 23/49 
(46.9) 
11/49  
(22.4) 
15/39 
(38.5) 
8/39  
(20.5) 
16/95  
(16.8) 
23/95  
(24.2) 
96/183 
(52.5) 
CVMNK-SVMNT 3/49 
(6.1) 
3/49  
(6.0) 
6/39  
(15.4) 
3/39  
(7.7) 
8/95  
(3.2) 
12/95  
(12.6) 
35/183 
(19.1) 
CVMNK-CVIET 0/49  
(0) 
1/49  
(2.0) 
0/39  
(0) 
3/39  
(7.7) 
0/95  
(0) 
4/95  
(10.3) 
8/183 
(4.4) 
CVIET-SVMNT 0/49 
(0) 
0/49  
(0) 
0/39  
(0) 
0/39  
(0) 
1/95  
(1.1) 
2/95  
(2.1) 
3/183 
(1.6) 
CVMNK-CVIET-SVMNT 1/49 
(2.0) 
1/49  
(2.0) 
1/39  
(0) 
0/39  
(0) 
1/95  
(1.1) 
2/95 
(2.1) 
6/183 
(3.3) 
 
5.3.2 Polymorphisms in pfmdr1 gene 
Analysis of polymorphisms in pfmdr1 gene were successful in 267, 262, 72, 74 and 70 
isolates for codons 86, 184, 1034, 1042 and 1246, respectively. Low success rates were seen 
for codons 1034, 1042 and 1246 genotyping and these were likely due to the difficulties to 
amplify the large fragment 2 of pfmdr1. But when amplifications were done separately for 
codon 1034 and 1042 in fragment 3, and 1246 in fragment 4, success rate was not improved. 
Low density parasites might have contributed to this poor success, and furthermore, higher 
success in fragment 1 amplification was likely due to better sensitivity of the PCR assay for 
fragment 1 amplification compared to that of other fragments. Sequences from the successful 
amplifications at these alleles of interest were then classified as wild-type (identical to 
reference 3D7 strain), mutant or mixed genotype. Prevalence of wild-type N86 differed 
according to study site, with the lowest at 38.9% (23 of 59; 95% CI 27.6-51.7) in Batubara, 57.6% 
(34 of 59; 95% CI 44.9-69.4) in Langkat, and 78.5% (117 of 149; 95% CI 71.3-84.4) in South Nias 
(Table 5.6.). Mutation to Tyrosine in allele 86 was the most prevalent mutation in all three sites 
(overall prevalence 34.8%, 95% CI 29.4-40.7), and in Batubara appeared in the majority of 
isolates (37 of 59; 62.7%, 95% CI 49.9-73.9). Rare mutations in allele 86 to phenylalanine (F) 
and to serine (S) were also observed (Figure 5.2.), each was identified twice (0.8%). Rare mutant 
86F was previously described in two isolates from Swaziland354, however we are not aware of 
any report of mutant 86S. In the locus of interest 184, prevalence of wild-type parasite carrying 
Y184 was the highest; 94.9% (56 of 59; 95% CI 86.1-98.3) in Batubara, 89.5% (51 of 57; 95% CI 
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78.9-95.1) in Langkat and 80.8% (118 of 146; 95% CI 73.7-86.4) in South Nias. Only very small 
proportion of samples harbored the mutant genotype 184F (39 of 262; 14.9%, 95% CI 11.1-
19.7), (Figure 5.3.). Whereas for the remaining alleles of interest, only wild-type parasites were 
detected at codons 1034, 1042 and 1246. 
 
Table 5.6. Proportion of polymorphisms in pfmdr1 gene according to sites 
Pfmdr1  
 
Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall, n 
(%) Patent Subpatent Patent Subpatent Patent Subpatent 
N86 
 
N86Y 
 
86Y 
 
86S 
 
86F 
 
4/59 
(6.8) 
1/59 
(1.7) 
26/59 
(44.1) 
0/59 
(0) 
0/59 
(0) 
18/59 
(3.1) 
0/59 
(0) 
10/59 
(16.9) 
0/59 
(0) 
0/59 
(0) 
4/59 
(6.8) 
2/59 
(3.4) 
19/59 
(32.2) 
1/59 
(1.7) 
0/59 
(0) 
27/59 
(45.8) 
1/59 
(1.7) 
5/59 
(8.5) 
0/59 
(0) 
0/59 
(0) 
31/149 
(20.8) 
0/149 
(0) 
18/149 
(12.1) 
1/149 
(0.7) 
0/149 
(0) 
86/149 
(57.7) 
0/149 
(0) 
11/149 
(7.4) 
0/149  
(0) 
2/149 
(1.3) 
170/267 
(63.7) 
4/267 
(1.5) 
89/267 
(33.3) 
2/267 
(0.8) 
2/267 
(0.8) 
Y184 
 
Y184F 
 
184F 
 
29/59 
(49.2) 
1/59 
(1.7) 
1/59 
(1.7) 
26/59 
(44.1) 
0/59 
(0) 
2/59 
(3.4) 
23/57 
(40.4) 
0/57 
(0) 
2/57 
(3.5) 
28/57 
(49.1) 
0/57 
(0) 
4/57 
(7.0) 
40/146 
(27.4) 
0/146 
(0) 
8/146 
(5.5) 
77/146 
(52.7) 
1/146 
(0.001) 
20/146 
(13.7) 
223/262 
(85.1) 
2/262 
(0.8) 
37/262 
(14.1) 
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Figure 5.2. Mutation at pfmdr1 86S and 86F as observed in each two isolates 
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Figure 5.3. Polymorphisms at alleles 86 and 184 of pfmdr1 according to study sites (n=267 for 
codon 86, and n=262 for codon 184). 
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 To determine the association between the polymorphisms in pfmdr1 with drug 
response, we then assembled the genotypes of alleles 86, 184 and 1246. Haplotype NFD at 
these positions has been associated with reduced sensitivity to AL, while on the other hand, 
amodiaquine select parasites carrying the opposite haplotype, YYY.273 Considering most isolates 
failed to genotype at codon 1246, the haplotype analysis was restricted to isolates successfully 
genotyped at both codons 86 and 184. We also included samples with mixed alleles, assuming 
that one haplotype of interest occured. Based on this criteria, we observed that haplotype-YY 
was most prevalent in Batubara (OR 4.6, 95% CI 2.4-8.9, P<0.001) compared to other regencies, 
haplotype-YY and haplotype-NY were equally common in Langkat, and haplotype-NY was the 
most common in South Nias (Table 5.7.). Both in Batubara (OR 31.4, 95% CI 8.3-169.4, P<0.001) 
and Langkat (OR 8.7, 95% CI 2.8-31.5, P<0.001), parasites were more likely to carry the YY-
haplotype than the NF-haplotype, as expected. Whilst, in South Nias both haplotypes YY and 
NF were equally distributed (Figure 5.4.). Interestingly, although different haplotypes were 
prevalent at different study sites, we observed that parasites carrying YY alleles was 
significantly more prevalent as patent infection than any other alleles at all sites (Batubara, OR 
9.7, 95% CI 2.5-41.2, P<0.0001; Langkat, OR 15.0, 95% CI 3.6-65.4, P<0.0001; South Nias, OR 
4.9, 95% CI 1.9-13.4, P<0.0002). 
 
Table 5.7. Proportion of haplotypes 86-184 of pfmdr1 according to sites 
Pfmdr1 
86-184 
haplotype 
Batubara, n (%) Langkat, n (%) South Nias, n (%) 
Overall, n 
(%) Patent Subpatent Patent Subpatent Patent Subpatent 
NY 3/59  
(5.1) 
16/59 
(27.1) 
5/57 
(8.8) 
23/57 
(40.4) 
22/145  
(15.2) 
66/145 
(45.5) 
135/261 
(51.7) 
NF 1/59 
(1.7) 
2/59 
(3.4) 
1/57 
(1.8) 
4/57 
(7.0) 
6/145  
(4.1) 
20/145 
(13.8) 
34/261 
(13.0) 
YY 27/59  
(45.8) 
10/59 
(16.9) 
20/57 
(35.1) 
6/57 
(10.5) 
18/145  
(12.4) 
10/145 
(6.9) 
91/261 
(34.9) 
YF 1/59 
(1.7) 
0/59 
(0) 
0/57  
(0) 
0/57 
(0) 
0/145  
(0) 
1/145  
(0.7) 
2/261  
(0.8) 
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Figure 5.4. Proportion of each haplotype at codons 86-184 of pfmdr1 in three study sites in North 
Sumatera province (n=59 for Batubara, n=57 for Langkat, and n=145 for South Nias). 
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5.3.3 Polymorphisms in pfk13 
Genotyping for the pfk13 gene was successful in 232 (57.4%) isolates. As previously 
described before, submicroscopic infections may have contributed to this low rate of success. 
Of these, 95.7% (222/232; 95% CI 92.2-97.6) harbored wild-type parasites, and 4.3% (10/232, 
95% CI 2.4-7.8) carried mutations (Table 5.8., Figure 5.5.). As this is the first study to show some 
proportion of pfk13 mutations in the parasite population in western Indonesia, we did extra 
measures before providing the evidence of these mutations among our samples (summarized 
in Table 5.9.). Ten isolates contained 24 non-synonymous polymorphisms. Of those, only one 
isolate carried single mutation, two had one mutation mixed with wild-type parasite, and the 
remaining had > 1 non-synonymous mutation with or without the presence of wild-type 
parasite. Mutant T474A, the most frequently mutant observed, was occurred in 7 isolates 
across three different sites, all presented mixed with wild-type parasite. Mutation at codon 
535, a change from threonine to alanine, was observed in 2 isolates from Batubara. Whereas, 
the remaining mutations were observed only once. The C580Y mutation, currently the most 
prevalent K13 genotype in western Cambodian parasites and is associated with delay clearance, 
was only seen in 1 patient from South Nias (Figure 5.5.). While other mutations previously 
reported to be associated with slow parasite clearance was not seen among our samples. There 
was no difference in the prevalence of K13 mutation between study sites (P>0.05). 
 
Table 5.8. Proportion of non-synonymous mutations in P. falciparum kelch13 propeller-domain  
Pfk13 Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall, 
n (%) Patent Subpatent Patent Subpatent Patent Subpatent 
Wild-
type 
30/66 
(45.5) 
32/66 
(48.5) 
27/60 
(45.0) 
29/60 
(48.3) 
34/106 
(32.1) 
70/106 
(66.0) 
222/232 
(95.7) 
Mutant 1/66 
(1.5) 
3/66 
(4.5) 
1/60 
(1.7) 
3/60 
(5.0) 
0/106 
(0) 
2/106 
(1.9) 
16/232 
(4.3) 
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Figure 5.5. Proportion of P. falciparum kelch13 mutations in three study sites in North Sumatera 
province (n=66 for Batubara, n=60 for Langkat, and n=106 for South Nias). 
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Table 5.9. Non-synonymous single-nucleotide polymorphisms in the pfk13 propeller domain  
Codon 
Reference  
sequence 
AA 
Nucleotide 
substitution 
AA 
change 
Frequency, 
n (%) 
Presence 
of wild-
type allele 
Evidence** 
Y456H Y Tyr t1366c H 1 (0.4) + + 
E461G E Glu a1382g G 1 (0.4) + + 
T474A T Thr a1420g A 7 (3.0) + + 
S521P S Ser t1561c P 1 (0.4) - + 
N523S N Asn a1568g S 1 (0.4) - + / - 
T535A T Thr a1603g A 2 (0.9) - + / - 
Y541H Y Tyr t1621c H 1 (0.4) + + 
C542R C Cys t1624c R 1 (0.4) - + 
V568A V Val t1703c A 1 (0.4) + + / - 
C580Y* C Cys g1739a Y 1 (0.4) + + 
T593A T Thr a1777g A 1 (0.4) - + / - 
N609S N Asn a1826g S 1 (0.4) - + 
Y616H T Thr t1846c H 1 (0.4) - + 
F628L F Phe t1882c L 1 (0.4) + + 
N642S N Asn a1925g S 1 (0.4) - + 
P655S P Pro c1963t S 1 (0.4) - + 
*Mutation in C580Y, associated with delay in parasite clearance in Greater Mekong parasites 
**+/- denotes weak evidence, on a single strand only, or not confirmed by subsequent repeat PCR
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Figure 5.6. Mutation at C580Y, a change from cysteine to leucine, in one sample from South Nias. Despite repeat experiments, this was only observed in one strand. 
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5.3.4 Associations between the pfcrt, pfmdr1 and pfk13 polymorphisms 
among Sumatera P. falciparum isolates 
The relationship between putative molecular markers, pfcrt and pfmdr1, has been 
previously characterized where mutations in these genes were linked to a variety of degree of 
resistance to chloroquine and amodiaquine.181, 355 In African settings, the pfcrt 76T mutation 
appeared exclusively in the background of pfmdr1 86Y mutation.356 In Southeast Asia, CVIET-
form appeared in a wild-type or mutant allele of pfmdr1.357 Combination of mutations in these 
two genes confer different levels of sensitivity to drugs.181, 355 Therefore, we further evaluated 
the association between polymorphisms in the tested genes in this study. Analysis of the pfcrt 
gene at codons 72 to 76 revealed that SVMNT variant was predominant across the three study 
sites. This haplotype demonstrated a strong association with the YY-haplotype of pfmdr1 
(X2=33.36, 1 degree of freedom; P<0.0001). This suggests that the SVMNT haplotype of pfcrt 
and the YY haplotype of pfmdr1 are in linkage disequilibrium in these parasite populations. 
Pfk13 mutant alleles also appeared in the background of SVMNT parasites, being detected 3 
of 3 (100%) of successfully evaluated isolates. However, these mutants appeared in both 
pfmdr1 background between parasites carrying YY haplotype (4 of 7, 57.1%) and NY haplotype 
(3 of 7, 42.9%). Nevertheless, these numbers are too small to give conclusive evidence. 
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5.4 Discussion 
This study provides genetic characterisation of P. falciparum parasites from north-
western Indonesia. We evaluated the frequency of polymorphisms in the pfcrt, pfmdr1 and 
pfk13, the drug resistance markers for chloroquine, amodiaquine, mefloquine, lumefantrine 
and artemisinin.181, 268, 269, 273, 349, 355 In North Sumatera, the prevalence of mutant pfcrt 76T, the 
resistance marker for aminoquinoline, were at 90% in 2004 before the initiation of ASAQ.108, 
109 Recently, in our study we show that this prevalence has been maintained at 91%, with a 
similar observation in different parts of Indonesia.109, 282 Although the discontinuation of 
chloroquine is often accompanied by the return of wild-type pfcrt 76K358, continuous selection 
to the mutant pfcrt 76T has also been reported when chloroquine is replaced by ACT-
containing amodiaquine.197, 359 Many studies have shown a strong selective pressure to mutant 
pfcrt with the use of ASAQ, while AL exerts selection favouring the wild-type genotype.197, 273 
Other studies have also shown a better fitness advantage of SVMNT haplotype compared to 
the CVIET form, where this former haplotype persists even after chloroquine is withdrawn286, 
360 and CVIET-variant is replaced by the wild-type haplotype with the abandonement of 
chloroquine.358, 361 Moreover, haplotype SVMNT of codons 72-76 pfcrt alone has shown to be 
sufficient to confer high-level resistance to amodiaquine in in vitro studies.181, 355  The pfcrt 
SVMNT was the dominant haplotype (76.5%) observed in our settings, and our findings 
suggest that reduced susceptibility of parasites to ASAQ previously shown in in vivo studies 
across Indonesia might be explained by the moderate to high proportion of mutant SVMNT in 
the country.279, 282  
Resistance to chloroquine and amodiaquine is also known to be mediated by variation 
at the pfmdr1 locus, encoding the PgH1. Alleles 86Y, 184Y and 1246Y are selected following 
treatment with ASAQ.273 Unlike to parasites carrying SVMNT, African/Southeast Asian 
parasites harboring CVIET-variant of pfcrt require these pfmdr1 mutations to confer higher 
grade of amodiaquine resistance.273, 349, 355 The prevalence of mutant N86Y in our study was 
different between sites. In 2003, all parasites tested in Nias were reported to harbour this 
mutant genotype before the prevalence decreased to 31.4% in 2005107, 109 and recently to as 
low as 19.5% in our study. However, the prevalences in Batubara (62.7%) and Langkat (45.8%) 
were still relatively moderate. The prevalence of wild-type allele Y184 is higher than that of 
N86 and estimated as above 80% in all three sites contributing in some proportion of wild-
type pfmdr1 86N/184Y in each sites. However, in vitro studies suggest that the impact of 
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polymorphisms in allele 184 to drug sensitivity are small and very dependent on the status of 
allele 86.355 In North Sumatera, mutant pfmdr1 86Y/184Y was the most prevalent in Batubara 
(62.7%) and slightly more predominant than wild-type halotype in Langkat (45.6%). This YY 
haplotype greatly reduced susceptibility to amodiaquine in vivo, whereas AL provides better 
sensitivity and selects the wild-type parasite NF. This selection has been evidently shown in 
studies where CVIET parasites are prevalent.273 Nevertheless, a recent gene-editing study 
showed parasites with the background line of SVMNT modified with pfmdr1 YY genotype are 
also associated with increased sensitivity to lumefantrine and mefloquine.355 
Selection by piperaquine on pfmdr1 is still unclear. Studies have shown conflicting 
results on the selective pressure by DP, with few studies in Uganda showing similar selection 
as in aminoquinoline resistance275, 362, but distinctive selection in some other studies in 
western Africa.363, 364 At the time of our sample collection, DP had been deployed for nearly 3 
years in western Indonesia. However, due to poor access to treatment in our study sites, we 
cannot say for certain whether DP had already been used extensively in these region and had 
selected certain genotype of the pfmdr1 gene. Our findings showed most isolates from 
Batubara and Langkat harboured pfmdr1 YY parasites, and parasites in South Nias carried 
pfmdr1 NY suggesting that pfmdr1 polymorphisms in these parasites were the results of 
previous drug pressures from chloroquine and amodiaquine. These findings nevertheless 
required further investigation. Prospective data from the in vivo study will provide a better 
opportunity to study the association between phenotypic response to DP and parasite 
genotype. 
 Our findings also permit some comparison with recent important findings on the rise 
of artemisinin resistance in the Greater Mekong sub-region. To our knowledge, this is the first 
study from western Indonesia to provide evidence of K13 polymorphisms among local 
parasites. Resistance to artemisinin is known to be mediated by mutation in the pfk13 
propeller domain, with two independent emergence events having been identified in the 
region of Cambodia, Vietnam and Laos, and in the region of Thailand, Myanmar, and China.301 
Several nonsynonymous mutations; F466I, N458Y, N537D, R539T, I543T, P553L, P574L and 
C580Y, have been associated with day 3 positivity by microscopy and are considered indicators 
of clinical resistance to artemisinin.302 In this study, wild-type K13 is still prevalent in over 90% 
of samples. Only a handful of K13 polymorphisms were documented. Among those, evidence 
was found in one sample of C580Y, the dominant haplotype in western Cambodia and 
Myanmar-Thailand255, 302, which in this study appeared as subpatent infection. Parasites 
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carrying the wild-type allele were also present in this isolate (Figure 5.6.), and repeat PCR 
failed to confirm presence of the mutant allele (Table 5.9.). However, the presence of mutant 
T474A in 7 (3%) individuals raises interests on the possible phenotypic impact. Changes in 
codon 474 in propeller domain of K13 has previously been observed in small numbers of 
parasites from western and northeastern Cambodia268, and later in Vietnam.302 However 
changes were seen from threonine to isoleucine without any impact on clinical resistance to 
artemisinin.268, 302 Nevertheless, it is still necessary to evaluate the growing trend of K13 
polymorphisms in this region and whether other genetic changes will facilitate this selection 
in the future. 
 This study provides important evidence on genetic characterisation of P. falciparum 
parasites from North Sumatera. We have shown that pfcrt SVMNT is still highly circulating in 
our three study sites, while prevalence on pfmdr1 86Y were high in Batubara and Langkat, but 
has decreased markedly in South Nias, compared to earlier studies. We also have provided 
preliminary evidence of potentially important polymorphisms in pfk13 gene region encoding 
the kelch13 propeller domain among our samples, although we cannot yet establish the 
association between our K13 findings with artemisinin resistance. We found no evidence of 
the spread of artemisinin-resistant parasites from neighboring Cambodia and Myanmar, as 
this phenotype only occurs on the pfcrt background of the CVIET in the Mekong357, whereas 
the SVMNT background dominates in Sumatera (Table 5.5.) Nonetheless, our study has some 
limitations. As described before, we observed low success rate of PCR to genotype our 
samples. This may be due to low density of parasites and different levels of sensitivity of our 
PCR methods. We also did not perform the pfmdr1 and pfplasmepsin2 copy numbers 
measurements, which are the molecular markers for mefloquine and piperaquine 
resistance199, 295, 351 and would be an important complement to our baseline genetic data. 
Lastly, we performed numbers of exploratory comparisons tests, which increased the chances 
of obtaining type I errors. Despite this, we decided not to use Bonferroni correction or other 
post hoc methods because in this exploratory study we want to generate new hypothesis for 
future testing which can be designed with adequate sample size. 
Our current findings have important implications. The data can be used to guide 
future therapeutic efficacy studies and to recommend antimalarial policy in the region. The 
polymorphisms in the pfcrt and pfmdr1 observed in this study are consistent with previous 
studies showing association with decreased susceptibility to amodiaquine, but increased 
sensitivity to lumefantrine component.273, 355, 359 Although DP is not yet failing in this corner of 
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Southeast Asia, in vivo studies to evaluate the efficacy of this current treatment in comparison 
with AL or AS-MQ would provide comprehensive information for alternative treatment and 
improved understanding on local parasites. More importantly, if either of the regimen proves 
to provide better efficacy, switching to this drug, or alternating use with DP, will accelerate 
the goal to eliminate P. falciparum in this regions and to reach the status of malaria free. 
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6 RESULTS      
The efficacy of dihydroartemisinin-piperaquine 
versus artemether-lumefantrine against 
uncomplicated Plasmodium falciparum infection 
 
6.1 Introduction 
Artemisinin combination therapy (ACT) is the recommended first-line therapy by WHO 
for falciparum malaria since 2005. It only took few years for ACT to replace the previous 
mainstays of treatment namely chloroquine and sulfadoxine-pyrimethamine and be deployed 
as first-line treatment in most malaria endemic countries. Artemisinin is a very potent 
component and is combined with a partner drug to prevent development of resistance.139 
However, artemisinin is not entirely a new drug. It has been used as monotherapy to treat 
malaria for over 30 years in Southeast Asia.123 Similar to previous antimalarials, decreased 
sensitivity to this component was also soon observed.252, 253 Today, artemisinin-resistant 
parasites have been well documented but are confined to the Greater Mekong subregion.255, 
302 
Low sensitivity to artemisinin is now commonly observed in parts of Southeast Asia, 
however treatment failures are still uncommon unless artemisinin is combined with 
ineffective partner drugs.255 Nevertheless, studies have shown that failures of artemisinin to 
clear parasites may lead to increased pressure to the partner drugs which subsequently cause 
selection of resistant-parasites. Thereafter, resistance to the partner drug would emerge.118, 
365 In addition, longer half-life provided by the partner drug also leaves this component at 
subtherapeutic level for longer period with a chance to develop and spread resistance. 
Indonesia is endemic for malaria, but endemicity differs between areas. Western part 
of the country is subject to low transmission risk with P. falciparum and P. vivax co-endemic 
together.88 Artesunate-amodiaquine (ASAQ) was used as the first-line antimalarial from 2004 
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before treatment failures led to its replacement by dihydroartemisinin-piperaquine (DP) in 
2012.128 Therapeutic efficacy studies on DP have shown high efficacy for both P. falciparum 
and P. vivax infections with excellent post-treatment prophylaxis effect resulting in delay of 
time to reinfection, greater time to haematological recovery and reduced chance for 
transmission.176, 193, 220 However, with ACTs failing in Cambodia and Thailand, regular 
monitoring is essential to evaluate the efficacy of ACT in this region. Therefore, the aim of this 
study is to evaluate the efficacy of two ACTs, DP and artemether-lumefantrine (AL) in 
Indonesia and to define the extent of artemisinin resistance. 
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6.2 Methods 
6.2.1 Study sites and design 
We conducted a prospective, open-label, randomised comparison of DP and AL for 
the treatment of uncomplicated falciparum malaria. The study was designed using the 2009 
World Health Organization (WHO) therapeutic efficacy protocol172, with modification to 
include mixed infections and parasite density > 250 parasite/µL. The study was conducted in 
Batubara regency, Langkat regency and South Nias regency in North Sumatera province, 
western Indonesia between January and June 2015 (see Chapter 3). 
The protocol was approved by the Ethics committee of the London School of Hygiene 
and Tropical Medicine (London, United Kingdom; 8504-01), and the Ethics committee of 
University of Sumatera Utara (Medan, Indonesia; 401/KOMET/FKUSU/2014). Written 
informed consent (Appendix 11 to 14) was obtained from adult patients and parents or 
guardians of enrolled children. The trial was registered with clinicaltrials.gov, number 
NCT02325180. 
 
6.2.2 Patients 
Patients were eligible if they were aged > 6 months, had acute symptomatic P. 
falciparum malaria confirmed by microscopy, parasitaemia > 250 parasite/µL, and 
temperature > 37.5 °C or fever during the preceding 48 hours. Patients were excluded from 
the study if they were pregnant or lactating women, had haemoglobin < 7 g/dL, use of 
antimalarial in the past 2 weeks and appeared with danger signs or signs of severe malaria. 
 
6.2.3 Study procedures 
After enrolment, patients were randomly assigned to receive either DP or AL. 
Randomisation lists were computer-generated in blocks of 20, and treatment allocation was 
printed on numbered case record forms that was only seen after patients were enrolled. We 
recorded demographic information, detailed clinical symptoms, history of antimalarial use, 
and physical examination findings in the case record forms (Appendix 5). Finger prick blood 
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sampling was performed for microscopy examination and blood was spotted on filter paper 
(Whatman 3MM) for polymerase-chain reaction (PCR) genotyping. 
Giemsa-stained thick blood films were assessed to determine parasite density against 
200 white blood cells, and was calculated with the assumption of a white cell count of 8000 
/µL. Blood smear is considered as negative after examination of 100 high power fields. Thin 
films were used to identify malaria species. All slides were single read by a certified 
microscopist. 
Patients were examined every 24 hours until they became aparasitaemic, and they 
were monitored at day 7 and then weekly until day 42. At each appointment, we assessed 
clinical symptoms and performed physical examination including axillary temperature 
measurement. We also obtained both thick and thin blood smears and blood spots on filter 
papers. We measured haemoglobin levels at enrolment and on day 28 using a portable 
photometer (HemoCue® 301). For the full clinical protocol see Chapter 3, Appendices 1 to 12. 
Patients with recurrent P. falciparum infection were classified as recrudescence or 
reinfection by msp1, msp2 and glurp genotyping of samples collected at enrolment and day 
of failure. Reinfection is defined by a subsequent occurring parasitaemia in which all the alleles 
in parasites from the post-treatment sample are different from those in the admission sample, 
for one or more loci tested. While recrudescence is defined as at least one allele at each locus 
being common to both paired samples.323 Nested polymerase chain reaction (PCR) reactions 
on msp1 block (K1, MAD20 and RO33), msp2 (FC27 and 3D7/IC) and glurp were performed 
using following previously published primers and cycling conditions.366 Nest 1 amplifications 
were performed in 25 µL reaction mixture containing 5 µL DNA, NH4 buffer, 4 mM MgCl2, 1 
mM deoxynucleotides (dNTPs), 0.2 µM forward primer, 0.2 µM reverse primer, and 1 unit of 
BIOTAQ (Bioline, UK). Cycling conditions for nest 1 amplification were: denaturation at 95 °C 
for 5 minutes, 25 cycles of 94 °C for 1 minute, 58 °C for 2 minutes and 72 °C for 2 minutes, 
followed by final extension of 5 minutes at 72 °C. Nest 2 amplifications were performed in 25 
µL reaction mixture containing 1 µL of nest 1 product, NH4 buffer, 4 mM MgCl2, 1 mM dNTPs, 
0.2 µM forward primer, 0.2 µM reverse primer, and 1 unit of BIOTAQ (Bioline, UK). Cycling 
conditions for nest 2 amplifications of msp1 and msp2 were: denaturation at 95 °C for 5 
minutes, 30 cycles of 94 °C for 1 minute, 58 °C for 2 minutes and 61°C for 2 minutes, followed 
by final extension of 5 minutes at 72 °C. Cycling conditions for glurp amplification were similar 
to nest 1 amplification. Ten µL of nest 2 products were analysed by electrophoresis in 2% 
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agarose gel in 0.5% TBE buffer stained with ethidium bromide. DNA was visualized using 
ultraviolet transillumination. 
 
Table 6.1.  Primers sequences for msp1, msp2 and glurp genotyping366 
Gene Reaction Primer Sequence 
msp1 Nest 1 M1-OF 5’-CTAGAAGCTTTAGAAGATGCAGTATTG-3’ 
 Nest 1 M1-OR 5’-CTTAAATAGTATTCTAATTCAAGTGGATCA-3’ 
 Nest 2-MAD20 family specific M1-KF 5’-AAATGAAGAAGAAATTACTACAAAAGGTGC-3’ 
 Nest 2-MAD20 family specific M1-KR 5’-GCTTGCATCAGCTGGAGGGCTTGCACCAGA-3’ 
 Nest 2-K1 family specific M1-MF 5’-AAATGAAGGAACAAGTGGAACAGCTGTTAC-3’ 
 Nest 2-K1 family specific M1-MR 5’-ATCTGAAGGATTTGTACGTCTTGAATTACC-3’ 
 Nest 1-RO33 family specific M1-RF 5’-TAAAGGATGGAGCAAATACTCAAGTTGTTG-3’ 
 Nest 1-RO33 family specific M1-RR 5’-CATCTGAAGGATTTGCAGCACCTGGAGATC-3’ 
msp2 Nest 1 M2-OF 5’-ATGAAGGTAATTAAAACATTGTCTATTATA-3’ 
 Nest 1 M2-OR 5’-CTTTGTTACCATCGGTACATTCTT-3’ 
 Nest 2-FC27 family specific M2-FCF 5’-AATACTAAFAFTFTAFFTFCARATGCTCCA-3’ 
 Nest 2-FC27 family specific M2-FCR 5’-TTTTATTTGGTGCATTGCCAGAACTTGAAC-3’ 
 Nest 2-3D7/IC family specific M2-ICF 5’-AGAAGTATGGCAGAAAGTAAKCCTYCTACT-3’ 
 Nest 2-3D7/IC family specific M2-ICR 5’-GATTGTAATTCGGGGGATTCAGTTTGTTCG-3’ 
glurp Nest 1 G-OF 5’-TGAATTTGAAGATGTTCACACTGAAC-3’ 
 Nest 1 and 2 G-OR 5’-GTGGAATTGCTTTTTCTTCAACACTAA-3’ 
 Nest 2 G-NF 5’-TGTTCACACTGAACAATTAGATTTAGATCA-3’ 
    
    
6.2.4 Treatment 
DP (Duo-Cotecxin, Holley Pharmaceutical, China; containing 40 mg dihydroartemisinin 
and 320 mg piperaquine) was given at a dose of 2.25 mg/kg/dose for dihydroartemisinin and 
18 mg/kg/dose for piperaquine, rounded up to the nearest half tablet. DP was administered 
at enrolment, and after 24 hour and 48 hour. AL (Coartem, Novartis Pharma, China) was also 
dispensed according to weight, with half a tablet consisting of 20 mg artemether and 120 mg 
lumefantrine given at every 5 kg body weight. AL was administered at enrolment, hour 8, hour 
24, hour 36, hour 48 and hour 60. Administration of all antimalarial drugs were supervised by 
a study staff. AL was given with drinking water on a full stomach, and biscuits and milk were 
provided for participants with an empty stomach. While DP was given in an empty stomach, 
and patients were instructed to fast for 2 hours after drug administration. As recommended 
in the Indonesian national guideline, additional single dose of primaquine at 0.75 mg/kg was 
given for P. falciparum infection and 14-day treatment of 0.25 mg/kg primaquine for P. vivax 
was also administered unsupervised on the final day of follow-up. G6PD testing was not 
performed prior to administration of primaquine.128 
If vomiting occurred within 30 minutes, administration of a full dose was repeated. If 
vomiting happened in between 30 to 60 minutes, a half dose was administered. Recurrent 
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vomiting removed patients from the study. Patients failing therapy with recurrent P. 
falciparum was treated with quinine (10 mg of salt/kg given 3 times a day for 7 days) and 
doxycycline (100 mg twice a day for 7 days) if they were not children aged < 8 years old and 
not pregnant. Patient who developed infection with other Plasmodium infection during the 
study was re-treated according to the national guidelines.128 
 
6.2.5 End points 
The primary outcome was the efficacy of DP and AL for P. falciparum infection within 
42 days after administration of the treatment, corrected by PCR genotyping. The secondary 
outcomes were parasite clearance times and proportion of patients with parasitaemia 
detected at 72 hours by microscopy.  
 
6.2.6 Statistical analysis 
Data were double-entered and analysed using Stata IC (version 15, StataCorp, TX, 
USA). We conducted analysis using a modified intention to treat method. Those who were lost 
to follow-up were considered to be censored, and withdrawn patients were considered as 
having treatment failure. Those whom we were not able to distinguish between 
recrudescence and reinfection due to failure to amplify pfmsp1, pfmsp2 and glurp were 
regarded as not being treatment failure. 
Normally distributed and non-normally distributed data were analysed using student 
t-test and rank-sum test. Cox-regression analysis was used to predict risk factor for treatment 
failures. Efficacy endpoints were determined by calculating the cumulative risk of 
recrudescence with P. falciparum at day 42 assessed with the use of Kaplan Meier survival 
analysis and Mantel-Haenszel log-rank test. P values of < 0.05 were considered statistically 
significant. 
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6.3 Results 
Of the 3731 screened participants, 302 met the selection criteria and were randomly 
assigned to receive DP or AL (Figure 6.1.). The number of patients in Batubara regency, Langkat 
regency and South Nias regency were each 36 (11.9%), 43 (14.2%), and 223 (73.8%), 
respectively. Of the 302 enrolled patients, 263 had P. falciparum infection and 39 had mixed 
P. falciparum and P. vivax infections identified by microscopy. Protocol violation 7  was 
observed within 72 hours in 9 (5.9%) and 3 (2.0%) patients in DP and AL groups, and patients 
were excluded from further analysis. Baseline characteristics were similar between treatment 
groups (Table 6.2.) Fifteen patients were lost to follow-up and considered as not being 
treatment failure and 8 patients withdrew from the trial and regarded as treatment failure. 
Overall, follow-up to day 42 or to the day of treatment failure was achieved in 92.4% (133/144) 
of patients who received DP and 91.1% (133/146) of those who received AL. 
                                                             
7 Protocol violation is established when a patient do not complete the 3-day course treatment. 
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Figure 6.1. Profile of a study of dihydroartemisinin-piperaquine versus artemether-lumefantrine 
for treatment of symptomatic uncomplicated P. falciparum infection. All infection was 
detected by microscopy; Early treatment failure, late treatment failure and adequate 
clinical and parasitological response was classified based on WHO classification for 
treatment outcomes.172 
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Table 6.2. Baseline characteristics of the patients 
Characteristic DP arm AL arm 
No. of evaluable patients 144 146 
Infecting species at enrolment* 
     P. falciparum (%) 
     P. falciparum and P. vivax (%) 
 
122 (84.7) 
22 (15.3) 
 
130 (89.0) 
16 (10.9) 
Median P. falciparum density at 
enrolment per µL (25%-75% range)* 
288 (256-520) 288 (256-400) 
Female sex (%) 81 (56.3) 79 (54.1) 
Age 
     Median, years (25%-75% range) 
     < 5 years (%) 
     5-14 years (%) 
     > 15 years (%) 
 
12.04 (8-35) 
20 (13.9) 
60 (41.7) 
64 (44.4) 
 
17.42 (8-36) 
15 (10.3) 
56 (38.4) 
75 (51.4) 
Temperature > 37.5 °C (%) 15 (10.4) 12 (8.2) 
Mean haemoglobin at enrolment, 
gr/dL (SD) 
11.96 (1.9) 11.94 (1.6) 
Proportion of anaemic patients (Hb < 
10.0 g/dL), % 
18 (12.5) 15 (10.3) 
 
History of malaria in previous month 
(%) 
8 (5.6) 13 (8.9) 
Use of any prevention (%) 
     Use of ITNs (%) 
     Use of commercial nets (%) 
     Use of repellent (%) 
     Use of insecticide spray (%) 
     Use of coil repellent (%) 
65 (45.1) 
33 (22.9) 
26 (18.1) 
3 (2.1) 
2 (1.4) 
8 (5.6) 
54 (36.9) 
29 (19.9) 
18 (12.3) 
4 (2.5) 
4 (2.5) 
4 (2.5) 
*Identification and measurement by microscopy. 
Abbreviations: ITNs: insecticide-treated bed nets; SD: standard deviation. 
 
6.3.1 Parasite and fever clearance 
By 24 hours, 97.9% (141 of 144, 95% CI 94.1 - 99.3) and 98.6% (143 of 146, 95% CI 
95.1 - 99.6) of patients in DP and AL groups were afebrile. By 72 hours, 100% (143 of 143) and 
98.6% (141 of 143, 95% CI 95.1 to 99.6) in both DP and AL groups were afebrile (Figure 6.2.). 
Figure 6.3. shows median parasite density at enrolment and during follow-up days 1, 2, and 3 
between DP an AL, excluding parasitaemia > 10,000 parasite/µL at enrolment. Overall, 98.6% 
(142 of 144, 95% CI 95.1 – 99.6) and 98.6% (144 of 146, 95% CI 95.1 – 99.6) of patients in DP 
and AL cleared parasitaemia within 72 after receiving treatment drugs (P=0.82, Figure 6.4.). 
Mean parasite reduction ratio to 50% (PRR50) and to 90% (PRR90) were 1.05 (SD 0.51) and 1.29 
(SD 1.03) days, respectively. There was no difference in parasite clearance times (1.52 days 
for DP versus 1.45 days for AL, P>0.05) between the two groups (Table 6.3.). There was no risk 
factor associated significantly with presence of parasitaemia on day 3. 
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Figure 6.2. Proportion of patients with axillary temperature > 37.5 °C (n=144 for DP and n=146 
for AL). 
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Figure 6.3. Median parasite density for patients with initial parasite density below 10,000 p/µL 
between two treatment (n=139 for DP and n=145 for AL) arms by microscopy.  
Parasite density above 10,000 p/µL are excluded from the analysis (five cases in DP 
arm and one case in AL arm, all cleared parasitaemia within 24 hours). 
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Figure 6.4. Proportion of patients with parasitaemia on days 0, 1, 2 and 3 in the DP (n=144) and 
AL (n=146) groups (P=0.82). 
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Table 6.3. Time to parasite clearance measured by microscopy 
 DP AL P 
Mean parasite clearance time, days 
(SD) 
1.52 (1.32) 1.45 (0.89) > 0.05 
Positive for sexual parasitaemia on day 
3, n (%, 95% CI) 
2/144 (1.4, 0.4-4.9) 2/146 (1.4, 0.4-4.9) > 0.05 
Mean time to 50% parasite clearance, 
days (SD) 
1.08 (0.72) 1.01 (0.85) > 0.05 
Mean time to 90% parasite clearance, 
days (SD) 
1.32 (1.28) 1.27 (0.71) > 0.05 
 
6.3.2 Clinical and haematological findings 
Both DP and AL were well tolerated and all symptoms improved rapidly following 
treatment (Figure 6.5.). By 72 hours, 96.5% (139 of 144, 95% CI 92.1 – 98.5) and 97.3% (142 
of 146, 95% CI 93.2 – 98.9) patients in DP an AL reported no symptom (Figure 6.6.). 
Haemoglobin recovery between two groups did not differ significantly at day 28 (P=0.87), 
although when we performed separate analysis for patients who were enrolled with anaemia 
(Hb < 10.0 gr/dL), we observed significant haemoglobin recovery (P<0.001) compared to 
patients with initial Hb  > 10.0 gr/dL (P=0.13), (Figure 6.7.). The risk factor associated with 
anaemia was living in Langkat regency (OR 2.76, 95% CI 1.02 – 6.87).   
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Figure 6.5. Occurrence of symptoms at enrolment and follow-up days in patients receiving DP 
(n=144) and AL (n=146). Fever was defined as self-reported fever in the preceding 48 
hours on admission or 24 hours during follow-up. 
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Figure 6.6. Proportion of patients with any symptoms during the first 3 days following treatment. 
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Figure 6.7. Comparisons of haemoglobin levels at enrolment and at day 28 between individuals with Hb > 10.0 gr/dL at enrolment, and individuals with Hb < 10.0 gr/dL 
at enrolment. 
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6.3.3 Treatment efficacy 
Recurrent infection with either P. falciparum or P. vivax was detected by microscopy 
in 37 patients (12.8%) during follow-up, each 23 (15.9%) and 14 (9.6%) in DP and AL groups, 
respectively. Of those, 1.4% were early treatment failure with 3 cases in DP arm and 1 case in 
AL arm. One case from each treatment group withdrew on day 3, and two patients treated 
with DP had detectable day 3 parasitaemia greater than 25% of baseline parasite density. 
Three among 29 patients with late failure were associated with clinical symptoms, all were in 
DP treatment group. Two cases of P. vivax parasitaemia emerging after treatment occurred in 
patients with initial diagnosis of P. falciparum only, each at day 7 and day 35. One patient with 
mixed P. falciparum and P. vivax at enrolment had reappearance of P. vivax only at day 42. 
Mean time to any parasite reappearance was similar in both groups with 15.8 (SD 3.5) days 
for those receiving DP and 17.4 (SD 4.0) days in AL (P=0.29). There was no difference for risk 
of treatment failures among patients with mono-inflection of P. falciparum or co-infection of 
P. falciparum and P. vivax at enrolment (13.9% vs 5.3%, P=0.14). 
The uncorrected efficacy of both treatment at day 42 was 84% (95%CI 76.9 – 89.1) for 
DP and 90.4% (95% CI 84.4 – 94.2) for AL (Hazard ratio 0.58, 95% CI 0.29 – 1.1, log-rank=0.09) 
(Figure 6.8.). After correction with PCR, only 1 patient had true recrudescence (Table 6.4.), 
giving 99.3% (95% CI 95.2 – 99.9) efficacy for DP and 100% for AL (log-rank=0.31) (Figure 6.8.). 
Using Cox-regression model, predictors for recurrent infection was age between 5 and 15 
years old (adjusted Hazard Ratio 1.9, 95% CI 1.35 – 2.75, P=0.001), living in South Nias 
(adjusted Hazard Ratio 3.0, 95% CI 1.39 – 6.51, P=0.005) and presence of parasite on day 3 
(adjusted Hazard Ratio 21.2, 95% CI 4.38 – 102.58, P=0.001) (Table 6.6.). 
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Figure 6.8. (A) Survival rate from recurrent Plasmodium infection between DP an AL at day 42 
(log-rank=0.09); (B) Survival rate from recrudescence infection between DP and AL at 
day 42 (log-rank=0.31). 
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Table 6.4. PCR-uncorrected and PCR-corrected efficacy of DP and AL at day 42 
 DP (n=144) AL (n-=146) Hazard Ratio Log-rank 
Uncorrected-PCR     
Early treatment failure     
     P. falciparum only 2.1% (3/144,  
95% CI 0.7 – 6.3) 
0.7% (1/146, 95% 
CI 0.1 – 4.8) 
3.0 (95% CI 
0.32 – 29.2), 
P>0.05 
 
0.31 
     P. vivax only 
 
0% 0%   
Late failure     
     P. falciparum only 14.6% (21/144,  
95% CI 9.8 – 21.6) 
8.9% (13/146,  
95% CI 5.3 – 14.9) 
1.7 (95% CI 
0.85 – 3.4), 
P>0.05 
 
0.12 
     P. vivax only 1.5% (2/144,  
95% CI 0.4 – 5.9) 
0.8% (1/146, 
95% CI 0.1 – 5.2) 
2.14 (95% CI 
0.19 – 23.6), 
P>0.05 
 
0.52 
Adequate clinical and 
parasitological 
outcomes 
 
84% (121/144, 
95% CI 76.9 – 89.1) 
90.4% (132/146, 
95% CI 84.4 – 
94.2) 
0.58 (95% CI 
0.29 – 1.1), 
P>0.05 
0.09 
Corrected-PCR     
Adequate clinical and 
parasitological 
outcomes 
 
99.3% (143/144,  
95% CI 95.2 – 99.9) 
100% (146/146)  0.31 
 
Table 6.5. Unadjusted Hazard Ratio for Plasmodium carriage during post-treatment follow-up 
Risk Factor Hazard Ratio 95% Confidence Interval P Value 
Treatment (DP) 1.7 0.89 – 3.37 0.11 
Location (Batubara) 4.9 1.39 – 17.35 0.01 
Location in South Nias 2.4 1.24 – 4.66 0.009 
Age 
     <5 years  
     5 - <15 years 
     > 15 years 
 
0.2 
1.6 
0.8 
 
0.03 – 1.42 
1.15 – 2.23 
0.66 – 1.04 
 
0.11 
0.006 
0.10 
Sex (Male) 1.2 0.61 – 2.22 0.64 
Temperature > 37.5 at 
enrolment 
3.9 0.53 – 28.22 0.18 
History of malaria in previous 
1 month 
0.8 0.33 – 1.71 0.50 
Log parasite density 0.8 0.53 – 1.18 0.21 
Monoinfection with P. 
falciparum 
0.4 0.09 – 1.51 0.17 
Presence of parasites on day 3  7.6 1.83 – 31.86 0.005 
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Table 6.6. Adjusted Hazard Ratio for Plasmodium reinfection by day 42 
Risk Factor Hazard Ratio 95% Confidence Interval P Value 
Treatment (DP) 1.98 0.98 – 3.98 0.06 
Age between 5 and <15 years 1.92 1.35 – 2.75 0.001 
Location in South Nias 3.00 1.39 – 6.51 0.005 
Log parasite density 1.36 0.83 – 2.23 0.22 
Presence of parasites on day 3  21.2 4.38 – 102.58 0.001 
 
One patient with true recrudescence was an 11 year-old girl from South Nias regency 
diagnosed with P. falciparum infection with initial asexual density of 1,120 p/µL. The patient 
received 3 doses of DP according to her weight (two tablets daily). Her physical examination 
and nutritional status were normal and her clinical symptom was only fever. On follow-up day 
1, asexual parasite density slightly decreased to 1,040 p/µL with emergence of 256 p/µL of 
gametocytes. On follow-up day 2, asexual and sexual parasites densities became 920 p/µL and 
1,240 p/µL, respectively. By day 3, the parasite density was 1,240 p/µL for asexual and 260 
p/µL for sexual parasites. Despite slow parasite clearance, there was no clinical complaints 
recorded on any of the follow-up days. However, due to a delay in the microscopic slide 
reading, the next data obtained was on follow-up day 7 when patient was subsequently 
treated with rescue medication (quinine and doxycycline). At this follow-up, parasite density 
was 480 p/µL for asexual and 1,160 p/µL for sexual parasites before the administration of the 
rescue treatment. PCR genotyping on day 0, day 3 and day 7 was performed to distinguish 
recrusdescence from reinfection. DNA amplification targeting pfmdr1 and pfk13 genes on day 
3 was successful (further discussed in Chapter 7), although amplification was failed by msp1, 
msp2 and glurp genotyping. However, day 7 amplification showed similar band size to the DNA 
amplified from day 0 by msp1, msp2 and glurp genotyping therefore confirming the case as 
true recrudescence (Figure 6.9.). The parasites negativity results on day 3 by this method of 
genotyping might be due to the different variants of subpopulations parasites present in the 
blood or parasites were not present in the peripheral blood during the single sampling 
reflecting a synchronicity in the subpopulations growth.367-369 The use of capillary 
electrophoresis could give an advantage and show more detailed parasite population 
including minority clones in asymptomatic and symptomatic patients.370, 371 
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Figure 6.9. One case of early treatment failure confirmed as true recrudescence by msp1 K1 family genotyping (A), msp2 FC27 family genotyping (B), and glurp 
genotyping (C).
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6.4 Discussion 
Our study demonstrated excellent efficacy of both DP and AL for falciparum malaria 
in western Indonesia. The risk of P. falciparum recrudescence at day 42 was very low at 0.7% 
for DP, while none for AL group. These results are paralleled with previous in vivo studies of 
DP and AL showing efficacy above 90% in both western and eastern parts of the country.176, 
178, 193, 194, 209-212, 217, 218 Artemisinin component kills substantial proportion of parasites rapidly 
in the first few days, and the partner drug acts to clear the residual parasites and protects 
individual for longer period. DP was adopted in Indonesia in 2007, initially as the 
recommended treatment for falciparum malaria in the eastern region but was expanded to 
the whole country in 2012. AL is available in the private sector. 
Despite increasing reports of resistance to artemisinin in the Greater Mekong 
subregion, as manifested by slow clearing parasites (or parasite half-life longer than 5 hours) 
and increased day 3 positivity255, both treatments in our study showed rapid clinical and 
parasitological cure after treatment. However, our study showed lesser protection given by 
DP compared to AL as post-treatment prophylaxis. In this study, patients treated with DP had 
higher risk for recurrent parasitaemia two weeks after receiving their first dose. P. falciparum 
or P. vivax recurrence as detected by microscopy were 16% and 9.6% in DP and AL groups, 
respectively. Weight less than 25 kg has been associated with higher risks of treatment failure 
in children when using the lower DP dosage recommendation (as in this study), with revised 
dose of at least 2.5 mg/kg of dihydroartemisinin and 20 mg/kg of piperaquine per day is now 
being recommended.372 In this study, 13 out of 37 patients (32.4%) with treatment failures 
had body weight less than 25 kg. Inadequate blood level of piperaquine (piperaquine blood 
level < 30 ng/ml at day 7) has also been associated with higher recurrences211, although some 
other studies have demonstrated recrudescent infections in patients with adequate 
piperaquine level.365 We did not measure piperaquine plasma level in patients in this study. 
In western Cambodia where parasite sensitivity to artemisinin is low, emergence of 
resistance to the partner drugs including piperaquine has been documented which resulted 
in declining efficacy of ACTs.118, 365 However, there is no indication that this threat has emerged 
in west Indonesia or elsewhere in the rest of the country. Treatment failures with ACT have 
only been reported using the previous first-line antimalarial ASAQ and were not associated 
with artemisinin resistance.171, 176 Resistant-parasite genotypes to chloroquine are widely 
present in this region (as previously described in Chapter 5) due to intensive historical use of 
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chloroquine, and is suggested to contribute in resistance to amodiaquine. However, this 
association was not directly studied therefore we cannot confirm the correlation of 
chloroquine-resistant alleles with amodiaquine failures. Whether the Sumateran parasite 
genetic background is associated with lesser protection by piperaquine also requires further 
investigation. Chapter 7 discusses the genetic profile of parasites at baseline, parasites 
clearance times measured by quantitative PCR and the association of these factors to 
treatment outcomes. 
 Malaria transmission in North Sumatera is considered to be unstable and low, with 
elimination status aimed by 2020.88 However, our parasite prevalence survey (Chapter 4) prior 
to the start of the study found PCR positivity rates at 25.2%, 33.5% and 34.8% for Batubara, 
Langkat and South Nias regencies, respectively.29 Higher parasite rates in Langkat and South 
Nias suggest higher transmission risk in these regions. Villages in Langkat and South Nias are 
remotely located with limited access to drugs. In the present study, all (97.3%) but one patient 
experiencing recurrent infections were originated from South Nias regency. These data 
demonstrated that increased exposure in South Nias might have contributed to malaria 
recurrences. Other predictor for recurrences was children aged between 5 and 15 years, but 
not in children under 5 years old. This risk is similar to those found in high transmission 
settings, where younger ages have less developed host immunity to malaria infection. 
 One patient with true recrudescence after treatment with DP failed to clear parasites 
until rescue medication was given at day 7. All study drugs were administered according to 
weight-based recommendation and given concomitantly with food as drug absorption is 
increased by fatty food.373 Drug administrations were also directly observed by study staff. The 
patient’s nutritional status was within normal range, and there was no other complaint that 
could be related to poor absorption. Nevertheless, parasite density within the first 72 hours 
was only slightly reduced suggesting poor drug absorption or low sensitivity to artemisinin to 
cause treatment failure. However, the parasites were still not eliminated by day 7 indicating 
partner medicine failed also to clear parasites. There is a strong suggestion that inadequate 
drug level plays a role in the treatment failure. However, as we did not measure piperaquine 
blood level in patients, it is difficult to confirm the cause of treatment failure in this case. 
Assessment on genotypic profile of the parasites including analysis of pfk13-propeller domain 
and copy number of pflasmepsin2 as the resistance markers for this drug combination will 
provide explanation on the contribution of genetic factors on drug efficacy. Chapter 7 
discusses further the association of genetic profiles and treatment outcomes. 
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Other limitation of the study is that we included patients with mixed infection, hence 
not allowing true assessment of P. falciparum infection alone. How further multiple infections 
contribute in treatment outcomes still has to be studied. However, epidemiological studies 
have shown that multiple infections of P. falciparum with P. vivax or P. malariae are often 
occurred together.29, 193 In Indonesia, DP is the drug of choice for all malaria species and also 
given in mixed infections.128 Therefore, inclusion of mixed infections reflects routine clinical 
practice. In this study, only small proportion (13.1%) of mixed infections were enrolled. We 
found no association between species multiplicity at enrolment and treatment outcomes. 
True recrudescence occurred in a patient diagnosed with single P. falciparum infection, and 
only 2 out of 37 patients with recurrent infections had mixed infections with P. vivax. We did 
not perform specific analysis for mixed P. falciparum and P. vivax infections due to small 
numbers of cases.  
In conclusion, our study provides additional information on the extent of artemisinin 
resistance in Southeast Asia beyond Greater Mekong subregion. We show clear evidence on 
high efficacy of two ACTs 5 years after their deployment in west Indonesia. In history, 
chloroquine-resistant parasites took about 10 years before spreading eastward from its origin 
in Cambodia to Indonesia.141 However, whether artemisinin resistance will spread following 
the same historical path or emerge independently in this region remains unknown. Routine 
monitoring by performing regular drug efficacy study supported by molecular markers analysis 
are the key strategy to halt the development of resistance to ACTs in this corner of Southeast 
Asia. 
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7 RESULTS      
Molecular detection and characterisation of 
recurrent parasitaemia following ACT treatment  
 
7.1 Introduction 
Resistance to antimalarial drugs has been a constant challenge for malaria control and 
elimination programmes. Currently artemisinin-based combination therapies (ACTs) are the 
first-line treatment in almost all malaria endemic countries.1, 139 However, reduced 
susceptibility of Plasmodium falciparum toward this combination (artemisinin and the partner 
drugs) has been reported in western Cambodia and other countries in the Greater Mekong 
subregion (GMS).118, 255 The drug failures appearance is so far contained to this region302, but 
stresses the importance of regular monitoring on drug efficacy in all endemic regions, and 
early identification of genetic changes in the parasites.  
P. falciparum polymorphisms associated with reduced sensitivity to ACTs have been 
characterised by mutations in the transporter genes pfcrt and pfmdr1, and the amplification 
of pfmdr1 gene copy number and pfplasmepsin2 gene copy number.199, 268, 269, 294, 295, 359, 374  
Certain mutations in the pfk13 have been identified as markers for artemisinin resistance, the 
currently most potent antimalarial. Polymorphisms in the kelch propeller domain of this gene 
are associated with delayed parasite clearance determined by microscopy268, and residual 
parasites surviving artemisinin pose a risk to facilitate selection of parasites to the partner 
drugs. Moreover, subpatent residual parasites detected on day 3 by quantitative polymerase 
chain reaction (qPCR) have also been suggested to contribute to a higher risk of recurrences 
at day 28 and day 42, which was potentially contributing to parasite transmission to 
mosquitoes.188, 196  
Previous studies from North Sumatera revealed that the majority of P. falciparum 
isolates from this region harbour the pfcrt mutant 76T and pfmdr1 mutant 86Y.107, 109 
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Nevertheless, despite the abandonment of chloroquine and the utilisation of ACT, artesunate-
amodiaquine (ASAQ), since 2004 in this region, our study still documented similar genetic 
signatures of P. falciparum population as previously reported (see Chapter 5). Most P. 
falciparum parasites in our three study sites were shown to harbor the pfcrt SVMNT and 
pfmdr1 86Y and 184Y, and a small proportion of isolates also carried mutant pfk13 (see 
Chapter 5). This is the first study to report the presence of this kelch13 mutant parasites in 
western Indonesia. However, the impact of this mutation on ACT in the background of SVMNT 
and pfmdr1 YY parasites needs further investigation. 
In this study, we evaluated the responses of P. falciparum parasites to 
dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) treatment (Chapter 
6). In this chapter, we characterise the genetic profiles of parasites prior to treatment, we 
assess parasite clearance dynamics following ACTs treatment, and determine the association 
between baseline polymorphisms, parasite clearance rate and parasite genotypes from 
recurrent isolates on days 28 and 42 to evaluate post-treatment selection in vivo.  
Comparisons are made between the two treatment arms and among study sites. 
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7.2 Methods 
7.2.1 Samples collection  
Samples were obtained from patients enrolled in the in vivo drug efficacy study 
collected between January and June 2015 in North Sumatera province, Indonesia. Inclusion 
and exclusion criteria for enrollment were described in Chapter 6. Patients with P. falciparum 
malaria were randomised to receive either DP or AL, and patients were followed-up for 42 
days after treatment. Samples were then analysed for drug resistance markers related to the 
study drugs including pfcrt, pfmdr1, pfk13, and pfmdr1 copy numbers. Parasite clearance 
times following treatment were also measured by qPCR assay. End-point outcome was the 
cumulative risk of P. falciparum recurrences at day 42 as detected by polymerase chain 
reaction (PCR). 
The study protocol was approved by the ethics committee of the London School of 
Hygiene and Tropical Medicine, United Kingdom (London, United Kingdom; 8504-01) and by 
the ethics committee of University of Sumatera Utara, Indonesia (Medan, Indonesia; 
401/KOMET/FKUSU/2014). The study was registered at ClinicalTrials.gov under number 
NCT02325180. 
 
7.2.2 Characterisation of parasite polymorphisms 
7.2.2.1 Polymorphisms in the pfcrt, pfmdr1 and pfk13 
Parasite DNA was extracted from blood spots on 3MM Whatman filter papers and 
from rapid diagnostic tests following either the Chelex or QIAsymphony extraction 
methods.320 Protocols for amplification and sequencing of pfcrt270, pfmdr1273 and pfk13268 
genotyping were as described in the methods section of chapter 5. Codons 72 to 76 in pfcrt, 
codons 86, 184, 1034, 1042 and 1246 in pfmdr1, and propeller domain of pfk13 are of 
particular interest. The proportion of each haplotype was calculated and compared between 
the two treatment arms and study sites. 
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7.2.2.2 Pfmdr1 copy number 
Pfmdr1 gene copy number was assessed by a multiplex real-time qPCR Rotor-gene® 
Q thermocycler (Corbett Research, Australia) following a protocol by Price with 
modification.199 Each isolate was tested in duplicate with control DNA from P. falciparum lines 
3D7 and 7G8 (1 copy of pfmdr1 each) and Dd2 (2 copies of pfmdr1) included in each 
experiment. The primers and probes for the amplification are provided in Table 7.1. Mastermix 
reaction was prepared in 25 µL containing 5 µL of template DNA, NH4 buffer, 5.5 mM MgCl2, 
300 µM deoxynucleotides (dNTPs), 300 nM for each forward and reverse primer, 100 nM of 
each probe, 8% glycerol, and 1 unit of BIOTAQ (Bioline, UK). The amplification cycling 
conditions were 95 °C for 6 minutes as initial denaturation, followed by 45 cycles of 95 °C for 
15 seconds and 58 °C for 1 minute. 
 
Table 7.1. Primers and probes for pfmdr1 copy number amplification199 
Gene Primer 5’ Fluorophore Sequence 3’ 
Quencher 
Pfmdr1 Pfmdr1-1F  5’-TGC ATC TAT AAA ACG ATC AGA CAA A-3’  
 Pfmdr1-1R  5’-TCG TGT GTT CCA TGT GAC TGT-3’  
 Pfmdr1-
probe  
FAM 5’-TTT AAT AAC CCT GAT CGA AAT GGA ACC 
TTT G-3’ 
BHQ2 
ß-
tubulin 
ß-tubulin-
1F 
 5’-TGA TGT GCG CAA GTG ATC C-3’  
ß-tubulin-
1R 
 5’-TCC TTT GTG GAC ATT CTT CCT C-3’  
ß-tubulin-
probe  
JOE 5’-TAG CAC ATG CCG TTA AAT ATC TTC CAT 
GTC T-3’ 
BHQ2 
 
The qPCR assay generates fluorescent signals for the target (pfmdr1) and reference 
(P. falciparum ß tubulin) genes. The threshold was set above negative controls run in the same 
assay. The cycle threshold (Ct) is determined when the amplification of target (CtG) and 
reference (CtR) genes cross the set threshold. The concentration of genomic DNA was then 
estimated using the formula Ct=CtR-CtG. This value was plotted against the log of initial DNA 
concentration. Then the formula Ct=CtE-CtB was calculated, with CtE as the experimental Ct 
and CtB as the baseline Ct. Relative expression was then calculated as 2-Ct to account for the 
exponential properties of PCR. Results were rejected if Ct spread > 1.5 or Ct values >35. 
Value above 1.5 classified as multicopy.199 
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7.2.3 Parasite clearance times 
Parasite density at day 0, 1, 2 and 3 were also measured with Rotor-gene® Q 
thermocycler (Corbett, Australia) using the method described by Beshir.321 Reaction mixture 
of 25 µL was prepared containing 5 µL of template DNA, 10X NH4 buffer, 5.5 mM MgCl2 buffer, 
300 µM dNTPs, 300 nM forward and reverse primer, 200 nM of each probes (Eurofin), 1.0 unit 
of BIOTAQ DNA polymerase (Bioline, UK). Cycling conditions were 95 °C for 6 minutes, 
followed by 40 cycles of 95 °C for 15 seconds and 68 °C for 1 minute. Primers and probes for 
Plasmodium tRNA methionine (PgMET) and human β tubulin gene (HumTuBB) amplification 
are provided in Table 7.2. All samples were run in duplicate with the WHO International 
Standard as control for P. falciparum DNA.335 Difference of parasite target gene (PgMET) Ct 
and the human reference gene (HumTuBB) Ct was calculated with the formula of Ct=Ct PgMET-
Ct HumTuuBB. The change over time in Ct was calculated using formula Ct(n)= Ct(n)- Ct(0), with 
n as time after treatment and 0 as time before treatment. Parasite density was then measured 
against the calibrator sample (day 0) using formula 2-Ct.321 Using this model, parasite 
prevalence and relative density over the first 72 hours after treatment were determined. 
Parasite reduction ratio to 50% (PRR50) and to 90% (PRR90) were also determined. 
 
Table 7.2. Primers and probes for parasite clearance time assay321  
Primer 5’ 
Fluorophore 
Sequence 3’ 
Quencher 
PgMET_F1  5’-TGAAAGCAGCGTAGCTCAGA-3’  
PgMET_R2  5’-CGCGTGGTTTCGATCCACG-3’  
PgMET_pB FAM 5’-GGGGCTCATAACCCCCAGGA-3’ BHQ2 
HumTuBB_F2  5’-AAGGAGGTCGATGAGCAGAT-3’  
HumTuBB_R2  5’-GCTGTCTTGACATTGTTGGG-3’  
HumTuBB_Joe JOE 5’-TTAACGTGCAGAACAAGAACAGCAGCT-
3’ 
BHQ2 
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7.2.4 Study outcomes 
7.2.4.1 Microscopy-detected treatment failures 
Samples with detectable parasites by microscopy on follow-up days which met the 
criteria for treatment failure according to the WHO classification172 were further analysed. A 
conventional nested PCR amplification targeting the 18S rRNA and sicavar genes were 
performed for species determination.29, 332 Genetic characterisations were also performed on 
samples with PCR-corrected confirmed recrudescence.199, 268, 270, 273 
 
7.2.4.2 PCR-detected recurrences 
To further evaluate post-prophylaxis protection by both ACTs, we performed 
molecular screening to detect any subpatent recurrences on samples collected on day 28 and 
day 42 or on any last day samples available. All available samples were screened using qPCR 
Rotor-gene® Q assay (Corbett, Australia) targeting parasite PgMET gene following similar 
protocol in the parasite clearance times assay (see Chapter 7.2.3.). This assay amplifies a 
fragment of PgMET in all human Plasmodium species.321 Hence, samples with Ct value < 35 
were further analysed for Plasmodium speciation using nested PCR with a target of 18S rRNA 
gene.332 Additional nested PCR targeting pfmdr1 was also performed to increase the sensitivity 
to detect P. falciparum recurrences. 
 
7.2.5 Statistical analysis 
Data analysis was done using Stata IC (version 15, StataCorp, TX, USA). Logistic 
regression analysis was used to estimate the association between baseline genotypes and  day 
3 positivity by qPCR or the event of recurrences. Odds ratio and 95% confidence intervals were 
estimated. Treatment outcomes were determined by calculating the cumulative of 
recurrences with P. falciparum at day 42 using Kaplan Meier survival analysis and log-rank test. 
Cox-regression analysis was used to predict risk factor for recurrences. P values of < 0.05 are 
considered statistically significant. 
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7.3 Results 
A total of 302 patients with uncomplicated P. falciparum infection were enrolled in 
the drug efficacy study. Baseline characteristics of patients were described in Chapter 6. Post 
hoc PCR assays targeting the 18S rRNA332, pfmdr1273 and sicavar29 gene were performed to 
confirm the presence of P. falciparum parasites and to identify other Plasmodium species in 
each isolate prior to treatment (see Section 4.2.). Surprisingly, in Batubara, Langkat and South 
Nias regencies, parasite DNA was detected in 91.7% (33 of 36), 72.1% (31 of 43), and 58.8% 
(131 of 223) of samples (Table 7.3.), respectively. Of these, only 117 (38.8%) samples were 
positive for P. falciparum infection, 57 (48.8%) in the DP-treated arm and 60 (51.2%) in the 
AL-treated arm. 
 
Table 7.3. Confirmation of Plasmodium species by PCR among enrolled patients 
PCR diagnosis* 
Batubara,  
n (%) 
Langkat,  
n (%) 
South Nias,  
n (%) 
Overall,  
n (%) 
Negative 3/36  
(8.3) 
12/43 
(27.9) 
92/223  
(41.3) 
107/302 
(35.4) 
P. falciparum 20/36  
(55.6) 
23/43 
(53.5) 
34/223 
(15.2) 
77/302 
(25.5) 
P. falciparum + other 
Plasmodium species 
10/36  
(27.8) 
2/43  
(4.7) 
28/223 
(12.6) 
40/302 
(13.2) 
Other Plasmodium species 3/36  
(8.3) 
6/43 
(13.9) 
69/223 
(30.9) 
78/302 
(25.8) 
*Diagnosis was determined by PCR assays targeting the 18S rRNA, Pfmdr1, sicavar gene (see text). 
 
7.3.1 Genetic markers of parasites at baseline 
Genotyping of the pfcrt gene using qPCR assay was successful in 60.1% (71 of 117; 34 
isolates in DP, 37 isolates in AL) of samples harbouring P. falciparum infection. Mutant 
haplotype encoding SVMNT was the most prevalent haplotype in both DP (22 of 34, 64.7%) 
and AL groups (30 of 37, 81.1%). Wild-type CVMNK was present in 32.4% (11 of 34) and 16.2% 
(6 of 37) isolates in DP and AL treatment arms, while CVIET was less common with prevalence 
of 8.8% (3 of 34) and 8.1% (3 of 37) in DP and AL groups, respectively. 20.6% of DP-treated 
samples and 16.2% of AL-treated samples harboured mixed wild-type and mutant haplotypes. 
Stratified by regency, the pfcrt-SVMNT remained the most observed haplotype in each site 
(Table 7.4., Figure 7.1.).  
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Table 7.4. Baseline prevalence of pfcrt polymorphisms in DP and AL treatment arms according 
to site 
Pfcrt 72-76  
haplotype 
Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall, 
n (%) DP AL DP AL DP AL 
CVMNK 0/25  
(0) 
0/25 
(0) 
1/22  
(4.5) 
0/22  
(0) 
3/24 
(12.5) 
0/24 
(0) 
4/71 
(5.6) 
CVIET 0/25 
(0) 
0/25 
(0) 
0/22  
(0) 
0/22  
(0) 
2/24 
(8.3) 
2/24 
(8.3) 
4/71 
(5.6) 
SVMNT 11/25 
(44.0) 
12/25 
(48.0) 
6/22 
(27.3) 
9/22 
(40.9) 
4/24 
(16.7) 
8/24 
(33.3) 
50/71 
(70.4) 
CVMNK-SVMNT 0/25 
(0) 
1/25 
(4.0) 
4/22 
(18.2) 
1/22 
(4.5) 
2/24 
(8.3) 
3/24 
(12.5) 
11/71 
(15.5) 
CVMNK-CVIET-SVMNT 1/25 
(4.0) 
0/25  
(0) 
0/22 
(0) 
1/22 
(4.5) 
0/24 
(0) 
0/24 
(0) 
2/71 
(2.8) 
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Figure 7.1. Baseline pfcrt 72-76 polymorphisms according to study sites (Overall n=71, n=25 for 
Batubara, n=22 for Langkat, and n=24 for South Nias). 
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Amplification of the pfmdr1 gene was successful in 82.1% (96 of 117) isolates. Pre-
treatment prevalence of pfmdr1 86, 184, 1034, 1042 and 1246 alleles are presented in Table 
7.5, with mutant 86Y and wild-type 184Y were shown as the most prevalent. The wild-type 86 
occurred in 34.0% and 21.3% of samples in DP and AL, respectively, and rare mutant 86S was 
also present in two isolates in the AL group. The genotypes from alleles 86 and 184 were then 
collated into haplotype (see Chapter 5). Mixed alleles were included in the analysis, assuming 
one of the haplotypes of interest occurred. Our analysis showed haplotype YY of pfmdr1 gene 
was the most predominant haplotype with proportions of 65.3% (32 of 49) in DP and 76.6% 
(36 of 47) in AL, respectively. Isolates harbouring haplotype NF and NY were 6.1% and 22.5% 
in DP group, and 4.3% and 14.9% in AL group. Haplotype-YY was also found to be the most 
predominant in Batubara and Langkat, while haplotype NY was equally common as mutant 
haplotype-YY in South Nias. The proportions of these haplotypes according to site are shown 
in Table 7.6 and Figure 7.2. 
 
Table 7.5. Baseline prevalence of pfmdr1 alleles in DP and AL treatment arms  
Pfmdr1 
DP, n (%) AL, n (%) 
Wild-
type 
Mutant Other  Mixed Wild-
type 
Mutant Other  Mixed 
N86Y  
16/47  
(34.0) 
30/47  
(63.8) 
0/47 
(0) 
1/47  
(2.1) 
8/45 
(21.3) 
34/45 
(75.6) 
2*/45 
(4.5) 
1/45  
(2.2) 
Y184F 
42/46 
(91.3) 
4/46 
(8.7) 
0/46 
(0) 
0/46 
(0) 
41/45 
(91.1) 
4/45 
(8.9) 
0/45 
(0) 
0/45 
(0) 
S1034 
22/22 
(100) 
0/22 
(0) 
0/22 
(0) 
0/22 
(0) 
25/25  
(100) 
0/25 
(0) 
0/25 
(0) 
0/25 
(0) 
N1042  
22/22 
(100) 
0/22 
(0) 
0/22 
(0) 
0/22 
(0) 
25/25  
(100) 
0/25 
(0) 
0/25 
(0) 
0/25 
(0) 
D1246Y  
22/22 
(100) 
0/22 
(0) 
0/22 
(0) 
0/22 
(0) 
21/21 
(100) 
0/21 
(0) 
0/21 
(0) 
0/21 
(0) 
*86S was present in two samples in the AL group. 
Table 7.6. Baseline prevalence of pfmdr1 86/184 haplotypes in DP and AL treatment arms 
according to site 
Pfmdr1  
haplotype 
Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall,  
n (%) DP AL DP AL DP AL 
86N/184Y 0/27 
(0) 
0/27 
(0) 
0/22 
(0) 
0/22 
(0) 
11/43 
(25.6) 
7/43 
(16.3) 
18/92 
(19.6) 
86N/184F 0/27 
(0) 
0/27 
(0) 
1/22 
(4.5) 
0/22 
(0) 
2/43 
(4.7) 
2/43 
(4.7) 
5/92  
(5.4) 
86Y/184Y 13/27 
(48.2) 
14/27 
(51.8) 
10/22 
(45.5) 
10/22 
(45.5) 
9/43 
(20.9) 
12/43 
(27.9) 
67/92 
(72.8) 
86S/184F 0/27 
(0) 
0/27 
(0) 
0/22 
(0) 
1/22 
(4.5) 
0/43 
(0) 
1/43 
(2.3) 
2/92 
(2.2) 
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Figure 7.2. Baseline pfmdr1 haplotypes according to study sites (Overall n=92, n=27 for Batubara, 
n=22 for Langkat, and n=43 for South Nias). 
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Pfmdr1 copy number was successfully determined in 35 samples and gene 
amplifications were observed in 14 (40%) samples. There was no difference in the proportion 
of single copy pfmdr1 between location or treatment (Table 7.7.). 
 
Table 7.7. Proportion of single and multicopy numbers of pfmdr1 gene according to treatment 
arms 
Copy numbers 
Single copy, n (%) Multi copy, n (%) 
Batubara Langkat South Nias Batubara Langkat South Nias 
     DP, n (%) 9/11 
(81.8) 
1/11 
(9.1) 
1/11 
(9.1) 
1/5 
(20.0) 
0/5 
(0) 
4/5 
(80.0) 
     AL, n (%) 3/10 
(30) 
3/10 
(30) 
4/10 
(40) 
6/9 
(66.7) 
1/9 
(11.1) 
2/9 
(22.2) 
 
Genotyping analysis on pfk13 propeller domain revealed high proportion of wild-type 
parasites. All isolates (38 of 38, 100%) in DP arm and 91.9% (34 of 37) in AL arm harboured 
artemisinin-sensitive parasites. Three isolates (8.1%) in the AL group had a mixed wild-type 
and mutant K13 carrying T474A mutation (Figure 7.3.), these were detected in Batubara and 
Langkat (Table 7.8. and Figure 7.4.). All three mutant K13 isolates had a background of pfcrt-
SVMNT haplotype. Two of the three had pfmdr1 haplotype YYSND on the interest alleles, and 
one sample had SFSND haplotype. None of the known K13 mutations associated with 
artemisinin resistance was detected in any of our samples.  
Overall, the majority of the samples harboured the pfcrt SVMNT and pfmdr1 YYSND 
haplotypes. These haplotypes were also observed as the majority haplotypes in Batubara (96% 
for pfcrt and 100% for pfmdr1) and Langkat (72.7% for pfcrt and 86.9% for pfmdr1). In contrast, 
only 50% and 44.7% of patients in South Nias displayed these haplotypes at baseline. These 
findings are similar to our previous observations described in Chapter 5. 
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Figure 7.3. Sequences of propeller domain of pfk13 in three patients with mixed wild-type and mutant at allele T474A. 
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Figure 7.4. Baseline pfk13 propeller domain polymorphisms according to study sites (Overall n=75, 
n=25 for Batubara, n=23 for Langkat, and n=27 for South Nias). 
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Table 7.8. Baseline prevalence of pfk13 wild-type and mutant alleles in DP and AL treatment arms 
according to site 
Pfkelch13 Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall,  
n (%) DP AL DP AL DP AL 
Wild-type 12/25 
(48.0) 
12/25 
(48.0) 
12/23 
(52.2) 
9/23 
(39.1) 
14/27 
(51.9) 
13/27 
(48.1) 
72/75 
(96.0) 
Mutant 0/25 
(0) 
1/25 
(4.0) 
0/23 
(0) 
2/23 
(8.7) 
0/27 
(0) 
0/27 
(0) 
3/75 
(4.0) 
 
7.3.2 Parasite clearance dynamics by qPCR 
A total of 126 (41.7%) patients showed qPCR amplification on day 0 and these samples 
were then measured for parasite clearance dynamics for the first 72 hours following ACT 
treatment using the duplex qPCR assay. Of these, 72 samples were in the DP group and 54 in 
the AL group. The proportion of patients with detectable parasite DNA and relative parasite 
density were measured daily by qPCR as plotted in Figure 7.5. At 72 hours, 8.3% (6/72) and 
11.1% (6/54) of patients in DP and AL groups harboured residual parasitaemia (P=0.59). These 
proportion detected by qPCR were significantly higher compared to those detected by 
microscopy (9.3% by qPCR versus 1.4% by microscopy, P=0.002). The median density of these 
residual parasites was 17.2% (of initial density 464 parasite/µL, IQR 7.0% - 70.9%) in DP and 
2.4% (of initial density 304 parasite/µL, IQR 0.6% - 12.8%) in AL against pre-treatment parasite 
density. We did not find any risk factor including age, regency, treatment, or baseline genetic 
profiles including the presence of K13 mutation T474A to be associated with qPCR positivity at 
72 hours (Table 7.9.). Two out of three patients with this mutation cleared parasites within 24 
hours, and one patient was excluded from the study due to failure to amplify DNA by qPCR. All 
but one isolate with qPCR-detectable parasites on day 3 were also not detected by microscopy, 
and patients were only followed-up again on the next scheduled follow-up on day 7. We 
assumed that parasites would be cleared by day 7, therefore the mean parasite clearance times 
were 1.6 and 1.9 days in DP and AL groups, respectively. Mean PRR50 and PRR90 were 1.01 
and 1.04 days in DP group, and 1.0 and 1.04 days in AL group.  
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Figure 7.5. Parasite prevalence and relative parasite density as determined by qPCR from days 0 to 3. Left-y-axis, qPCR parasite prevalence (bars). Right-y-axis, 
median relative parasite density relative to enrollment value. (n=72 for DP and n=54 for AL).
INKE LUBIS                                                            CHARACTERISATION OF RECURRENT PARASITAEMIA 211 
Table 7.9. Risk factor associated with qPCR positivity at day 3 
Risk Factor n Odds Ratio 95% Confidence Interval P Value 
Treatment 
    DP 
 
129 
 
0.75 
 
0.23 – 2.45 
 
0.63 
Location 
    Batubara 
    Langkat 
    South Nias 
 
129 
 
Reference 
2.0 
1.37 
 
 
0.19 – 21.23 
0.15 – 11.78 
 
 
0.56 
0.78 
Age 129 0.99 0.96 – 1.03 0.84 
Agegroup 
     <5 years 
     5 - <15 years 
     > 15 years 
 
129 
 
 
Reference 
1.15 
1 
 
 
0.34 – 3.87 
 
 
 
0.82 
 
Sex 
     Male 
 
129 
 
0.31 
 
0.08 – 1.19 
 
0.07 
Self-reported fever at 
enrollment 
 
129 
 
1.29 
 
0.32 – 5.14 
 
0.721 
Log-parasite density 121 0.86 0.50 – 1.47 0.56 
Pfcrt haplotype* on day 0 
     CVMNK 
     CVIET 
     SVMNT 
 
41 
40 
41 
 
1.21 
1 
0.7 
 
0.11 – 13.25 
 
0.06 – 7.78 
 
0.88 
 
0.77 
Pfmdr1 haplotype* on day 0 
     86N/184F 
     86Y/184Y 
     86N/184Y 
 
59 
59 
58 
 
4.17 
1.21 
0.68 
 
0.33 – 53.12 
0.21 – 6.9 
0.07 – 6.34 
 
0.27 
0.83 
0.73 
*Odds ratio was calculated against other isolates harbouring haplotypes other than the measured 
haplotype 
 
7.3.3 Treatment failures 
Thirty-seven (12.8%) patients were classified as having treatment failures according to 
the WHO treatment outcomes in a modified intention to treat (mITT) analysis. Of those, 29 
patients were parasite positive by microscopy during follow-up period and 8 withdrew from 
the study. Samples on day of failure from the 29 patients were screened by nested PCR for 
species determination. 34.7% (10/29) amplified parasite DNA (Table 7.10.) and only 10.4% 
(3/29) had recurrent P. falciparum infection. Among P. falciparum recurrences, only one 
patient was confirmed as having true recrudescence, while two had new infections. Genetic 
profiles of recrudescent parasite at enrolment and day of failure are shown in Table 7.11.  
Interestingly, PCR revealed P. malariae to be the predominant species among samples 
with microscopy-positive treatment failures. 50% of post-treatment P. malariae infection 
appeared as single infection and 20% as mixed infection with one case occurring each at days 
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3, 7, 21, 35 and 42, and two cases were detected at day 14. Only 2 of these patients had P. 
malariae detected by PCR at enrolment and failed treatment at day 7 and 14. 
 
Table 7.10. Species confirmation by PCR for patients classified for treatment failures identified by 
microscopy 
Treatment Patient 
ID 
Species at enrolment 
by PCR 
Day of 
failure 
Species at day of failure  
by PCR 
DP 051 P. falciparum, P. malariae, P. 
knowlesi 
7 P. malariae 
 172 P. vivax 14 P. malariae 
 190 P. falciparum, P. vivax 7 P. falciparum 
 208 P. falciparum, P. knowlesi 21 P. malariae 
 217 P. falciparum, P. vivax 42 P. malariae 
 226 Negative 14 P. knowlesi 
 286 P. malariae 14 P. malariae 
 354 P. falciparum 3 P. falciparum, P. malariae 
AL 220 P. vivax, P. knowlesi 35 P. falciparum, P. vivax, P. malariae 
 266 Negative 14 P. knowlesi 
 
Table 7.11. Genetic profiles at baseline and follow-up days for DP-treated patient ID 190 with 
recrudescent P. falciparum parasitaemia 
Sampled day Pfcrta Pfmdr1b Pfk13 Pfmdr1 CN 
Day 0 SVMNT YYD WT Multi copy 
Day 1 SVMNT YYD WT NA 
Day 2 SVMNT YYD WT NA 
Day 3 SVMNT YYD WT Multi copy 
Day 7 SVMNT YYD WT Single copy 
aCodon 72-76 of Pfcrt gene; bCodon 86, 184 and 1246 of Pfmdr1 gene; WT=Wild-type; 
NA=Not available 
 
7.3.4 Subpatent Plasmodium recurrences detected by qPCR 
qPCR detected 7 (2.6%) and 14 (5.2%) patients with subpatent Plasmodium spp. 
recurrences at day 28 and day 42, respectively. Species confirmation by nested PCR for the 
majority of these, 5 and 11 patients in days 28 and 42, respectively, were indeterminate, and 
these patients were regarded as cured in the analysis. Two patients with confirmed diagnosis 
at day 28 each had mixed P. falciparum and P. vivax infection, and P. vivax only, respectively, 
while at day 42, 2 patients were confirmed as having P. vivax infection (Table 7.12.). qPCR 
positivity on day 3 (OR 10.5, 95% CI 1.3 – 82.8, P=0.03) was associated with increased qPCR 
positivity at day 28. 
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Table 7.12. Plasmodium spp. recurrences at day 28 and day 42 as detected only by qPCR between 
two treatment arms 
 qPCR positive DP, n (%) AL, n (%) P value 
18S rRNA nested PCR Day 28    
    Negative 
   P. falciparum 
3/137 (2.2) 
1/137 (0.7) 
2/135 (1.5) 
0/135 (0) 
0.26 
    P. falciparum &  vivax 1/137 (0.7) 0/135 (0)  
18S rRNA nested PCR Day 42 
   Negative 
 
5/137 (4.4) 
 
6/135 (4.4) 
 
0.46 
    P. falciparum (%) 0/137 (0) 0/135 (0)  
    P. vivax (%) 2/137 (1.5) 0/135 (0)  
 
7.3.5 Subpatent P. falciparum recurrences detected by nested PCR of 
pfmdr1 
Amplification of pfmdr1 fragment 1 was the most sensitive tool for detection of P. 
falciparum infection, therefore to increase our ability to detect P. falciparum recurrences, we 
deployed this assay to screen our samples for recurrences. The proportion of subpatent P. 
falciparum recurrences as determined by nested-PCR targeting pfmdr1 gene was higher during 
follow-up than those detected by qPCR (Figure 7.6.), however it was not statistically different 
between the two treatment arms (Hazard ratio 1.08; 95% CI, 0.70-1.62, P=0.09). There were a 
total of 31 and 45 treatment failures at days 28 and 42 in the DP arm, and a total of 28 and 43 
treatment failures at days 28 and 42 in the AL arm, respectively (Table 7.13.). The risk of having 
subpatent P. falciparum recurrence increased in patients residing in Langkat (unadjusted HR 
2.87; 95% CI, 2.29-3.60; P<0.001), and with starting higher parasite density (unadjusted HR 
1.28, 95% CI 1.10-1.49; P<0.001), (Table 7.15.). However, after adjustment with other risk 
factors (Table 7.16.), living in Langkat was the only factor increased the risk to acquire 
subpatent P. falciparum infection at day 42 (adjusted HR 3.28; 95% CI, 2.14-4.73; P<0.001). 
 
Table 7.13. Subpatent P. falciparum recurrences after DP and AL at day 28 and day 42 
PCR recurrences DP (n=139)* AL (n-=142) Hazard Ratio Log-rank 
Day 28 21.7% (95% CI 
0.16 – 0.29) 
19.7% (95% CI 
0.14 – 0.27) 
1.13 (95% CI 
0.68 – 1.88), 
P=0.639 
0.607 
Day 42 31.5% (95% CI 
0.24 – 0.39) 
30.4% (95% CI 
0.24 – 38.7) 
1.08 (95% CI 
0.70 – 1.62), 
P=0.09 
0.741 
*DP as the reference for treatment 
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Table 7.14. Proportion of P. falciparum recurrences according to study sites 
Recurrence Batubara, n (%) Langkat, n (%) South Nias, n (%) Overall, n (%) 
Day 28     
     Yes 5/32 (15.6) 35/41 (85.4) 13/206 (6.3) 53/279 (19.0) 
     No 27/32 (84.4) 6 (14.6) 193/206 (93.7) 193/206 (81.0) 
Day 42     
     Yes 4/33 (12.1) 36/41 (87.8) 19/206 (9.2) 59/280 (21.1) 
     No 29/33 (87.9) 5/41 (87.8) 187/206 (90.8) 221/280 (78.9) 
 
Table 7.15. Unadjusted Hazard Ratio for Plasmodium spp. recurrences by day 42 
Risk Factor Hazard Ratio 95% Confidence Interval P Value 
Treatment  
     DP 
 
1.07 
 
0.70 – 1.62 
 
0.09 
Location 0.63 0.49 – 0.79 0.001 
Location in Langkat 2.87 2.29 – 3.60 0.001 
Age 
     <5 years 
     5 - <15 years 
     > 15 years 
 
1.05 
0.84 
1.11 
 
0.55 – 1.98 
0.67 – 1.05 
0.96 – 1.28 
 
0.87 
0.11 
0.14 
Sex 
     Male  
 
0.82 
 
0.54 – 1.26 
 
0.37 
Temperature > 37.5 at 
enrollment 
0.81 0.42 – 1.57 0.54 
History of malaria in previous 
1 month 
1.24 0.62 – 2.51 0.54 
Parasite density 1.28 1.10 – 1.49 0.001 
Presence of parasites on day 3 
     By microscopy 
     By qPCR 
 
2.30 
1.50 
 
0.56 – 9.35 
0.59 – 3.84 
 
0.24 
0.39 
Pfcrt haplotype* on day 0 
     CVMNK 
     CVIET 
     SVMNT 
 
0.83 
1.15 
1.18 
 
0.34 – 2.03 
0.35 – 3.78 
0.51 – 2.76 
 
0.68 
0.82 
0.69 
Pfmdr1 haplotype* on day 0 
     86N/184F 
     86Y/184Y 
     86N/184Y 
 
1.23 
2.09 
0.12 
 
0.29 – 5.13 
0.87 – 5.02 
0.02 – 0.86 
 
0.77 
0.10 
0.03 
*Hazard ratio was calculated against other isolates harbouring haplotypes other than the measured 
haplotype 
 
Table 7.16. Adjusted Hazard Ratio for Plasmodium spp. recurrences by day 42 
Risk Factor Hazard Ratio 95% Confidence Interval P Value 
Treatment (DP) 1.31 0.66 – 2.60 0.45 
Location in Langkat 3.28 2.14 – 4.73 0.001 
Parasite density 1.11 0.85 – 1.46 0.45 
Presence of parasites on day 3 
by qPCR 
1.15 0.42 – 3.15 0.78 
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Figure 7.6.  Survival rate of P. falciparum subpatent recurrences detected by pfmdr1 between DP and AL at day 42 (log rank=0.741). 
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7.3.6 Post-treatment parasite selection 
As we have provided evidence of subpatent recurrences in patients receiving DP and 
AL treatment, we investigated the differences in the pfmdr1 polymorphisms between the two 
treatment arms before and after treatment at follow-up days 28 and 42. Genotyping data of 
pfmdr1 alleles 86 and 184 from enrolment day, day 28 and day 42 were compared between 
both treatment arms (Table 7.17.). Similar criteria to collate the pfmdr1 haplotype were used 
as in section 7.3.1. In previous studies, patients with parasites harbouring pfmdr1 
86Y/184Y/1246Y haplotype treated with AL were significantly less likely to retain this 
haplotype during post-treatment follow-up, and instead AL selected parasites with pfmdr1 
86N/184F/1246D.273, 297 However, there are conflicting results of parasites selection after the 
use of DP, with some studies showed selection for the polymorphisms associated with 
aminoquinoline resistance362 while others showed the opposite selection.364 In this study, we 
observed a significant increase of wild-type N86 and mutant 184F at day 28 and day 42 in both 
treatment arms (Table 7.17.). Our findings also observed stronger selection for wild-type N86 
for parasites treated with AL than that with DP at days 28 (P=0.70) and 42 (P=0.89), although 
they were not significant (Table 7.18). The proportion of patients carrying the haplotype NF 
prior to treatment were 6% and 4.3% in DP and AL, also increased to 70% and 52% in DP and 
AL at day 28, and to 45.4% and 56% at day 42, respectively. This post-treatment haplotype-NF 
replaced the dominant haplotype-YY at baseline (64.0% for DP and 76.6% for AL). Based on 
the study sites, we also observed increased changes to N86 in all study sites, however changes 
for 184F were seen in Batubara and Langkat only, but not in South Nias (Figure 7.8.).  
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Table 7.17. Prevalence of polymorphisms in pfmdr1 gene before and after treatment with DP and 
AL in 47 individuals positive by pfmdr1 PCR at day 28 or 42 
Pfmdr1 
DP, n (%) AL, n (%) P 
Value Wild-type Mutant Mixed Wild-type Mutant Mixed 
Day 0        
   N86Y  
16/47  
(34.0) 
30/47  
(63.8) 
1/47  
(2.1) 
8/45  
(21.3) 
36/45*  
(80.0) 
1/45  
(2.2) 
 
   Y184F  
42/46 
(91.3) 
4/46 
(8.7) 
0/46 
(0) 
41/45 
(91.1) 
4/45 
(8.9) 
0/45 
(0) 
 
Day 28        
   N86Y  10/20  
(50) 
3/20  
(15) 
7/20  
(35) 
16/26 
(61.5) 
5/26 
(19.2) 
5/26  
(19.2) 
0.48 
   Y184F  3/20  
(15) 
13/20  
(65) 
4/20  
(20) 
8/25  
(32) 
12/25  
(48) 
5/25  
(20) 
0.39 
Day 42        
   N86Y 14/22 
(63.6) 
4/22  
(18.2) 
4/22 
(18.2) 
15/26 
(57.7) 
3/16  
(11.5) 
8/26  
(30.8) 
0.55 
   Y184F 8/22  
(36.4) 
11/22  
(50) 
3/22  
(13.6) 
9/25  
(36.0) 
13/25  
(52.0) 
3/25  
(12.0) 
0.98 
*Proportion contained 2 (4.4%) samples harbouring mutant 86S. 
 
Table 7.18. Prevalence of pfmdr1 haplotypes after treatment with DP and AL at days 28 and 42 
Pfmdr1 alleles 
N86 and 184F 
Odds Ratio: Occurrence on day 28 
versus baseline (95% CI) 
Odds Ratio: Occurrence on day 42 
versus baseline (95% CI) 
DP   
     N86/184F OR 36.6, 95% CI 6.9-235.4, P=0.0001 OR 13.1, 95% CI 2.7-81.4, P=0.0001 
AL        
     N86/184F OR 24.4, 95% CI 4.4-237.2, P<0.0001 OR 28.6, 95% CI 5.1-277.7, P<0.0001 
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Figure 7.7. Prevalences of wild-type, mutant and mixed alleles of pfmdr1 86 and 184 at baseline, 
day 28 and day 42 in patients treated with DP and AL which harboured PCR detectable 
P. falciparum during follow-up. 
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Figure 7.8. Prevalences of wild-type, mutant and mixed alleles of pfmdr1 86 and 184 among 
patients with P. falciparum infection according to study sites during follow-up at 
baseline, day 28 and day 42.  
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7.4 Discussion 
This study investigated the responses of P. falciparum parasites to two ACTs, DP and 
AL in North Sumatera. We characterised the genetic profiles of Sumateran parasites, including 
key drug resistance markers including pfcrt, pfmdr1 and pfk13, before and after treatment. 
We assessed parasite survival for the first 72 hours following treatment, and evaluated the 
occurrence of subpatent infection at days 28 and 42 by qPCR and nested PCR assays. In the 
rise of ACT failures in Greater Mekong sub-region, we provided important information on the 
efficacy status of two ACTs in western Indonesia and described the selective drug pressure on 
the pfmdr1 gene given by these two tested ACTs. 
Prior to treatment, the majority of Sumateran parasites carried mutant alleles of pfcrt 
and pfmdr1. For pfcrt, the SVMNT-genotype, associated with high-grade of amodiaquine 
resistance181, was commonly found (73.2%), whereas in Africa and Southeast Asia CVIET-
variant was the most common.357 For pfmdr1, mutations in pfmdr1 86Y and 184Y were 
prevalent, of which 86Y alone or if collated with 184Y and 1246Y into haplotype is associated 
with resistance to chloroquine and amodiaquine.273, 350 These characteristics of pfcrt and 
pfmdr1 are strongly associated with amodiaquine resistance273, 355, 359, and offer possible 
explanations for weaker performance of ASAQ for P. falciparum infection in previous studies 
in Indonesia.171, 176-178 
We also provided evidence that K13 mutations were present in a small proportion of 
patients. Certain mutations in this pfk13 gene propeller region have been associated with 
clinical artemisinin resistance, as shown by day 3 positivity after artesunate monotherapy or 
after 3-day treatment course of ACT.255, 268 The polymorphisms in pfk13 have dominated P. 
falciparum parasite populations in GMS296, 302, whereas in this study only three (4%) patients 
had mutations in this gene, all carried point mutation at T474A. The mutant T474A found in 
our study is also different to those primarily circulated in the GMS (C580Y, F446I) or previously 
reported in eastern Indonesia (0.9% prevalence of C469F).296, 302 This mutation at codon 474 
has been previously reported in a small number of Cambodian isolates, however changes 
occurred from threonine to isoleucine and this mutant was not associated with delay in 
clearance.268, 302 Patients harboring this mutant K13 parasites in this study also showed no 
association and treatment cleared parasites rapidly. 
Genetic characterisations of P. falciparum populations in this study showed high 
frequency of wild-type pfk13, pfcrt variant of SVMNT and pfmdr1 haplotype 86Y/184Y among 
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our parasites, suggesting high sensitivity of these parasites to artemisinin and lumefantrine in 
vivo268, 273, 297, and modest sensitivity to piperaquine in vitro.355 Our findings on low prevalence 
of day 3 positivity detected by both microscopy (1.4%) and qPCR (9.3%) also supported the 
expected high sensitivity of local parasites to artemisinin. Both regimens cleared parasites 
rapidly within 2 days after receiving the first dose, implying no immediate threat for 
artemisinin sensitivity in western Indonesia. However, the presence of variation at the pfk13 
locus in Sumateran parasites still reinforces the need for further surveillance of this gene. 
Future study needs to evaluate whether this pfk13 T474A has a role in conferring resistance 
to artemisinin or will further spread at the expense of wild-type K13 parasite.  
In this study, we observed high proportions of subpatent recurrences at days 28 and 
42 in both treatment groups despite a suggested sensitive parasite background to the study 
drugs. The occurrence of submicroscopic infection, however, was not associated with qPCR-
detected residual parasitaemia at day 3, different to the association previously shown in a 
study from Kenya.196 Following excellent parasite clearance, proportion of submicroscopic P. 
falciparum carriages in this study were detected as high as 20% and 30% of all individuals at 
days 28 and 42. One plausible explanation for this event is that individuals were exposed by 
drug-tolerant parasites and survived the post-treatment protection given by the partner drug 
of ACT, and therefore they appeared to have became re-infected. We have demonstrated that 
our study sites in North Sumatera posed a high transmission risk of malaria (see Chapter 4), 
despite having a pre-elimination status by the national malaria control programmes. Thus, 
subjects in our study posed high risk to develop reinfection. Our observation also revealed 
significant changes in the pfmdr1 polymorphisms from dominant YY prior to treatment to 
majority NF at both days 28 and 42 (Figure 7.7.). Parasites with the pfmdr1 86Y/184Y have 
been associated with decreased sensitivity to amodiaquine but increased sensitivity to 
lumefantrine, while parasites carrying alleles 86N/184F have been associated with 
amodiaquine-sensitive but lumefantrine-tolerance.273, 374 Our findings supported these studies 
with AL effectively cleared YY-parasites but hosts were later reinfected with parasites carrying 
NF. On the other hand, DP is known for the long post-treatment protection among other 
ACTs.203 Therefore, our findings were unexpected. Selective pressure given by DP in Pfmdr1 
gene is still unclear. Our parasites predominantly harboured the wild-type pfmdr1 N86 during 
recurrent episodes. This finding is in contrast to previous studies where DP select for mutant 
86Y197, 275, 362, but consistent with others.297, 363, 364 Moreover, our pfmdr1 copy numbers data 
was too small, and we lack of information on pfplasmepsin2 copy numbers which have 
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restraint our efforts to understand parasites genetic responses to the study drugs in particular 
for DP.  
Our study shows DP and AL are still highly effective for treating uncomplicated P. 
falciparum infection. P. falciparum recrudescence was only confirmed in a single participant 
during 42 days of follow-up. By PCR, we noted P. malariae to be the most common cause of 
treatment failures among our microscopy-detected treatment failures. We have shown in our 
study settings that multiple malaria infections were not uncommon.29 In Indonesia, the 
recommendation for any malaria infection is 3-day therapy with DP and additional primaquine 
depending on infecting species.128 However, the efficacy of this combination to non-
falciparum malaria has not been widely studied. Few studies have shown low density 
Plasmodium spp. infections persisted following the standard 3-day regimen of ACT.51, 52, 375 
Mixed infections in Ghanaian and Ugandan children treated with DP and AL observed less 
sensitivity of P. malariae to these drugs as shown by persistence or recurrence of P. malariae 
on follow-up days.51, 52 One plausible explanation is that parasites were sequestered or 
dormant and therefore evade antimalarials activity. Another theory is that the 72-hour life-
cycle of P. malariae gives advantage for the parasites to evade the effect of artemisinin and 
leaves survivors.15, 51, 376 Further studies are needed to determine the adequate dosage and 
length of treatment of ACT for this particular species.  
This study has several limitations. First, poor microscopy specificity was presented 
especially in South Nias (see Chapter 4), resulting in only one-third of our samples to be able 
to be genotyped for drug resistance markers. The small sample size was not ideal, but our data 
was sufficient to conclude the baseline genetic profiles of Sumateran parasites. Second, we 
have limited information on markers of piperaquine sensitivity to these parasites, as we were 
only successful to analyse pfmdr1 copy number in a small numbers of isolates, and we did not 
perform analysis on pfplasmepsin2 copy number. Another weakness of our study was that 
post-treatment genotyping was only done for pfmdr1 gene. Amplification for pfcrt and pfk13 
on recurrences isolates were performed but failed to show results, this is mainly due to low 
density of parasites of P. falciparum carriages during recurrences. Last, we hypothesized that 
high proportion of subpatent recurrences was due to reinfection by piperaquine and/or 
lumefantrine resistant-parasites. Nevertheless, we did not analyse the multiplicity of infection 
of isolates at enrolment, thus we are not able to exclude that recurrent infections with 
parasites carrying wild-type genotype were due to a recrudescence event by undetected 
subpopulations carrying N86 prior to treatment. 
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Our work has important implication for the national malaria control programmes. This 
is the first study to report the presence of pfk13 mutation in an in vivo study from western 
Indonesia. We also show that DP and AL are still highly efficacious for the treatment of 
uncomplicated falciparum malaria, with strong evidence of low risk for artemisinin resistance. 
Submicroscopic infection was detected in high proportion within 4 weeks after ACT treatment. 
Potential contribution of these subpatent infections on post-treatment transmission is 
worrying and threatens the efforts for malaria elimination in this region, therefore need to be 
studied further. Training for microscopists is recommended to enable malaria case detection 
and correct identification of parasite species. Regular monitoring on the prevalence of K13 
mutants and further investigations on ACT efficacy for P. falciparum and other Plasmodium 
species are needed to maintain the sensitivity of antimalarial drugs in western Indonesia. 
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8 DISCUSSION AND FUTURE 
DIRECTIONS    
 
8.1 Discussion 
Malaria is still a major public health problem with 3.8 billion people at risk in 2016 as 
estimated by the WHO.1 In the Southeast Asian and Western Pacific region, all countries are 
committed to eliminate malaria by 2030 and many of those are already in malaria elimination 
or pre-elimination stage.1, 377, 378  Nevertheless, these countries, in particular those in the 
Greater Mekong sub-region (GMS), pose the highest risk of developing drug resistance to P. 
falciparum parasite.185 Resistance of P. falciparum to the most potent antimalarial existing, 
artemisinin, has been described in western Cambodia in 2008.252, 253 Since then, resistance to 
this drug has also been reported in other parts of Southeast Asia including Thailand, Vietnam, 
Myanmar, Laos and China.120, 203, 254-259 A substantial progress in understanding of the 
resistance mechanisms to artemisinin and the extent of this drug resistance in Southeast Asia 
has been made, with most investigations performed in the area where resistant-parasites 
were first described, and to the countries adjacent to the epicenter of drug resistance.185, 268, 
379 These efforts were aimed to contain the spread of resistance especially westward to Africa 
where the highest burden of malaria is taking place.1 
Indonesia is on the east of mainland Southeast Asia and does not share borders with 
the countries that are currently affected by artemisinin-resistant parasites. However, nearly 
70 million of its population are at risk of acquiring malaria infection.1  Hence, the development 
of P. falciparum resistance to antimalarial in this region would become a public health disaster, 
and would interrupt malaria control and elimination programmes. The work presented in this 
thesis adds to the knowledge base of malaria epidemiology and parasites response to ACT 
treatment in North Sumatera, Indonesia. The insights from this work allow greater 
understanding of P. falciparum genotypic and phenotypic responses to ACTs particularly for 
DP and AL, and help the national malaria control programmes to progress towards malaria 
elimination by providing updates on recommendation for antimalarial use in this region. 
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The first objective of the thesis was to investigate malaria distribution in reportedly 
low transmission settings in North Sumatera province, Indonesia. In chapter 4, we have 
described the molecular epidemiology of Plasmodium species in three regencies: Batubara, 
Langkat and South Nias, in North Sumatera province, Indonesia. We identified 4 Plasmodium 
species to be transmitted in this region including P. falciparum, P. vivax, P. malariae, and P. 
knowlesi. We detected a substantial numbers of infection by P. knowlesi (443 cases) in the 
population using a novel assay for detection of this species. We stress the importance on 
training microscopists for better identification of Plasmodium species now that we have 
shown Plasmodium species other than P. falciparum and P. vivax were widely distributed. We 
also emphasise the importance to include treatment recommendation for P. knowlesi in the 
national malaria guidelines. North Sumatera is currently aiming for malaria elimination status 
in 2020, but our study has shown that a substantial numbers of individuals still carried 
parasites. These 3 regions however could not represent the whole region of North Sumatera. 
These areas were particularly complex and remotely located, and they were selected because 
of their high burden of malaria as reported in the Provincial Health Report.312, 316 But, with the 
use of molecular tools, our findings revealed a higher burden of malaria than previously 
reported. Furthermore, we have identified a huge proportion of submicroscopic infections 
contributing to overall malaria burden (71.3% of all infections). This means a substantial 
number of infected individuals were left undiagnosed and untreated. Although this was not 
studied further in this work, submicroscopic infection has been associated with higher 
transmission potential to mosquitoes.188 Therefore, these results have important implication 
on the update of malaria status in this region, and further to help the national malaria control 
programmes on developing strategies for malaria control plans to achieve the goal of 
elimination in 2020. 
We further characterised samples identified as P. falciparum infection by polymerase 
chain reaction (PCR) for drug resistance markers. Polymorphisms in the pfcrt, pfmdr1 and 
pfkelch13, the markers for chloroquine, amodiaquine, mefloquine, lumefantrine and 
artemisinin resistance, were described in Chapter 5.181, 268, 269, 273 We show that the haplotype 
SVMNT of pfcrt gene was prevalent in this region, different to that found in Southeast Asia 
and Africa.181, 272, 357 We also show that the pfmdr1 86Y and 184Y were prevalent in two of our 
study sites (Batubara and Langkat), but not in South Nias where 86N and 184Y were dominant. 
Prevalence of the pfcrt SVMNT and pfmdr1 86Y/184Y as shown in our findings were similar as 
reported before, and these haplotypes have been reported to confer chloroquine and 
amodiaquine resistance.181, 355 Therefore, as described in Chapter 5, we propose the treatment 
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failures following treatment with ASAQ as demonstrated in previous in vivo studies across 
Indonesia171, 176-178 might be due to the high prevalence of the pfcrt-SVMNT and pfmdr1-YY 
haplotypes among P. falciparum isolates. Additionally, we were the first to describe mutations 
in the pfkelch13 among samples from western Indonesia. One mutation at T474A was of 
particular interest, occurring in 3% of analysed samples. However, the impact of this mutation 
phenotypically has to be confirmed by in vivo and in vitro phenotypic studies.  
The second objective of the thesis was to evaluate the efficacy of DP and AL for the 
treatment of uncomplicated P. falciparum malaria with a randomised controlled trial. Slow 
parasite clearance manifests when parasites are less sensitive to artemisinin and this 
phenotype has been reported in the Mekong countries.120, 203, 254-259 In this study as described 
in Chapter 6, both drugs cleared parasites rapidly within two days after receiving the first dose 
of treatment (parasite clearance times of 1.52 and 1.45 days for DP and AL). Only a very small 
proportion of patients had parasites on day 3, 1.4% of samples in DP group and and 0.7% in 
AL group. We were also able to show that both regimens were highly effective (99.3% and 
100% efficacy for DP and AL), suggesting parasites were sensitive to both of the partner drugs, 
piperaquine and lumefantrine. Interestingly, our evidence showed that DP was not superior 
to AL for treating P. falciparum infection, as reported before.186, 204  
We also investigated the association between genetic polymorphisms and treatment 
outcomes, as further discussed in chapter 7. P. falciparum isolates in this study carried a 
specific genetic signature including mutant SVMNT of pfcrt haplotype and the YY 
pfmdr1haplotype. Wild-type pfkelch13 was prevalent, and only 4% of patients carried mixed 
wild-type and mutant T474A. This parasite background does not seem to be associated with 
day 3 positivity or submicroscopic recurrences at days 28 or 42. This is in accordance to 
previous observations of high sensitivity of these genotypes to artemisinin, lumefantrine and 
piperaquine.181, 268, 355 Our data also showed there was no difference between parasites 
harboring the pfkelch13 mutant T474A and wild-type parasites in the parasite clearance 
dynamics, implying that point mutation at this codon does not modulate artemisinin 
susceptibility. Using a highly sensitive quantitative polymerase chain reaction (qPCR), the 
proportion of day 3 positivity were at 8.3% in DP and 11.1% in AL groups. Despite some 
proportion of submicroscopic recurrences at day 42 after both treatment DP (31.5%) and AL 
(30.4%), these findings were not associated with baseline genotypic profiles, day 3 positivity 
or parasite density at enrolment. The only factor strongly associated with day 42 recurrences 
was residency in Langkat.  
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This study also described parasite selection after treatment with DP and AL, as 
described in Chapter 7. Both regimens exerted selection for parasites harbouring wild-type 
pfmdr1-86, as shown with increased proportion of parasites carrying pfmdr1 NF at days 28 
and 42 compared to baseline proportion. Based on this evidence, we suggested that DP and 
AL were still highly efficacious for treating P. falciparum infection in particular for parasites 
with a background of pfcrt SVMNT and pfmdr1 YY. But neither of the drugs provided adequate 
post-treatment protection to completely prevent the occurrence of submicrosopic infections 
by parasites carrying the pfdmr1 NF genotypes. Given the interest of these findings, it is 
important to continue to monitor the efficacy of both drugs and to evaluate the selective 
pressure given by these drugs as manifests by changes in the genotypic profiles of P. 
falciparum parasites. 
Furthermore, our findings also revealed that recurrence with P. malariae was not 
uncommon, and this species presented as the most common cause of microscopically patent 
recurrences in the study. Previous studies have proposed the ability of this species to evade 
short exposure from artemisinin which leaving survivors after treatment.15, 51, 376 However, this 
hypothesis needs further confirmation and there is a need to further investigate the efficacy 
of ACTs for this species, more importantly to determine the accurate dosing and length of 
treatment of ACT for P. malariae infection. 
 Despite the several strengths of this work mentioned in each results chapter, this 
thesis is subject to several limitations. First, specificity of microscopy was noticeably poor in 
South Nias, as shown by PCR failure to amplify samples detected as positive by microscopy. 
PCR confirmation is not the standard methods for therapeutic efficacy studies and it is not 
requested (yet) in the WHO guidelines.172, 323 However, in attempts to evaluate the association 
between baseline genetic polymorphisms and treatment outcomes as part of our objectives, 
we performed PCR amplifications on our collected samples. Due to poor microscopy, we then 
observed a reduced number of true P. falciparum isolates evaluated in the trial. The trial with 
300 participants was powered to detect 5% superiority in subjects treated with DP. The 
reduced numbers of evaluated samples then may have resulted in the lack of statistical power 
to detect differences. Second, as described in Chapter 4, our cross-sectional study did not 
deploy a systematic sampling procedure and may have introduced bias. We previously had 
not worked in these 3 regions, and methods were adapted to reflect the facilities available 
and particular local challenges. Therefore, sampling procedures were not standardized, and 
were therefore not ideal for an epidemiological study and may not have provided accurate 
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estimation on parasite prevalence in each of the study sites. Third, more than one-third of 
PCR-confirmed P. falciparum isolates failed to subsequently amplify DNA for genotyping. This 
may be caused by low density of parasites as explained by large proportion of submicroscopic 
infections among our PCR positive samples, and reflects different levels of sensitivity in our 
various PCR amplification protocols. Moreover, we also faced challenges in sample storage. 
The settings in the three study sites were difficult and particularly for South Nias, sample 
collection included frequent sea journeys in small boats which may have prevented samples 
from being dried and stored appropriately following samplings. This could have caused poor 
quality of DNA in the filter papers. Fourth, we have identified mutations in the pfkelch13 
among our samples, but these findings were not reproducible during several further attempts 
for PCR amplifications. Therefore, our findings, although potentially important, offer only 
weak to moderate evidence of the presence of these variants. Furthermore, we also did not 
provide information on other important drug resistance markers. Analysis on pfmdr1 copy 
numbers were only available in small numbers of cases, and we did not perform analysis on 
pfplasmepsin2 copy numbers. Both markers have been strongly associated with the sensitivity 
of ACTs partner drugs including mefloquine and piperaquine. By the time we started our 
laboratory analysis for the trial, we had used most of our DNA for the purpose of molecular 
detection in our epidemiological work. The limited time also restrained us from further 
experiments with the remaining DNA. Further analysis on the drug resistance markers from 
recurrences isolates would have also added important values in our study. But, our efforts to 
amplify DNA for pfcrt and pfkelch13 genotyping were not successful in recurrent infections 
and these could be contributed by the low density parasites detected in the cases. An 
additional limitation is that we did not measure piperaquine and lumefantrine drug levels 
following treatment. The aforementioned investigation would provide us with further 
understanding on DP and AL post-treatment prophylaxis for subpatent recurrences. 
  
8.2 Future directions 
This thesis described above extends our understanding of molecular epidemiology of 
malaria in North Sumatera and P. falciparum parasites responses to DP and AL treatment in 
this region. We have described the presence of four Plasmodium species in North Sumatera, 
and human P. knowlesi infection was not uncommon. We have also successfully shown that 
both DP and AL are still highly efficacious for treating uncomplicated P. falciparum infection, 
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but subsequent submicroscopic recurrences were frequent. Nevertheless, our findings raise 
further questions, and with awareness of challenges that lie ahead of the complicated 
dynamics of Sumateran parasites, the following future studies can be deployed to answer 
those questions: 
 Case-control study to investigate human risk to acquire P. knowlesi infection and 
further to evaluate the virulence of this species in the presence of other 
Plasmodium species in this region. This is necessary to recognise which group is at 
the highest risk of infection thus interventions to mitigate the risk could be 
targeted at the right population, and to investigate within-host dynamics in the 
presence of multi-species infections and the contribution of this infection to cause 
symptomatic clinical malaria; 
 Epidemiological survey to determine the true prevalence of all Plasmodium species 
in this region, the contribution of submicroscopic infections, and the role of 
submicroscopic infection in further transmission to mosquitoes. A strong 
surveillance system is important to measure progress to elimination. Consideration 
of circulating species when designing malaria control and elimination strategies is 
crucial to help in achieving malaria elimination status; 
 In vitro study to assess P. falciparum and P. knowlesi (if not possible yet to include 
P. vivax and P. malariae) susceptibility to a panel of antimalarial drugs. This is 
especially important for a region like North Sumatera where multi-species of 
malaria are common.  Therefore recommendation for the use of an antimalarial 
that is sensitive to all Plasmodium species can be given and adopted into the 
national policy for treatment of malaria; 
 Evaluation on the pfmdr1 copy numbers, pfplasmepsin2 copy numbers, and the 
polymorphisms of other potentially important genes among P. falciparum isolates. 
This should be done in a regular manner to allow early changes detection in the 
genotypic profiles; 
 Regular in vivo drug efficacy studies evaluating the current national 
recommendation, DP, in comparison with other ACTs. In this context, comparison 
of DP with AS-MQ will provide baseline information on the efficacy of AS-MQ and 
offer an alternative treatment if DP starts to fail.
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Appendix 3. Case screening form 
 
Case Screening Form – A                 Day 0 
 
 
 
 
 
 
 
 
Case Screening Form 
Health centre  name: 
 
Village/Town: 
 
Regency: 
 
Patient identity number: 
 
Date: 
Patient initial: 
 
Patient father/husband name: 
 
Demographic Data 
Age:                  Date of birth (dd/mmm/yyyy): 
 
Sex:        M         F   
Weight:                       kg Height:                       cm 
Patient address: 
 
 
 
 
 
 
 
 
Contact number: 
 
 
Socioeconomic status: 
 
 
Education level: 
 
 
Job: 
 
 
Father’s job if under 20 years: 
Staff name: 
 
Sign: 
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Case Screening Form – B                 Day 0 
 
Pre-Treatment Assessment 
Patient identity number: 
 
Age:  
 
Sex:        M         F   
 
Place of assessment: 
 
Study site        
Home               
Date: 
Symptoms Yes / No Scale Duration 
Fever Yes   No    
Headache Yes   No    
Body ache Yes   No    
Vomit Yes   No    
Nausea Yes   No    
Diarrhea Yes   No    
Rigors/chill Yes   No    
Anemia Yes   No    
Cyanosis Yes   No    
Convulsion Yes   No    
Dark colored urine Yes   No    
Skin disorder Yes   No    
Use of antimalarial in the 
past 
< 1 month: 
Yes   No  
1-2 months: 
Yes   No  
> 2 months 
Yes   No  
If yes, please specify: 
- Name of antimalarial 
 
- Diagnosis of malaria was 
made by: 
 
 
 
Doctor          
Midwive       
Traditional    
    healer       
Self                
Other            
 
 
 
 
Doctor          
Midwive       
Traditional    
    healer       
Self                
Other            
 
 
 
 
Doctor          
Midwive       
Traditional    
    healer       
Self                
Other            
 
Use of malaria prevention Insecticide treated nets                   Insecticide spraying         
Repellent                                            Larvacide on stagnant  
Others: …..                                                 water                          
 
Pre-Treatment Examination 
Body weight:                                    kg 
Height:                                               cm 
 
Temperature:                               C 
Pulse:                                             times/min 
Respiratory rate:                         times/min 
Blood pressure:                           mmHg 
Liver enlargement:       Yes   No  
Spleen enlargement :   Yes   No  
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Laboratory 
Thick and thin blood smears: 
Species: P. falciparum          P. vivax          P. malariae          P. ovale    
 
Were species other than P. falciparum present? Yes   No   (If yes, patient is not eligible) 
 
Parasite density:                /L    (If parasite density < 250 L, patient is not eligible) 
 
Presence of P. falciparum gametocyte:          Yes   No  
 
Rapid diagnostic test:     
P. falciparum                                  Yes    
Mixed infection                              Yes  
Other Plasmodium infection        Yes  
Negative                                           Yes  
 
(If other species than P. falciparum is present, 
patient is not eligible) 
 
Filter paper taken:                Yes   No  
 
Pregnancy:                             Yes   No   
(If yes, patient is not eligible) 
 
Hemoglobin:                          gr/dL 
Inclusion Criteria 
 Male or female; 
 All patients over 6 months of age; 
 Fever as defined by axillary temperature > 37.5 C or history of fever during the 48 hours 
before recruitment; 
 Infection with P. falciparum detected by microscopy; 
 Parasitaemia >250 /l blood; 
 Ability to swallow oral medication; 
 Ability and willingness to comply with the protocol for the duration of the study and to 
comply with the study visit schedule; 
 Informed consent from the patient of from a parent or guardian in the case of children; 
 Absence of history to hypersensitivity reactions or contraindication to antimalarial drugs; 
 Not currently consuming antibiotic with antimalarial activity (such as cotrimoxazole, 
macrolides, tetracycline or doxycycline) (Appendix 5) 
Does the patient meet all inclusion criteria? Yes   No      (If no, patient is not eligible) 
Exclusion Criteria 
 Presence of P. vivax infection detected by microscopy; 
 Presence of general danger signs in children under 5 years or signs of severe falciparum 
malaria according to the definitions of WHO (2000) (Appendix 6); 
 Presence of severe malnutrition according to WHO child growth standards (Appendix 7); 
 Presence of febrile conditions caused by diseases other than malaria; 
 Presence of severe anemia (Hemoglobin < 7 gr/dl); 
 Received any of the study drugs within the past 4 weeks; 
 Received any antimalarial within the last 2 weeks; 
 Recurrent vomiting (necessitating more than a single repeat dose); 
 Pregnant (demonstrated by positive result of -HCG in women of childbearing age); 
 Lactating mother 
Does the patient meet any of the exclusion criteria? Yes   No      
(If yes, patient is not eligible) 
If yes, please specify the reason for exclusion: 
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Patient Informed Consent and Assent 
Consent form signed      Yes   No  
Assent form signed         Yes   No  
Patient identity number: 
Date (dd/mmm/yyyy): 
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Appendix 4. Case record form 
 
Case Record Form – A      Follow-Up Day 0 
 
 
 
 
Case Record Form 
Health centre  name: 
 
Village/Town: 
 
Regency: 
 
Patient identity number: 
 
Date: 
Patient initial: 
 
Patient father/husband name: 
 
Demographic Data 
Age:                  Date of birth (dd/mmm/yyyy): 
 
Sex:        M         F   
Weight:                       kg Height:                       cm 
Patient address: 
 
 
 
 
 
 
 
 
Contact number: 
 
 
Socioeconomic status: 
 
 
Education level: 
 
 
Job: 
 
 
Father’s job if under 20 years: 
Randomised treatment allocation: Arm 1:   DHA-P                  
 
Arm 2:    AL                        
 
Outcome of trial: ACPR:                                   
ETF:                                      
LCF:                                      
LPF:                                      
Withdrawn:                        
Lost to follow-up :             
 
Staff name: 
 
Sign: 
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Case Record Form – B       Follow-Up Day 0 
 
Pre-Treatment Assessment 
Patient identity number: 
 
Age:  
 
Sex:        M         F   
 
Place of assessment: 
 
Study site        
Home               
Date: 
Symptoms Yes / No Scale Duration 
Fever Yes   No    
Headache Yes   No    
Body ache Yes   No    
Vomit Yes   No    
Nausea Yes   No    
Diarrhea Yes   No    
Rigors/chill Yes   No    
Anemia Yes   No    
Cyanosis Yes   No    
Convulsion Yes   No    
Dark colored urine Yes   No    
Skin disorder Yes   No    
Other complaints: 
 
   
 
Pre-Treatment Examination 
Body weight:                                    kg 
Height:                                               cm 
 
Temperature:                               C 
Pulse:                                             times/min 
Respiratory rate:                         times/min 
Blood pressure:                           mmHg 
Liver enlargement:       Yes   No  
Spleen enlargement :   Yes   No  
 
 
Laboratory 
Thick and thin blood smears: 
Species: P. falciparum          P. vivax          P. malariae          P. ovale    
 
Were species other than P. falciparum present? Yes   No   (If yes, patient is not eligible) 
 
Parasite density:                /L    (If parasite density < 250 L, patient is not eligible) 
 
Presence of P. falciparum gametocyte:          Yes   No  
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Rapid diagnostic test:     
P. falciparum                                  Yes    
Mixed infection                              Yes  
Other Plasmodium infection        Yes  
Negative                                           Yes  
 
(If other species than P. falciparum is present, 
patient is not eligible) 
 
Filter paper taken:                Yes   No  
 
Pregnancy:                             Yes   No   
(If yes, patient is not eligible) 
 
Hemoglobin:                          gr/dL 
 
Medication Administration 
Dihydroartemisinin Piperaquine        Artemether Lumefantrine       
Name of 
antimalarial 
Time of dose 
(hh:mm) 
Number of 
tablets 
Vomit Time (hh:mm) 
   Yes   No   
   Yes   No   
   Yes   No   
   Yes   No   
Other medication     
   Yes   No   
   Yes   No   
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Case Record Form – C               Follow-Up Day 1,2,3,7,14,21,28,35,42 
 
Assessment 
Patient identity number: 
 
Age:  
 
Sex:        M         F   
 
Place of assessment: 
 
Study site        
Home               
Date: 
Symptoms Yes / No Scale Duration 
Fever Yes   No    
Headache Yes   No    
Body ache Yes   No    
Vomit Yes   No    
Nausea Yes   No    
Diarrhea Yes   No    
Rigors/chill Yes   No    
Anemia Yes   No    
Cyanosis Yes   No    
Convulsion Yes   No    
Dark colored urine Yes   No    
Skin disorder Yes   No    
Other complaints: 
 
   
 
Examination 
Body weight:                                    kg 
Height:                                               cm 
 
Temperature:                               C 
Pulse:                                             times/min 
Respiratory rate:                         times/min 
Blood pressure:                           mmHg 
 
 
Laboratory 
Thick and thin blood smears: 
Presence of asexual P. falciparum parasite:         Yes   No  
 
Parasite density:                /L     
 
Presence of P. falciparum gametocyte:          Yes   No  
 
Were species other than P. falciparum present? Yes   No   (If yes, patient is not eligible) 
If yes, which species: P. vivax      P. malariae      P. ovale  
 
Filter paper taken:                                               Yes   No  
Filter paper taken for drug concentration:     Yes   No  
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Adverse Events 
Presence of an adverse event:   Yes   No  
If yes, name the adverse event: 
 
Is it a serious adverse event?     Yes   No  
 
 
Medication Administration 
Dihydroartemisinin Piperaquine        Artemether Lumefantrine       
Name of 
antimalarial 
Time of dose 
(hh:mm) 
Number of 
tablets 
Vomit Time (hh:mm) 
   Yes   No   
   Yes   No   
   Yes   No   
   Yes   No   
Other medication     
   Yes   No   
   Yes   No   
 
If patient is not treated    
Loss to follow up Date of patient loss Day of study/visit 
Yes   No    
Reason of loss to follow-up: 
 
 
 
Staff name: Sign: Date: 
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Appendix 5. Medications with antimalarial activity103 
 
 Chloroquine, amodiaquine; 
 Quine, quinidine; 
 Mefloquine, halofantrine, lumefantrine; 
 Artemisinin and its derivatives (artemether, arteether, artesunate, dihydroartemisinin); 
 Proguanil, chlorproguanil, pyrimethamine; 
 Sulfadoxine, sulfalene, sulfamethoxazole, dapsone; 
 Primaquine; 
 Atovaquone; 
 Antibiotics: tetracycline*, doxycycline, erythromycin, azithromycin, clindamycin, 
rifampicin, trimethoprim; 
 Pentamidin 
*Tetracycline eye ointments can be used 
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Appendix 6. Definition of severe falciparum malaria380  
 
Severe manifestation of P. falciparum malaria in adults and children 
Clinical manifestation: 
 Prostration 
 Impaired consciousness 
 Respiratory distress (metabolic acidosis) 
 Multiple convulsions 
 Circulatory collapse 
 Pulmonary edema (radiological) 
 Abnormal bleeding 
 Jaundice 
 Haemoglobinurea 
 
Laboratory findings  
 Severe anemia (hemoglobin < 5 gr/dL, hematorcrit < 15%) 
 Hypoglycemia (blood glucose < 2.2 mmol/L or 40 mg/dL) 
 Acidosis (plasma bicarbonate < 15 mmol/L) 
 Hyperlactatemia (venous lactic acid > 5 mmol/L) 
 Hyperparasitaemia (>4% in non-immune patients) 
 Renal impairment (serum creatinine above normal range for age) 
 
Classification of severe malaria in children  
Group 1: children at increased risk for death 
 Prostration 
 Respiratory distress 
Group 2: children at risk for clinical deterioration  
 Hemoglobin < 5 g/dL, hematocrit < 15%) 
 Two or more convulsions within 24 h 
Group 3: children with persisting vomiting 
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Appendix 7. WHO child growth standards90 
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Appendix 8. Summary of case record form 
Case Record Form – Summary 
Study Site Patient address: Patient identity number: 
 
Patient initial: Date of birth (dd/mmm/yyyy): 
 
Age:  
Sex:        M         F   
Weight:                       kg 
Job: 
Education: 
Socioeconomic status: 
Treatment: 
- DP      
- AL       
Outcome of trial: 
ACPR                   LPF                             
ETF                      Withdrawn               
LCF                      Loss to follow up     
 
Visits 0 1 2 3 7 14 21 28 35 42 
Date           
Danger signs (Yes/No)           
Temperature (C)           
Presence of asexual parasite           
Parasite density (L)           
Gametocyte (Yes/No)           
Hemoglobin (gr/dL)           
Filter paper taken (Yes/No)           
Treatment (DP / AL)           
Concomitant medication (Yes/No)           
Adverse events (Yes/No)           
Serious adverse events (Yes/No)           
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Appendix 9. Adverse event report form 
Adverse Event Report Form 
 
Case Record Form 
Health centre  name: 
 
Village/Town: 
 
Regency: 
 
Patient identity number: 
 
Date: 
 
Follow-up day: 
Patient initial: 
 
Patient father/husband name: 
 
Demographic Data 
Age:                  Date of birth (dd/mmm/yyyy): 
 
Sex:        M         F   
Weight:                       kg Height:                       cm 
Patient address: 
 
 
 
 
 
 
 
 
Contact number: 
 
 
Socioeconomic status: 
 
 
Education level: 
 
 
Job: 
 
 
Father’s job if under 20 years: 
Randomised treatment allocation: Arm 1:   DP               
 
Arm 2:    AL                        
 
 
Adverse Event 
Type of event: 
        Anorexia 
        Headache 
        Dizziness 
        Cold 
        Cough 
        Flu 
     
 
        Bronchitis 
        Rhinitis 
        Shivering 
        Sore throat 
        Nausea 
        Vomiting 
      
 
        Abdominal pain 
        Diarrhea 
        Pruritus 
        Asthenia 
        Fever 
 
Describe the duration and severity of adverse event: 
 
 
 
 
 
 
 
Describe how the reaction was treated: 
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Medicines 
(List the medicine suspected of causing the adverse event as well as all concomitant medicines) 
Brand name, batch number, 
manufacturer name 
Daily dose Route Start date End date Indications 
for use 
      
      
      
      
      
Outcome: 
        Recovered completely 
        Not yet recovered 
        Recovered with long-term consequences 
 
If patient recovered, provide date of recovery (dd/mmm/yyyy): 
 
 
Reporting Staff 
Name: 
Qualification: 
Address: 
Phone: 
Email: 
Date: 
 
Sign: 
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Appendix 10. Serious adverse event report form 
Serious Adverse Event Report Form 
 
Case Record Form 
Health centre  name: 
 
Village/Town: 
 
Regency: 
 
Patient identity number: 
 
Date: 
 
Follow-up day: 
Patient initial: 
 
Patient father/husband name: 
 
Demographic Data 
Age:                  Date of birth (dd/mmm/yyyy): 
 
Sex:        M         F   
Weight:                       kg Height:                       cm 
Patient address: 
 
 
 
 
 
 
 
 
Contact number: 
 
 
Socioeconomic status: 
 
 
Education level: 
 
 
Job: 
 
 
Father’s job if under 20 years: 
Randomised treatment allocation: Arm 1:   DP               
 
Arm 2:    AL                        
 
 
Serious Adverse Event 
Type of event: 
        Death 
        Life-threatening 
        Hospitalization or prolongation of hospitalization 
        Permanent disability 
        Congenital anomaly or birth defect 
 
Date of occurrence (dd/mmm/yyyy): 
 
Describe the serious adverse event (include all relevant laboratory results): 
 
 
 
 
 
 
Describe how the reaction was treated: 
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Medicines 
(List the medicine suspected of causing the serious adverse event as well as all concomitant 
medicines) 
Brand name, batch number, 
manufacturer name 
Daily dose Route Start date End date Indications 
for use 
      
      
      
      
      
Outcome: 
        Recovered completely 
        Not yet recovered 
        Recovered with long-term consequences 
 
If patient recovered, provide date of recovery (dd/mmm/yyyy): 
 
 
Reporting Staff 
Name: 
Qualification: 
Address: 
Phone: 
Email: 
Date: 
 
Sign: 
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Appendix 11. Participant information sheet 
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Appendix 12. Informed consent form 
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Appendix 13. Participant information sheet in Bahasa Indonesia 
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Appendix 14. Informed consent form in Bahasa Indonesia 
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Malaria epidemiology in central 
Myanmar: identification of a multi-species 
asymptomatic reservoir of infection
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Abstract 
Background: The spread of artemisinin-resistant Plasmodium falciparum is a global health concern. Myanmar stands 
at the frontier of artemisinin-resistant P. falciparum. Myanmar also has the highest reported malaria burden in South-
east Asia; it is integral in the World Health Organization’s plan to eliminate malaria in Southeast Asia, yet few epidemio-
logical data exist for the general population in Myanmar.
Methods: This cross-sectional, probability household survey was conducted in Phyu township, Bago Region (central 
Myanmar), during the wet season of 2013. Interviewers collected clinical and behavioural data, recorded tympanic 
temperature and obtained dried blood spots for malaria PCR and serology. Plasmodium falciparum positive samples 
were tested for genetic mutations in the K13 region that may confer artemisinin resistance. Estimated type-specific 
malaria PCR prevalence and seroprevalence were calculated, with regression analysis to identify risk factors for sero-
positivity to P. falciparum. Data were weighted to account for unequal selection probabilities.
Results: 1638 participants were sampled (500 households). Weighted PCR prevalence was low (n = 41, 2.5%) and 
most cases were afebrile (93%). Plasmodium falciparum was the most common species (n = 19. 1.1%) and five (26%) 
P. falciparum samples harboured K13 mutations. Plasmodium knowlesi was detected in 1.0% (n = 16) and Plasmodium 
vivax was detected in 0.4% (n = 7). Seroprevalence was 9.4% for P. falciparum and 3.1% for P. vivax. Seroconversion to P. 
falciparum was 0.003/year in the whole population, but 16-fold higher in men over 23 years old (LR test p = 0.016).
Discussion: This is the first population-based seroprevalence study from central Myanmar. Low overall prevalence 
was discovered. However, these data suggest endemic transmission continues, probably associated with behavioural 
risk factors amongst working-age men. Genetic mutations associated with P. falciparum artemisinin resistance, the 
presence of P. knowlesi and discrete demographic risk groups present opportunities and challenges for malaria con-
trol. Responses targeted to working-age men, capable of detecting sub-clinical infections, and considering all species 
will facilitate malaria elimination in this setting.
Keywords: Malaria, Myanmar, Prevalence, Serology, Transmission, Artemisinin, Resistance, Risk factors, Elimination
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Background
The last decade has seen global progress in malaria 
control [1, 2]. This is threatened by the emergence of 
Plasmodium falciparum resistant to artemisinin, the 
world’s front-line anti-malarial [3]. So far, P. falcipa-
rum with reduced susceptibility to artemisinin has been 
described in Cambodia, Thailand, Vietnam, Laos and 
Myanmar [4–7]. The World Health Organization (WHO) 
recently set its sights on malaria elimination in Southeast 
Asia in order to contain this threat [2]. The emergence of 
the zoonotic primate malaria Plasmodium knowlesi as a 
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parasite of significant public health importance in Malay-
sian Borneo complicates elimination [8, 9]; the distribu-
tion and prevalence of this species in other countries in 
the region remains uncertain.
Myanmar is reported to account for the vast majority 
of malaria cases and deaths within Southeast Asia [10]. 
Better understanding the epidemiology of malaria here 
would likely contribute to successful elimination. Malaria 
distribution in Myanmar is heterogeneous; forests are a 
major environmental factor driving patterns of disease 
[11, 12] and international and internal migration are also 
risk factors [13, 14]. Whilst transmission is relatively well 
documented in border areas [13], few data exist from 
central Myanmar and the burden and drivers of infection 
in this area remain poorly understood.
Light microscopy and rapid diagnostic tests (RDTs) 
underestimate the prevalence of infection with Plas-
modium spp, particularly in low-endemic settings [15]. 
Polymerase chain reaction (PCR) is more sensitive in 
detecting current infection and allows further testing 
such as for drug resistance-associated mutations [16]. 
Serological methods have been shown to reliably esti-
mate malaria transmission and can identify risk factors 
with achievable sample sizes in low prevalence areas [17]. 
Prevalence of antibodies to specific malaria antigens, 
which indicate malaria exposure, can be used to calcu-
late the seroconversion rate (SCR, equivalent to the force 
of infection) [18]. Changes in SCR over time are of par-
ticular utility in monitoring the success of public health 
campaigns.
This study combined highly sensitive PCR testing 
and serological evidence of transmission intensity in a 
household survey in central Myanmar with collection of 
detailed epidemiological data to investigate the preva-
lence of, and risk factors for, malaria exposure.
Methods
Study site and population
Phyu is the largest township in Eastern Bago Region. 
Phyu is located on the main highway between Yangon 
(largest city) and Nay Pyi Taw (capital). It is 100 km west 
of the border with Thailand, and lies on a plain (high-
est altitude =  60  m) between forest-covered mountains 
(Fig.  1). The forests attract migrant labour for logging, 
charcoal production and agro-forestry [14]. Phyu was 
selected for this study due to its relatively large size and 
location on busy transport routes near forests. The pop-
ulation is approximately 250,000, of whom 89% live in 
semi-urban or rural areas, with 11% in Phyu town.
Medical services vary from a 50-bed township hospi-
tal to sub-rural health centers with no inpatient facilities. 
The latter cover 5–15 villages each with a midwife who 
provides basic services including malaria prevention. The 
township malaria inspector and local midwives accompa-
nied the team for this study.
The monsoon begins in May and ends in October; pre-
cipitation is heaviest in August (approximately 450 mm/
month). Peaks in malaria transmission follow the rains 
by 1–2 months. This study was conducted in August and 
September 2013.
Field procedures
Sample size calculation
A required sample size of 1174 was calculated, assuming 
a malaria prevalence of 1 per 1000, with 95% confidence 
with 80% power; sampling 0.1% of the population, with a 
presumed design effect of 2 and a non-response rate of 
15%. Since the average household size in Myanmar is 4.7, 
30 clusters of 20 houses (~75 participants) were chosen 
(n = 1500).
Sampling technique
This cross-sectional study used a multistage cluster ran-
dom sample design. Administrative wards were the pri-
mary sampling unit, with villages and houses as the 
secondary and tertiary sampling units. 26 of 61 wards 
were included (population = 152,651, 60.2% of the total). 
The remaining wards (population = 101,078, 39.8%) were 
defined as inaccessible by vehicle by the local govern-
ment, necessitating exclusion. The included wards were 
weighted according to population size and randomly 
selected.
From each selected ward, villages were selected at ran-
dom with no population weighting. If a ward was selected 
more than once, more than one village was selected. 
Each selected village represented one cluster. A map was 
drawn by village leaders and houses were selected by sys-
tematic interval sampling and mapped using a Global 
Positioning System. Houses with no response were not 
revisited, the house with the closest street entrance was 
sampled in its place.
Questionnaires
Questionnaires were adapted from publicly available 
malaria indicator survey toolkits [19]. Pre-tested question-
naires were administered by pairs of community health-
care workers trained for this study. Households were 
defined as the group of people who had slept under the 
same roof the previous night and who shared a common 
entrance to the street. Household questionnaires recorded 
household structure, assets and demographic information 
for every household member, including those absent. Indi-
vidual questionnaires recorded self-reported forest expo-
sure, malaria symptoms and malaria prevention practices.
Participants were categorized as having exposure to 
forest if their occupation involved forest-related work 
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(forestry, farming, labouring) or if they reported visit-
ing the forest within the previous 6 months. Households 
were classified as having universal coverage of bed nets 
if they reported having at least 1 net per 2 people. Socio-
economic status (SES) was calculated using principal 
components analysis including household structure and 
assets. The derived score was divided into tertiles.
Clinical samples
Tympanic temperature was measured for all partici-
pants. Febrile participants (≥37.5  °C) were tested using 
RDT (SD Bioline Malaria Ag Pf/Pan) and referred for 
treatment. Capillary blood samples were spotted directly 
onto Whatman 3MM filter paper for all participants over 
6 months old regardless of tympanic temperature. Blood 
spots were air-dried, sealed with silica gel and sent to the 
London School for Hygiene and Tropical Medicine for 
storage at −20 °C before analysis.
Ethical approval
The study received approval from the Research Ethics 
Committee of University College London, the Myanmar 
Ministry of Health and Department of Medical Research, 
Lower Myanmar. Local and regional authorities were 
informed. Informed consent was obtained from all adults 
and from guardians of children aged under 15. For those 
aged between 15 and 18, informed consent from both 
parent and child was obtained.
Laboratory procedures
Serological analysis
Recombinant proteins: Plasmodium falciparum and 
Plasmodium vivax antigens MSP-119 were expressed in 
Escherichia coli as glutathione S-transferase-fusion pro-
teins [20] (Pv provided by A. Holder). PfAMA1_3D7 and 
PvAMA1_Sal1 were expressed as His-tagged proteins 
[21, 22].
Detection of anti-malarial antibodies by ELISA: IgG 
antibodies to each recombinant protein were assessed 
by ELISA as previously described [23]. Briefly, recombi-
nant antigens were coated overnight at 4 °C at the follow-
ing concentrations: PfAMA-1 at 0.5  μg/ml, PfMSP-119 
at 0.18  μg/ml, PvAMA-1 at 1  μg/ml and PvMSP-119 at 
1.8  μg/ml. Plates were washed using PBS plus 0.05% 
Tween 20 (PBS/T) and blocked with 1% skimmed milk 
powder in PBS/T. Samples and positive control sera (a 
pool of hyperimmune serum collected from a malaria 
endemic area) were tested in duplicate at 1/1000 and 
1/2000 dilutions against MSP and AMA, respectively. 
After washing, horseradish peroxidase-conjugated 
Fig. 1 Study site with GPS points (circles) demarcating each village cluster
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polyclonal rabbit anti-human IgG (Dako, Glostrup, Den-
mark) diluted at 1:5000 in PBS/T was added to all wells. 
All plates were developed using OPD substrate (OPD, 
sigma fast) and reactions were stopped with 2 M H2SO4. 
Plates were read at 492 nm and optical density (OD) val-
ues were recorded. Seropositivity was determined using 
a finite mixture model to define a cut-off value as previ-
ously described [18].
PCR analysis
Parasite DNA from blood spots was extracted using the 
Chelex method [24]. PCR amplifications targeting the 
18S rRNA gene was performed for initial screening for 
Plasmodium infections, using published PCR reactions 
and protocols with minor modifications [8]. PCR-posi-
tive samples were subsequently tested using an additional 
method targeting the cytochrome B gene (cytb) designed 
for the current study. The primer sets for the hemi-nested 
cytb assay were as follows: PgCytbF1 (5′-GAATTATG 
GAGTGGATGGTG-3′) and PgCytbR1 (5′-ACATC 
CAATCCATAATAAAGC-3′) for nest 1 and PgCytbF1 
and PgCytbR2 (5′-TTTTAACATTGCATAAAATGG-3′) 
for nest 2. Amplification cycling conditions were 95 °C 
for 3  min and then 30 cycles of 3 steps PCR, with 30  s 
annealing at 55  °C (nest 1) or 58  °C (nest 2) and elon-
gation at 72 °C for 1  min. Nested products were then 
characterized by direct sequencing for species determi-
nation. Polymorphisms at the propeller domain of the 
Kelch 13 (K13) encoded by the P. falciparum k13 gene 
(PF3D7_1343700) were also determined on P. falciparum 
PCR-positive isolates, using previously described proto-
cols for nested PCR methods and DNA sequencing [25].
Microscopic analysis
Thick and thin blood films were taken from each par-
ticipant. Giemsa-stained thick malaria films were exam-
ined under a 100×  oil-immersion lens. Samples were 
counted as negative if no parasite was seen after counting 
400 white blood cells. Samples were counted as positive 
if one or more parasites were seen—the corresponding 
thin films were then examined with a 100× oil-immer-
sion lens for speciation. All microscope slides were read 
in duplicate by technicians blinded to other reader’s 
findings.
Data analysis
Weighted prevalence of malaria species by PCR and sero-
logical status was estimated with 95% confidence inter-
vals using the Stata survey commands (v14, Statacorp, 
Texas).
To investigate transmission dynamics in the popula-
tion, a simple reversible catalytic conversion model was 
fitted to the age-seroprevalence data using maximum 
likelihood methods as previously described [17]. The 
model fits age-seroprevalence curves and estimates sero-
conversion rate (SCR) as analogous to the force of infec-
tion. Profile likelihood plots were used to test for any step 
change in SCR and, if present, identify the most likely 
age at which this occurred [26]. Models with two SCRs 
instead of one were assumed if the likelihood ratio com-
paring models indicated a statistically significant change 
(p < 0.05).
Univariate and multivariate logistic regression was 
used to investigate the relationship between gender, age, 
ethnicity, bed net ownership, SES, forest exposure, and 
seropositivity to P. falciparum antigens.
Results
A total of 701 houses in 27 clusters (villages) across 14 
administrative wards were visited, of which 500 houses 
had at least one resident present. Of the 2112 recorded 
residents of consenting households, 474 (22.4%) were 
absent (Table 1). 1638 were present and all consented to 
take part in the study.
The median age was 30 years (range 6 months-88 years) 
and 55% were female. 43% (57% of men and 27% of women) 
were classified as having had forest exposure (Table  1). 
80% of households were classified as having universal bed 
net coverage, but very few households were reported as 
having been sprayed with insecticide in the past year (3%). 
The majority of participants were of Burmese origin (63%) 
whilst people of Indian origin represented 33% of the sam-
ple and Shan origin 3%. Absent household residents were 
more likely to be male and less likely to be Indian com-
pared to those included in the study.
Malaria indicators
41 participants were found to have current infec-
tion when tested post hoc by PCR (2.6%, CI 1.5–4.3) 
(Table  2). The most common species detected was P. 
falciparum (1.1%, n = 19), followed by P. knowlesi (1.0%, 
n =  16). Plasmodium vivax (0.5%, n =  7) and Plasmo-
dium malariae (0.08%, n = 1) (Fig. 2). Only two mixed 
infections were detected. Three infected individuals 
were febrile (one each of P. falciparum, P. knowlesi and P. 
vivax), the remaining 38 were afebrile (93%). No infected 
individuals reported any other malaria symptoms and 
none had sought treatment for malaria in the past three 
months. 89 febrile people were tested with an RDT and 
none were found positive, including three PCR-con-
firmed infections. P. falciparum and P. knowlesi infec-
tions were found in all age groups. Plasmodium knowlesi 
was most common between ages 5 and 15. Plasmodium 
vivax was only detected in those aged 15 and above.
5 of the 19 (26.3%) P. falciparum samples harboured 
non-synonymous propeller domain mutations in 
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pfk13 (K13). These included the known variant Val534Ala 
[27] and four novel variants: Arg539Val, Asn572Asp, 
Glu602Gly, and Glu620Gly.
9.4% (n = 150) individuals were seropositive to P. fal-
ciparum antigens whilst 3.1% (n  =  50) were seroposi-
tive to P. vivax antigens. Of the 50, 19 (38%) were also 
positive to P. falciparum, indicating exposure to both 
species. Seropositivity to both P. falciparum and P. vivax 
was higher in men than women for both species (p 
value = 0.018 and 0.063 respectively).
Microscope slide positivity had high inter-observer 
variability, in part due to water damage and fungal con-
tamination of slides, and the microscopy results were 
therefore not included in the analysis.
Risk factors for exposure to malaria
Analysis of risk factors for malaria was restricted to 
seropositivity to P. falciparum due to the low numbers 
of infections detected by PCR. After adjusting for all 
other variables, seropositivity was more likely for men, 
[adjusted OR (AOR) 2.1 (1.3–3.4), p  =  0.006], and less 
likely for those with higher SES [AOR 0.6 (0.3–0.9), 
p  =  0.072], and of Indian origin  [AOR 0.3 (0.1–0.8)]. 
There was a strong association between seropositiv-
ity and forest exposure in the unadjusted model, which 
was lost after adjusting for gender, age, ethnicity and SES 
(Table  3). Migration status (moving to Phyu within the 
last 10  years or visiting outside Phyu in the preceding 
3  months) was not associated with an increased risk of 
malaria exposure in either the crude or adjusted analysis.
Serological estimates of malaria transmission
A reversible catalytic model and profile likelihood plots 
were used to investigate whether there was evidence for 
two SCRs, indicative of two discrete levels of exposure 
within the population. For P. falciparum, there was a 
clear peak in profile likelihood plot at age 23 years, indi-
cating a change in SCR (Fig.  3a). A model allowing for 
two SCRs fitted the data significantly better than a model 
with a single SCR (p = 0.016) (Fig. 3b).
When analysed separately by gender, a model with 
two SCRs fitted better for men (p = 0.004) whilst a sin-
gle SCR fit better for women (p  =  0.548) (Fig.  4). The 
SCR in men over the age of 23 was 0.050 (0.010–0.251) 
Table 1 Demographic characteristics of study participants
Study population
n %
Total 1638 100
Gender
 Males 752 45.9
 Female 886 54.1
Age
 0–5 163 9.9
 6–15 324 19.8
 16–25 255 15.6
 26–50 550 33.6
 51–100 346 21.1
Ethnicity
 Burmese 1086 64.1
 Indian 507 33.0
 Shan 45 2.9
Socioeconomic status
 Lowest 513 32.4
 Middle 549 34.6
 Highest 523 33.0
Work in or visit forest
 Yes 671 41.0
 No 967 59.0
Household bed net ownership
 Yes, universal coverage 398 79.6
 No 102 20.4
Table 2 Prevalence of symptoms (fever) and specific Plasmodium species by PCR and serology
a Includes two mixed infections, one P. falciparum and P.vivax, one P. knowlesi and P. vivax, therefore total percentages may not equal 100%
n Prevalence (95% CIs) Proportion of current infection (%)
Fever 89 4.9 (3.5–7.1) 3/89 (3.4%)
PCR
 Any Plasmodium species 41 2.6 (1.5–4.3) 100a
 P. falciparum 19 (0.4–3.0) 46.3 (28.7–59.1)
 P. knowlesi 16 (0.5–2.2) 39.0 (21.9–51.3)
 P. vivax 7 0.5 (0.1–2.0) 17.1 (2.2–22.2)
 P. malariae 1 0.04 (0.0–0.4) 2.4 (0–7.08)
Seropositive
 P. falciparum 150 9.4 (6.0–15.0)
 P. vivax 50 3.1 (1.9–6.3)
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compared to 0.003 (0.001–0.006) in those under 23 years 
old. In women, the SCR was similar to that of men under 
23 [0.003 (0.001–0.005)].
Seropositivity to P. vivax antigens was low and SCR 
was also low [0.002 (0.0009–0.006)], with no evidence for 
a change in SCR.
Discussion
This household study reveals low-level malaria transmis-
sion among the general population in central Myanmar. 
The WHO estimates that P. falciparum causes 75% of 
clinical malaria in Myanmar and P. vivax 25% [28], whilst 
in this study P. falciparum mono-infection comprised 
45% of infections and P. vivax 12% (Fig.  2). This study 
found P. knowlesi [29] in more than 35% of positive 
samples. Clinical diagnosis of malaria and most epide-
miological studies in Myanmar use microscopy or RDT 
positivity to identify infection and both RDT and micros-
copy have poor sensitivity and specificity for P. knowlesi 
[30, 31]. In this study, reliable microscopy also proved 
technically challenging. This may explain the underrepre-
sentation of P. knowlesi in national statistics and popula-
tion-level data when compared to the findings presented 
here. In Malaysia, P. knowlesi is responsible for a similar 
proportion of cases as found in this study and can cause 
fatal illness [32]. The epidemiology of P. knowlesi in 
Myanmar requires further study, utilizing sensitive diag-
nostic tools.
One quarter of P. falciparum samples harboured K13 
mutations, all from afebrile, asymptomatic participants, 
none of whom reported anti-malarial treatment within 
the previous three months and none were followed up—
it is therefore difficult to comment on the importance of 
these alleles as determinants of artemisinin susceptibil-
ity. Of the five K13 mutations detected, four have never 
previously been reported. One of the novel mutations, 
Arg539Val, is similar to previously described variants at 
codon 539 from Cambodia, Laos and Myanmar, though 
Table 3 Association between  demographic and  behavioural characteristics and  exposure to  P. falciparum in  study par-
ticipants
a Adjusted for: age, gender, forest exposure, ethnicity, bed net ownership and socio-economic status
Sero-positive (%) Odds ratio (OR) p value Adjusted ORa p value Denominators
Un-weighted Weighted
Gender
 Female 7.1 1.0 (baseline) 1.0 862 871
 Male 12.6 1.9 (1.3–2.8) 0.004 2.1 (1.3–3.4) 0.006 740 731
Age
 0–5 years 0.3 1.0 1.0 162 181
 5–15 years 3.1 9.0 (1.4–58.9) 9.0 (1.3–64.8) 311 292
 15–25 years 3.8 11.2 (1.6–81.5) 12.0 (1.5–94.8) 253 265
 25–50 years 13.0 42.7 (4.0–456.3) 43.8 (3.8–506.3) 541 544
 50–100 years 20.0 71.2 (6.4–796.3) 0.014 71.3 (5.6–904.2) 0.030 335 319
Working in/visiting forests
 No 5.8 1.0 1.0 1454 1454
 Yes 14.7 2.8 (1.5–5.1) 0.002 1.0 (0.6–1.8) 0.979 31 31
Bed net ownership
 Not universal coverage 6.6 1.0 1.0 391 417
 Universal coverage 11.0 1.8 (0.8–3.8) 0.134 1.1 (0.5–2.5) 0.760 1161 1145
Socio-economic status
 Low 11.6 1.0 1.0 506 462
 Medium 11.2 0.9 (0.6–1.5) 0.9 (0.6–1.6) 532 531
 Highest 7.2 0.6 (0.4–0.9) 0.035 0.6 (0.3–0.9) 0.072 512 566
Pf Pv Pk *K13
0 20 6040 80 100%
Pf Pv
a
b
Fig. 2 Proportion of Plasmodium species identified in a our sample 
and b WHO reporting for Myanmar. Pf, P. falciparum; Pv, P. vivax; Pk, P. 
knowlesi. K13 Pf samples with K13 mutations (not available for WHO 
statistics). * 1 × Pf Pv, 1 × Pk Pv, 1 × P. malariae
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these all encode threonine rather than valine as the vari-
ant amino acid [27]. K13 mutations have recently been 
mapped in convenience samples in Myanmar and appear 
prevalent in Upper Myanmar and eastern border areas; 
no K13 mutations were found in a clinical cohort of 52 
patients in Bago Region in 2013–2014 [33], although the 
prevalence of K13 mutations amongst clinical cohorts in 
the high-risk township of Shwe Kyin, Bago, was similar to 
that found in our population [5].
Most participants (n =  38; 93%) with current infec-
tion were afebrile and none reported symptoms. The 
three individuals with raised temperatures tested 
negative on RDT, possibly signifying a low-density par-
asitaemia (or alternative diagnoses) which may be asso-
ciated with mild clinical symptoms [34]. However, even 
sub-clinical infections are important during elimina-
tion campaigns [35]; accurate identification and treat-
ment of asymptomatic carriers—who might transmit 
infections and will tend not to seek treatment—proved 
crucial to eliminate malaria in a similar low-endemic 
setting [36].
The serological data support the PCR data and suggest 
that there has been ongoing low-level transmission of P. 
falciparum and P. vivax in the general population in Bago 
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region. There was a notable increase in exposure to infec-
tion in men aged over 23, who experience a SCR 16-fold 
higher than the general population. Because the antibod-
ies detected by these methods persist for an unknown 
period of time, there are two explanations indistinguish-
able by serology alone: malaria epidemiology may have 
changed 23  years ago such that men now  aged over 23 
were historically exposed to more malaria, or there may 
be ongoing behavioural risk factors specific to those aged 
over 23. The best working hypothesis is that the change 
in SCR is behavioural; it is confined to a well-defined 
epidemiological group (men of working age) and this 
population is overrepresented in contemporary clinic-
based studies suggesting they remain at increased risk of 
malaria [16].
Forest work is an established risk factor for malaria 
transmission [37]. Plasmodium knowlesi is particularly 
associated with forest malaria, due to the outdoor bit-
ing habits of P. knowlesi vectors and the natural primate 
reservoirs living in forests [38]. The questionnaire cap-
tured self-reported information relating to occupational 
exposure and forest visits. Individuals reporting forest 
exposure were three times more likely to have evidence 
of previous exposure to malaria in the unadjusted anal-
ysis. However, forest workers were significantly more 
likely to be men and aged over 23 and less likely to be 
Indian. After adjusting for other factors including age, 
ethnicity and SES the association with forest exposure 
was no longer significant, which is consistent with for-
est exposure being on the causal pathway (although it 
cannot be excluded that it is a confounder). Illicit forest-
related activities such as illegal logging are often unreli-
ably reported in surveys, and qualitative studies may be 
needed to obtain more information on the spectrum of 
forest exposure as a risk behaviour for malaria in this 
region.
The Myanmar Ministry of Health offers malaria pre-
vention, diagnosis and treatment to the general popu-
lation without distinction. This approach is reflected 
in the high level of bed-net ownership and might con-
tribute to the low levels of transmission observed. 
However, these data suggest that a strategy tailored to 
those at highest risk and with asymptomatic infection 
might be required to eliminate malaria since bed-nets 
will not protect those working in forest plantations at 
dawn and dusk [14]. Targeted interventions have been 
trialed in other areas with varying degrees of success, 
including: insecticide-treated clothing and hammocks 
(for use in the forest); toxic mosquito baits; and per-
sonal insect-repellents [39]. Targeted mass administra-
tion of anti-malarials to specific demographic groups is 
another option [40]. As yet, none have been evaluated 
in Myanmar.
This is the first study in Myanmar to combine detailed 
population-level epidemiological data with highly sensi-
tive molecular techniques. The strength and novelty of 
this study also lie in the size of this probability sample 
from an important but unstudied population, with gen-
eralizability to Bago Region and central Myanmar. How-
ever, higher diagnostic sensitivity has been achieved with 
the technique of high volume ultra-sensitive qPCR [16] 
though this requires collection of larger blood volumes 
by venepuncture, and an unbroken cold-chain for trans-
port of packed red cells to a specialist molecular biology 
laboratory. Point prevalence of current infection is sensi-
tive to seasonal variation, and this study was conducted 
towards the end of the rains—regarded as the malaria 
high season—to sample at the peak of malaria transmis-
sion (though different seasonal peaks have been reported 
for some areas nearby [41, 42]). Moreover, others report 
little by way of seasonal variation [43], and by correlating 
PCR findings with serology, which is less sensitive to sea-
sonal changes, robust hypotheses can be developed. The 
study aimed to minimize bias in this population-based 
study by weighting the sample so that it was broadly rep-
resentative of national demographic data in Myanmar 
in terms of gender and age [44], but the sampling strat-
egy excluded the population living closest to the flooded 
Sittang River due to adverse weather conditions, which 
made these areas inaccessible, and where malaria trans-
mission might be higher. In addition, the ethnic composi-
tion of this sample differs from national averages because 
ethnicity in Myanmar is clustered [44]; the sample over-
represented Indian participants (33% compared to 2% in 
national statistics) and underrepresented Shan (3% com-
pared to 9%). One-fifth of residents were absent during 
study visits, and these individuals were more likely to be 
male and less likely to be of Indian origin, and this house-
hold survey did not include hospital in-patients being 
treated for malaria. We were only able to provide popu-
lation weighting at the ward level due to a lack of avail-
able population statistics for individual villages. In our 
experience, village sizes did vary, though it is unlike that 
this would have affected our prevalence estimates, given 
the ward-level weighting applied and the small number 
of infections detected. The overall effect of our diagnostic 
techniques and sampling strategy is that the study design 
might have underestimated rather than overestimated 
malaria prevalence.
Conclusion
Malaria transmission in this area was low. However, there 
were low numbers of asymptomatic carriers who prob-
ably play an important role in maintaining local trans-
mission, and many were infected with P. knowlesi. A 
higher proportion of K13 mutations among P. falciparum 
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cases were observed than has previously documented in 
this region, and working age men appear at significantly 
higher risk of malaria exposure when compared to the 
general population, which needs further research. How-
ever, the public health implications are clear; the WHO 
goal of malaria elimination in this region will require 
identification and treatment of asymptomatic carriers 
among high-risk populations in order to control arte-
misinin resistance and successfully eliminate malaria in 
this setting.
Abbreviations
PCR: polymerase chain reaction; K13: propeller region of the kelch protein on 
chromosome 13 of the Plasmodium falciparum genome (mutations here may 
be responsible for conferring artemisinin resistance); RDT: rapid diagnostic test 
for malaria; WHO: World Health Organization; SCR: seroconversion rate (the 
rate at which individuals develop antibodies to malaria antigens).
Authors’ contributions
IG, TTWH, HMTH, DLH and NF designed the study protocol with advice from 
TH, TSL and MML. IG, TTWH, HMTH and YN collected the data and coordinated 
the field teams. IL and CS conducted the PCR analysis and K13 testing. TH 
and CD performed the ELISA analysis. JC performed the statistical analysis. IG, 
JC, RG and NF wrote the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Research Department of Infection and Population Health, University College 
London, London WC1E 6JB, UK. 2 Malaria Centre, London School of Hygiene 
and Tropical Medicine, London, UK. 3 Institute for Global Health, University 
College London, London, UK. 4 Department of Immunology & Infection, 
London School of Hygiene and Tropical Medicine, London, UK. 5 Haematology, 
Severn Deanery, Bristol, UK. 6 University of Medicine (2), Yangon, Myanmar. 
7 Department of Infectious Disease Epidemiology, London School of Hygiene 
and Tropical Medicine, London, UK. 
Acknowledgements
We would like to thank the study populations, village leaders and local mid-
wives for their support and assistance during the study. We are also grateful 
to Ye Myint Aung, Kyaw Min, Kyaw Tun Lwin, Wat Thon and Christina Aung 
for their help with data collection. Thanks to Professor Tint Swe Latt, Rector, 
University of Medicine (2), Yangon for his support at the conception of this 
study; Professor Mya Mya Lwin and her team at the Department of Microbiol-
ogy, University of Medicine (2), Yangon, for her continuous support and skilled 
microscopy analysis and Dr. Ohn at Parami Hospital, Yangon, for the use of 
their laboratory facilities. The recombinant proteins for serological analysis 
were prepared and provided by Kevin Tetteh. Many thanks to Clare Rogers, 
Debbie Nolder and Julie Tucker, LSHTM Malaria Reference Laboratory, for 
training in microscopy. We are indebted to Saw Lwin, Zaw Lim Maung and the 
Phyu Township Medical Officer for their guidance on the study. Thanks to Dr. 
U Thar Tun Kyaw and the Myanmar Ministry of Health, the Census and Popula-
tion Division of Phyu Township and the Department for Medical Research 
(Lower Myanmar) for their support.
Competing interests
The authors declare that they have no competing interests.
Ethical approval
The study received ethical approval from the Research Ethics Committee of 
University College London (4286/001), the Myanmar Ministry of Health (Letter 
no. 36) and Department of Medical Research, Lower Myanmar (Letter no. 19). 
Local and regional health authorities were informed. Informed consent was 
obtained from all adults and from guardians of children aged under 15. For 
those aged between 15 and 18, informed consent from both parent and child 
was obtained. Febrile participants were, with consent, reported to the Malaria 
Inspector and treated according to national guidelines.
Funding
This study was funded by two awards from UCL’s Grand Challenge for Global 
Health Small Grants scheme (NF and TH) and a personal Chadwick Trust award 
(IG). The funders had no role in study design, data collection, analysis, manu-
script preparation or the decision to publish.
Received: 20 August 2016   Accepted: 15 December 2016
References
 1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. 
Global malaria mortality between 1980 and 2010: a systematic analysis. 
Lancet. 2012;379:413–31.
 2. WHO. Strategy for malaria elimination in the greater Mekong Sub region 
(2015–2030). Geneva: World Health Organization; 2015.
 3. WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2015.
 4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte-
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 5. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. 
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl 
J Med. 2014;371:411–23.
 6. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence 
of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 
2008;359:2619–20.
 7. Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, Ha do M, Pockele E, 
et al. Delayed parasite clearance after treatment with dihydroartemisinin-
piperaquine in Plasmodium falciparum malaria patients in central 
Vietnam. Antimicrob Agents Chemother. 2014;58:7049–55.
 8. Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh 
J, et al. A large focus of naturally acquired Plasmodium knowlesi infections 
in human beings. Lancet. 2004;363:1017–24.
 9. Lee KS, Divis PC, Zakaria SK, Matusop A, Julin RA, Conway DJ, et al. Plas-
modium knowlesi: reservoir hosts and tracking the emergence in humans 
and macaques. PLoS Pathog. 2011;7:e1002015.
 10. Cui L, Yan G, Sattabongkot J, Cao Y, Chen B, Chen X, et al. Malaria in the 
Greater Mekong Subregion: heterogeneity and complexity. Acta Trop. 
2012;121:227–39.
 11. Guerra CA, Snow RW, Hay SI. A global assessment of closed for-
ests, deforestation and malaria risk. Ann Trop Med Parasitol. 
2006;100:189–204.
 12. Parker DM, Carrara VI, Pukrittayakamee S, McGready R, Nosten FH. Malaria 
ecology along the Thailand–Myanmar border. Malar J. 2015;14:388.
 13. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. 
Malaria burden and artemisinin resistance in the mobile and migrant 
population on the Thai–Myanmar border, 1999–2011: an observational 
study. PLoS Med. 2013;10:e1001398.
 14. WHO. Strategic framework for the containment of artemesinin resistant 
malaria in Myanmar, 2011–2015. Geneva: World Health Organization; 
2011.
 15. Wang B, Han SS, Cho C, Han JH, Cheng Y, Lee SK, et al. Comparison of 
microscopy, nested-PCR, and Real-Time-PCR assays using high-through-
put screening of pooled samples for diagnosis of malaria in asympto-
matic carriers from areas of endemicity in Myanmar. J Clin Microbiol. 
2014;52:1838–45.
 16. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, et al. The 
epidemiology of subclinical malaria infections in South–East Asia: find-
ings from cross-sectional surveys in Thailand–Myanmar border areas, 
Cambodia, and Vietnam. Malar J. 2015;14:381.
 17. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro 
I, et al. Estimating medium- and long-term trends in malaria transmission 
by using serological markers of malaria exposure. Proc Natl Acad Sci USA. 
2005;102:5108–13.
 18. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, et al. 
Dried blood spots as a source of anti-malarial antibodies for epidemio-
logical studies. Malar J. 2008;7:195.
 19. Malaria indicator surveys: malaria indicator survey toolkit. 2015.
Page 10 of 10Ghinai et al. Malar J  (2017) 16:16 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 20. Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal 
fragment of the Plasmodium falciparum merozoite surface protein-1 
in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. 
1994;64:165–9.
 21. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, et al. Purifica-
tion, characterization, and immunogenicity of the refolded ectodomain 
of the Plasmodium falciparum apical membrane antigen 1 expressed in 
Escherichia coli. Infect Immun. 2002;70:3101–10.
 22. Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, 
Valderrama A, et al. High-level expression of the malaria blood-stage vac-
cine candidate Plasmodium falciparum apical membrane antigen 1 and 
induction of antibodies that inhibit erythrocyte invasion. Infect Immun. 
2002;70:4471–6.
 23. Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, et al. 
Serum antibodies from malaria-exposed people recognize conserved 
epitopes formed by the two epidermal growth factor motifs of MSP1(19), 
the carboxy-terminal fragment of the major merozoite surface protein of 
Plasmodium falciparum. Infect Immun. 1995;63:456–66.
 24. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine 
and proguanil resistance-conferring mutations in Plasmodium falciparum 
dihydrofolate reductase: polymerase chain reaction methods for surveil-
lance in Africa. Am J Trop Med Hyg. 1995;52:565–8.
 25. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, 
et al. A molecular marker of artemisinin-resistant Plasmodium falciparum 
malaria. Nature. 2014;505:50–5.
 26. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, et al. Rapid 
assessment of malaria transmission using age-specific sero-conversion 
rates. PLoS ONE. 2009;4:e6083.
 27. Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, 
et al. A Worldwide map of Plasmodium falciparum K13-propeller polymor-
phisms. N Engl J Med. 2016;374:2453–64.
 28. WHO. World malaria report. Geneva: World Health Organization; 2015.
 29. Singh B, Daneshvar C. Human infections and detection of Plasmodium 
knowlesi. Clin Microbiol Rev. 2013;26:165–84.
 30. Foster D, Cox-Singh J, Mohamad DS, Krishna S, Chin PP, Singh B. Evalua-
tion of three rapid diagnostic tests for the detection of human infections 
with Plasmodium knowlesi. Malar J. 2014;13:60.
 31. Lee KS, Cox-Singh J, Singh B. Morphological features and differential 
counts of Plasmodium knowlesi parasites in naturally acquired human 
infections. Malar J. 2009;8:73.
 32. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, et al. 
Plasmodium knowlesi malaria in humans is widely distributed and poten-
tially life threatening. Clin Infect Dis. 2008;46:165–71.
 33. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. 
Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a 
cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 
2015;15:415–21.
 34. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: 
detectability, transmissibility and public health relevance. Nat Rev Micro-
biol. 2014;12:833–40.
 35. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. 
Factors determining the occurrence of submicroscopic malaria infections 
and their relevance for control. Nat Commun. 2012;3:1237.
 36. Lwin KM, Imwong M, Suangkanarat P, Jeeyapant A, Vihokhern B, Wong-
saen K, et al. Elimination of Plasmodium falciparum in an area of multi-
drug resistance. Malar J. 2015;14:319.
 37. Wen S, Harvard KE, Gueye CS, Canavati SE, Chancellor A, Ahmed BN, 
et al. Targeting populations at higher risk for malaria: a survey of national 
malaria elimination programmes in the Asia Pacific. Malar J. 2016;15:271.
 38. Marchand RP, Culleton R, Maeno Y, Quang NT, Nakazawa S. Co-infections 
of Plasmodium knowlesi, P. falciparum, and P. vivax among humans 
and Anopheles dirus mosquitoes, Southern Vietnam. Emerg Infect Dis. 
2011;17:1232–9.
 39. Gryseels C, Uk S, Sluydts V, Durnez L, Phoeuk P, Suon S, et al. Factors influ-
encing the use of topical repellents: implications for the effectiveness of 
malaria elimination strategies. Sci Rep. 2015;5:16847.
 40. Sturrock HJ, Hsiang MS, Cohen JM, Smith DL, Greenhouse B, Bousema 
T, et al. Targeting asymptomatic malaria infections: active surveillance in 
control and elimination. PLoS Med. 2013;10:e1001467.
 41. Phimpraphi W, Paul RE, Yimsamran S, Puangsa-art S, Thanyavanich N, 
Maneeboonyang W, et al. Longitudinal study of Plasmodium falcipa-
rum and Plasmodium vivax in a Karen population in Thailand. Malar J. 
2008;7:99.
 42. Oo TT, Storch V, Becker N. Anopheles dirus and its role in malaria transmis-
sion in Myanmar. J Vector Ecol. 2003;28:175–83.
 43. Richards AK, Smith L, Mullany LC, Lee CI, Whichard E, Banek K, et al. Preva-
lence of Plasmodium falciparum in active conflict areas of eastern Burma: 
a summary of cross-sectional data. Confl Health. 2007;1:9.
 44. Central Intelligence Agency. The World Factbook. Washington, DC: Cen-
tral Intelligence Agency; 2014.
1148 • JID 2017:215 (1 April) • Lubis et al
The Journal of Infectious Diseases
The Journal of Infectious Diseases®  2017;215:1148–55
Contribution of Plasmodium knowlesi to Multispecies 
Human Malaria Infections in North Sumatera, Indonesia
Inke N. D. Lubis,1,3 Hendri Wijaya,3 Munar Lubis,3 Chairuddin P. Lubis,3 Paul C. S. Divis,2,4 Khalid B. Beshir,1 and Colin J. Sutherland1
Departments of 1Immunology and Infection and 2Pathogen Molecular Biology, London School of Hygiene & Tropical Medicine, London, United Kingdom; 3Department of 
Paediatrics, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia; and 4Malaria Research Centre, Faculty of Medicine and Health Sciences, Universiti Malaysia 
Sarawak, Kota Samarahan, Malaysia
Background. As Indonesia works toward the goal of malaria elimination, information is lacking on malaria epidemiology from 
some western provinces. As a basis for studies of antimalarial efficacy, we set out to survey parasite carriage in 3 communities in 
North Sumatera Province.
Methods. A combination of active and passive detection of infection was carried out among communities in Batubara, Langkat, 
and South Nias regencies. Finger-prick blood samples from consenting individuals of all ages provided blood films for microscopic 
examination and blood spots on filter paper. Plasmodium species were identified using nested polymerase chain reaction (PCR) 
of ribosomal RNA genes and a novel assay that amplifies a conserved sequence specific for the sicavar gene family of Plasmodium 
knowlesi.
Results. Of 3731 participants, 614 (16.5%) were positive for malaria parasites by microscopy. PCR detected parasite DNA in 
samples from 1169 individuals (31.3%). In total, 377 participants (11.8%) harbored P. knowlesi. Also present were Plasmodium vivax 
(14.3%), Plasmodium falciparum (10.5%) and Plasmodium malariae (3.4%).
Conclusions. Amplification of sicavar is a specific and sensitive test for the presence of P. knowlesi DNA in humans. Subpatent 
and asymptomatic multispecies parasitemia is relatively common in North Sumatera, so PCR-based surveillance is required to sup-
port control and elimination activities.
Keywords. Malaria; Indonesia; Plasmodium knowlesi.
 
Malaria remains widespread across Southeast Asia. In 
Indonesia, 2 million cases of malaria are reported each year, 
with Plasmodium falciparum and Plasmodium vivax the 2 
major reported causes [1]. Among other species contributing to 
human infections, Plasmodium malariae malaria may require 
hospitalization in the eastern province of Papua [2] but is not 
frequently encountered in western Indonesia. Plasmodium 
knowlesi, a parasite of long-tailed and pig-tailed macaques, is 
also known to infect humans. The morphological features in 
the blood stage are similar to those seen in P.  falciparum and 
P. malariae, which in routine practice has led to frequent mis-
diagnosis [3–5]. High P.  knowlesi parasitemia occurs in some 
individuals and has been reported to cause fatal disease [6]. 
Despite this, a proportion of P. knowlesi infections are asymp-
tomatic and submicroscopic across all age groups [7]. A small 
number of human cases of P. knowlesi malaria have been docu-
mented in the province of Kalimantan, Indonesian Borneo [8] 
and in Aceh province [5], but this species has not yet emerged 
as a major cause of human malaria and is not considered in 
Indonesian government guidelines.
The Ministry of Health of Indonesia has implemented 
malaria control, aiming for elimination by 2030. Malaria sur-
veillance relies on passive case detection by microscopic exam-
ination and rapid diagnostic tests (RDTs) at primary health care 
centers [9]. These tests are sufficient to detect clinical malaria 
infection caused by the 2 major species in Indonesia, P.  falci-
parum and P. vivax [10]. However, identification of less com-
mon species, particularly at low-density parasitemia, is more 
difficult, which can lead to underdiagnosis [11]. Modeling of 
data from low-endemicity areas predicts that submicroscopic 
parasites may contribute 70%–80% of all malaria infections 
[12], and in vivo studies demonstrate that these contribute to 
ongoing malaria transmission [13]. Hence, the use of routine 
microscopy and RDTs in malaria surveillance fails to detect a 
substantial proportion of the human reservoir of infection and 
so may compromise malaria elimination strategies. One solu-
tion is to deploy molecular assays for parasite detection, because 
these can provide excellent sensitivity and specificity [14–17].
In preparation for a study of antimalarial drug efficacy in 
vivo, we performed intensive malaria screening in 3 regen-
cies of the Province of North Sumatera, western Indonesia. In 
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addition to microscopy, we used established polymerase chain 
reaction (PCR) assays [18]. However, these tests have limita-
tions for the identification of P. knowlesi infection, because the 
target region of the 18S ribosomal RNA (rRNA) can cross-re-
act with P. vivax [19]. Therefore, we developed a sensitive and 
highly P. knowlesi–specific nested PCR assay to ensure reliable 
determination of all Plasmodium species, including submicro-
scopic infection, in our study areas.
METHODS AND MATERIALS
Study Sites
A parasitological survey was conducted between January and 
June 2015 among persons attending outpatient clinics tempo-
rarily established in >80 localities across 3 selected regencies in 
North Sumatera province, Indonesia: Batubara, Langkat, and 
South Nias regencies (Figure 1). North Sumatera has a total area 
of 71 680.68 km2 with a population of 13 215 401. The province is 
subject to stable low malaria transmission and is currently plan-
ning for elimination by 2020. The 3 regencies were selected based 
on published malaria endemicity data [20]. Batubara, situated on 
the east coast facing peninsular Malaysia, comprises semiforested 
and plantation areas. Langkat is a forested highland area (altitude, 
105–530 m above sea level), and South Nias is a cluster of islands 
in the Indian Ocean. Each regency is served by a district hospital 
and peripheral health clinics, but some rural villages in the study 
areas have very limited access to these services.
Ethics Approval
The study was approved by the ethics committees of the 
University of Sumatera Utara, Indonesia (identifier 401/
KOMET/FK USU/2014) and the London School of Hygiene & 
Tropical Medicine, United Kingdom (identifier 8504-01).
Sampling
Sampling strategies differed among the 3 sites, owing to con-
trasting geography and inconsistencies in access to health facili-
ties. In Batubara, most communities had good access to a health 
clinic, which was open to patients from 8 am to noon, 6 days 
per week. We established a 24-hour, 7-day clinic for an 8-week 
period of screening, after intensive health promotion and edu-
cation on malaria and sensitization concerning to our study 
objectives. This sensitization was facilitated by local leaders and 
carried out at the level of the whole community, but clinic atten-
dance was entirely voluntary. Thus, sampling was not designed 
to reach the whole community. Local health clinics were also 
Figure 1. Map of North Sumatera province, Indonesia. The 3 studied regencies (Batubara, Langkat, and South Nias) are indicated.
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asked to refer patients with a malaria diagnosis to our team. 
Langkat is a forested area, with isolated villages that have poor 
access to health facilities; we therefore adopted a village-by-vil-
lage approach, in which a sensitization meeting was followed by 
2–3 days of screening, before the team moved to another village. 
The 31 communities we sampled in South Nias were spread 
across several islands, and sea journeys were required to move 
our team and the samples between each village and our study 
clinic/diagnostic laboratory, which was temporarily set up in a 
central location on Tello Island.
Malaria testing was done in 3 groups of persons. First, patients 
with fever (axillary temperature, ≥37.5°C) or a history of fever in 
the preceding 48 hours who presented at the health clinics were 
tested for malaria. Tests were also offered to healthy individu-
als who, after our community sensitization activity, came for a 
voluntary malaria check. This second group includes children 
who volunteered during school sensitization visits (Batubara 
and South Nias only). Third, household members of any indi-
viduals who were slide positive for malaria parasites were sub-
sequently visited and also offered malaria testing. Finger-prick 
blood samples were taken from all participants for thick and 
thin blood films for microscopy examination (single reading), 
and blood was also spotted onto filter papers (3MM Whatman) 
for molecular analysis. Participants confirmed as malaria posi-
tive by microscopy were clinically assessed and treated accord-
ing to national guidelines, regardless of symptoms.
Laboratory Procedures
DNA Extraction
Parasite DNA was extracted from filter papers using the Chelex 
method [21, 22].
Parasite Species Identification by rRNA Gene Amplification
A conventional nested PCR assay targeting the genes encod-
ing the Plasmodium 18S rRNA was performed on all samples 
for species determination and detection of submicroscopic 
infections [3, 18]. Positive controls for P.  falciparum, P. vivax, 
P.  malariae, Plasmodium ovale spp. and P.  knowlesi were 
included in all nested PCR assays.
Development and Validation of a Novel Highly Specific P. knowlesi 
PCR Assay
To overcome the cross-reactivity between P. knowlesi and P. vivax 
that occurs in the rRNA gene PCR assays, we developed a hemin-
ested PCR assay based on a conserved region of the amino-ter-
minal exon of the 50–70 members of the gene family encoding 
P. knowlesi–specific schizont-infected cell agglutination variant 
antigens (SICAvar) [23]. The following primers were used: first 
amplification, SICAf1, 5’-GGTCCTCTTGGTAAAGGAGG-
3’and SICAr1, 5’- CCCTTTTTGACATTCGTCC-3’; second 
amplification, SICAf2, 5’-CTTGGTAAAGGAGGACCACG-3’ 
and SICAr1; these generated a final amplicon of 228–249 base 
pairs, encoding 76–83 amino acids. This sequence occurs in 
both types I and type II sicavar genes [23, supplementary table 
1]. For the first round of amplification, 5 µL of DNA template 
was used in a total volume of 25 µL, and 0.2 µL of this product 
was the template for the 25-µL reaction mixture of the hemin-
ested amplification round. Amplifications were performed 
under the following conditions: 94°C for 3 minutes, then 30 
cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 65°C for 
1 minute, with extension at 65 °C for 5 minutes. 
This assay was tested against control DNA from all human 
malaria parasites (P. falciparum, P. vivax, P. malariae, P. ovale cur-
tisi, and P. ovale wallikeri), simian malaria parasites (P. knowlesi 
and Plasmodium inui, cynomolgi, coatneyi, and fieldi), clinical 
P. knowlesi isolates obtained from Kapit of Malaysian Borneo, 
and human DNA from malaria-free individuals to assess speci-
ficity. To determine the limit of detection of the assay, P. knowlesi 
culture of known parasitemia (kindly provided by F. Mohring) 
was serially diluted in whole human blood and spotted on fil-
ter paper, and DNA was extracted with a QIASymphony auto-
mated DNA extraction system. All field isolates were tested for 
P.  knowlesi infection using this novel PCR assay. The sicavar 
amplicons from a subset of samples were verified by direct 
sequencing using BigDye Terminator v3.1 cycle sequencing kits 
and analysis on an ABI 3730 Sequencer (Applied Biosystems). 
Results were aligned and compared with the P. knowlesi strain 
H reference genome, using Geneious (version 8.0.5) and BLAST 
(Basic Local Alignment Search Tool) software.
RESULTS
Validation of SICAvar Assay for P. knowlesi–Specific Identification
The novel SICAvar gene assay was validated against DNA from 
a range of Plasmodium species DNA and from in vitro cul-
tured P. knowlesi. The test was found to be specific, because the 
primers did not generate bands from the DNA of any of the 
Plasmodium species tested other than P.  knowlesi (Figure  2). 
The sicavar-targeted primers detected 377 P.  knowlesi infec-
tions, suggesting significantly higher sensitivity than the rRNA 
assay, which identified only 76 P. knowlesi–infected individuals 
(Table 1). Furthermore, comparison of the results showed that 
only 10 persons (2.3%) had a positive test result in both assays. 
The finding that 66 individuals were P.  knowlesi positive by 
rRNA nested PCR alone suggests that the test cross-reacts with 
P. vivax DNA in the absence of P. knowlesi under the conditions 
used in this study. 
Because we did not deploy a “tie-breaker” test for P. vivax, we 
cannot say for certain whether the P. vivax rRNA gene prim-
ers also cross-react with P. knowlesi DNA. We did find that 18 
individuals were positive for both P. vivax and P. knowlesi rRNA 
amplicons in the nested PCR. Given this ambiguity, and the fact 
we were not able to repeat test the sample set, we proceeded 
with analysis taking the sicavar assay result as definitive for 
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P. knowlesi. Nearly half of all sicavar-positive P. knowlesi infec-
tions were also rRNA amplicon positive for ≥1 other species, 
P.  vivax being the most common coinfection (Table  1). The 
limit of detection of the assay, as performed on dried filter paper 
blood samples, was estimated as 0.1 parasite per µL of whole 
blood (data not shown).
As further confirmation of our results, 7 P. knowlesi isolates 
detected by SICAvar were PCR amplified, and the products 
directly sequenced. The sequences exhibited high variability, as 
expected for variant antigens, even in this most conserved exon 
(Figure 3). Interestingly, 2 of the 7 sequences obtained harbored 
an insert encoding an additional 7 amino acids. These 2 forms 
were used to probe the current P.  knowlesi reference genome 
(http://www.sanger.ac.uk/resources/downloads/protozoa/plas-
modium-knowlesi.html). and both queries identified a number 
of distinct sequences in the reference genome (Supplementary 
Table 1).
After this successful validation of the SICAvar PCR assay, we 
were able to deduce robust estimates of the contribution of each 
species to malaria infections in each of our 3 sites. The most 
abundant in both Langkat and South Nias were P.  falciparum 
and/or P. vivax, as expected. However in Batubara, P. knowlesi 
(39.7%) was more abundant than P. vivax (35.1%) among our 
tested participants (Figure 4). Of patients reporting fever symp-
toms in the previous 72 hours, 22 were carrying P.  knowlesi 
monoinfection by PCR, with another 47 having P.  knowlesi 
double infections with P. vivax (n = 20), P. falciparum (n = 19), 
or P. malariae (n = 2) or various combinations of triple-species 
infection.
Parasite Carriage
A total of 3731 individuals from Batubara (n = 1270), Langkat 
(n = 544), and South Nias (n = 1917) were included in the malaria 
screening (Supplementary Table  2). In these 3 regencies, 117 
(9.2%), 98 (18.0%), and 397 (21.3%) individuals, respectively, 
were positive for Plasmodium infections by microscopy. Three 
species (P. falciparum, P. vivax, and P. malariae) were identified. 
A  considerable number of participants with malaria-positive 
slides were negative by PCR subsequently performed on stored 
blood spots. Thus, the total number of patent infections con-
firmed by both microscopy and PCR decreased to 93 (8.1%), 74 
(13.6%) and 169 (9.1%), respectively, indicating poor specificity 
of microscopy in South Nias in particular. Conversely, a sub-
stantial number of submicroscopic infections were identified by 
PCR alone, with a PCR-confirmed parasite carriage in 25.2%, 
33.5%, and 34.8% of tested individuals, respectively, in the 3 
sites (Table  2). All Plasmodium species with the exception of 
P. ovale spp. were detected among our samples by a combination 
of the rRNA gene and SICAvar PCR assays.
Carriage of Submicroscopic Infections
PCR analysis revealed that the majority of the 1169 infected 
individuals (71.3%) harbored submicroscopic parasites 
(Table 2). Among these submicroscopic infections, 77.7% (647 
of 833) were single-species infections predominated by P. vivax 
(n = 227) and P. knowlesi (n = 220). Submicroscopic infections 
of any species were more often found in older individuals, 
the mean age in this group being 23.0 years, (95% confidence 
interval [CI], 21.7–24.3  years). The mean age of individuals 
with patent infections was significantly lower, at 18.0  years 
Table  1. Comparison of 2 PCR Assays for Plasmodium knowlesi Case 
Detection
Infection  
Detected
Cases, No. (%)
18S rRNA 
Assay
SICAvar  
Assay
Any  
Assay
Both  
Assays
Total P. knowlesi 
cases
76 (100) 377 (100) 443 (100) 10 (100)
P. knowlesi 
monoinfection
42 (55.3) 215 (57.0) 254 (57.34) 3 (30)
P. knowlesi plus 
P. vivax
16 (21.1) 65 (17.2) 77 (17.38) 4 (40)
P. knowlesi plus 
other Plasmodium 
spp. infections
18 (23.7) 97 (25.7) 112 
(25.28)
3 (30)
Abbreviations: PCR, polymerase chain reaction; rRNA, ribosomal RNA; SICAvar, schizont-in-
fected cell agglutination variant antigen.
Figure 2. Validation of Plasmodium knowlesi primers targeting sicavar against human and simian malaria parasites reported from Southeast Asia. Control DNA of human 
malaria Plasmodium species were from imported cases in the United Kingdom (courtesy of the Public Health England Malaria Reference Laboratory); 2 isolates each are 
shown for Plasmodium falciparum, Plasmodium vivax, and Plasmodium malariae. Genus-specific primers for the cytochrome B gene (cytb) were used to confirm presence of 
detectable Plasmodium DNA in each sample, indicated by plus signs; bp, base pairs. 
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(95% CI, 16.2–19.7  years; P  <  .001, 2-sided t-test) (Table  3). 
Submicroscopic carriage was observed more often in Batubara 
(odds ratio, 1.67; 95% CI, 1.14–2.45) or South Nias (2.02; 1.43–
2.85) than in Langkat. However, individuals with multispecies 
infections were not significantly older than those infected with 
a single species (P = .66, 2-sided t test).
DISCUSSION
In this study, a total of 3731 febrile and nonfebrile residents 
of 3 regencies in North Sumatera province were screened for 
malaria infection by both microscopy and PCR detection of 
parasite DNA. Microscopy identified 612 infected participants, 
whereas PCR identified 1169 individuals harboring ≥1 of the 
4 Plasmodium species identified: P.  falciparum, P.  knowlesi, 
P. malariae, and P. vivax. Using a novel assay developed for this 
study, which detects a conserved motif in the multicopy sicavar 
gene family, we found that P. knowlesi was present in 377 indi-
viduals (10.1%), including both patent and subpatent infec-
tions. P. vivax and P. falciparum were both frequently detected, 
occurring in 11.3% and 8.2% of all individuals tested.
Although P. knowlesi infection has been widely recorded in 
Southeast Asia, only a handful of confirmed cases have been 
from Indonesia, from Kalimantan, eastern Borneo [8, 24], and, 
more recently, 20 cases from Aceh province, on the northwest 
extremity of Sumatera [5]. This latter study of 1532 individu-
als used a combination of passive and reactive case detection to 
identify a total of 20 P. knowlesi, 15 P. vivax, and 8 P. falciparum 
infections, almost all of which were symptomatic. This contrasts 
with our findings of more frequent parasite carriage, and a sig-
nificant proportion of subpatent and asymptomatic infections. 
Figure 3. Sequence alignment of representative 120 and 141 nucleotide sequences of sicavar amplicons from the peripheral blood DNA of 4 participants from Batubara (BB) 
and 2 each from Langkat (LK) and South Nias (NS). Amplicons were produced by heminested polymerase chain reaction, as described in Materials and Methods. Sample order 
is determined by the alignment. Representative amplification products were chosen for this sample and sequenced directly using amplification primers to prime forward and 
reverse sequencing reactions. Sequences shown were confirmed in both directions. Two loci from the Plasmodium knowlesi strain H reference genome (PKNH_0932000, type 
I schizont-infected cell agglutination variant antigen (SICAvar), chromosome 9, centrally located; PKNH_0118500, type II SICAvar, chromosome 1, subtelomeric) are shown for 
comparison. Double peaking was seen in some samples; only the peak with highest amplitude was read for this analysis.
Figure 4. Proportion of Plasmodium species and multiplicity of infections by regency. The denominator for each site (total number of individuals tested) is given under the 
regency name, and the number of parasite-positive individuals is shown at the top-left of each bar graph.  The horizontal axis represents the proportion of the total number of 
infections in each bar. Colored bars denote species; gray bars denote proportions of mixed-species infections identified in each site. Abbreviations: Pf , Plasmodium falciparum; 
Pk, Plasmodium knowlesi; Pm, Plasmodium malariae; Pv, Plasmodium vivax.
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Malaria transmission intensity is much lower in Aceh than 
in North Sumatera, and this neighboring province is closer to 
eliminating the disease. North Sumatera’s natural forests have 
been affected by deforestation in the last few years. Residents of 
rural districts may live in close proximity to semiforested, for-
ested, or plantation areas, with a high likelihood of forest expo-
sure, but may not have adequate access to health facilities and 
antimalarial medication. In the Aceh study, the more frequent 
occurrence of symptoms in persons with knowlesi malaria 
reflects observations in Malaysian Borneo where, as in Aceh, 
other Plasmodium species have decreased in prevalence over 
the past decade [4, 25]. In North Sumatera, as our data show, 
P. falciparum and P. vivax remain common and it may be that 
acquired immunity to these human parasites protects individu-
als subsequently infected with P. knowlesi, although asymptom-
atic infections have also been reported in Sabah [7].
Our novel PCR assay identified an unexpectedly large num-
ber of P.  knowlesi infections, and so we made some effort to 
validate its sensitivity and specificity (Figure 2). SICAvar genes 
encode an antigen family unique to P.  knowlesi, estimated to 
number >100 members, including both multiexon and trun-
cated forms randomly distributed across all 14 chromosomes 
[23]. SICAvar proteins undergo antigenic variation in the 
course of a single infection [26, 27] and are likely to play a key 
role in maintaining chronic parasitemia in semi-immune hosts. 
Sequencing of a handful of sicavar amplicons from our samples 
confirmed nucleotide diversity in our short target sequence, 
double peaking indicative of multiple loci being amplified in 
some cases, and distinguished a variant form with a 7–amino 
acid insert (Figure 3). Probing the P. knowlesi reference genome 
with these 2 forms generated many hits with both length vari-
ants, including both types 1 and 2 loci (Supplementary Table 1). 
These findings suggest our assay is performing as hoped and is a 
useful tool for identifying P. knowlesi infections among complex 
mixtures of Plasmodium species.
The national malaria control program focuses on case man-
agement through passive surveillance at primary health cen-
ters, deploying microscopy or RDTs to detect malaria cases 
to be treated [9]. In our study, microscopy identified many 
Plasmodium spp. infections, but lacked accuracy in distin-
guishing among the 4 species present, as previously reported in 
Malaysia [28]. Although personnel differed between sites, iden-
tification of the less common species was problematic in all sites. 
P. malariae was only detected in 1 case and P. knowlesi was left 
unrecognized. In South Nias, microscopy results showed poor 
specificity (Supplementary Table  2), leading to a number of 
false-positives, whereas specificity was good at the other 2 sites. 
RDTs have limitations for detection of P. knowlesi because they 
include only P. falciparum and P. vivax parasite lactate dehydro-
genase monoclonal antibodies [11]. Most importantly, almost 
half of the infections detected with PCR were not identified by 
Table  3. Age and Sex of Participants With Positive PCR Results for 
Plasmodium spp.
Age and Sex by Plasmodium 
Speciesa PCR Positive, No. (%)
Parasite carriage by age group, y
 P. falciparum
  <5 24 (9.72)
  5–14 91 (36.84)
  >15 132 (53.44)
 P. vivax
  <5 41 (12.24)
  5–14 143 (42.69)
  >15 151 (45.07)
 P. malariae
  <5 4 (10.00)
  5–14 18 (45.00)
  >15 18 (45.00)
 P. knowlesi
  <5 28 (11.02)
  5–14 96 (37.80)
  >15 130 (51.18)
Parasite carriage among female 
participants
608 (52.01)
 P. falciparum 137 (55.47)
 P. vivax 171 (51.04)
 P. malariae 15 (37.50)
 P. knowlesi 129 (50.79)
Abbreviation: PCR, polymerase chain reaction. 
aAge and sex data are presented for single-species infection only.
Table  2. Submicroscopic Infections in 1169 Participants With Positive 
PCR Results for Plasmodium spp. 
Infection Type
Participants, No. (%)a
All PCR Positive
PCR Positive and
Microscopy Negative
All Plasmodium infections 1169 (31.33) 833 (71.26)
Plasmodium falciparum 247 (6.62) 165 (14.11)
Plasmodium vivax 335 (8.97) 227 (19.41)
Plasmodium malariae 40 (1.07) 35 (2.99)
Plasmodium knowlesi 254 (6.80) 220 (18.81)
Mixed infections 293 (7.85) 186 (15.91)
No. of species by PCR
 1 876 (74.94) 647 (77.67)
 2 256 (21.90) 163 (19.57)
 3 35 (2.99) 21 (2.52)
 4 2 (0.17) 2 (0.24)
PCR positive by regency
 Batubara 320/1270 (25.19) 227/320 (70.93)
 Langkat 182/544 (33.45) 108/182 (59.34)
 South Nias 667/1917 (34.79) 498/667 (74.66)
Abbreviation: PCR, polymerase chain reaction.
aFrequencies are shown together with relative frequency expressed as a percentage of 
all participants (N = 3731), all PCR-positive participants (n = 1169), or all participants with 
submicroscopic infections (n = 833). Top-row percentages read horizontally; percentages 
for other indented categories read vertically within the appropriate subgroup, apart from 
the regency-specific data (with denominators as shown).
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either of the conventional tests. Therefore, although RDTs and 
microscopy remain satisfactory for diagnosis of symptomatic 
falciparum and vivax malaria requiring treatment, these are not 
adequate tools for malaria elimination and control activities, 
because submicroscopic Plasmodium carriage is associated with 
subsequent transmission to mosquitoes [13].
On the other hand, molecular tests are highly sensitive and 
specific, provide the capacity to detect low-density infections 
missed by microscopy or RDTs, and are well established for 
detection of human malaria infections [11, 29]. To overcome 
cross-amplification of P. vivax isolates with ribosomal gene PCR 
assays [3, 19], Ghinai et al [30] have recently described a PCR-
sequencing approach to detect P.  knowlesi cytb DNA, which 
also provided satisfactory sensitivity. However, our sicavar 
target assay provides greater sensitivity for P. knowlesi identifi-
cation in our hands and was effective in detecting submicrosco-
pic parasites. This is a species-specific test, because the sicavar 
gene family is unique to P. knowlesi (Figure 2). Because of this 
improved specificity and sensitivity, we can confidently report 
moderate numbers of P. knowlesi coinfections with P. vivax in 
the present study.
Despite the aim to achieve malaria elimination by 2020 in 
Sumatera, our study demonstrated that a substantial num-
ber of individuals in our study areas carried parasites. P. falci-
parum contributed one-fifth of infections, and P. vivax was seen 
slightly more often. Interestingly, our findings also demonstrate 
that P. knowlesi carriage is not uncommon. Many P. knowlesi–
infected individuals harbored additional Plasmodium spe-
cies (Table 1), in contrast to areas in Malaysian Borneo where 
P. vivax and P. falciparum are now very scarce [4, 7]. Multiple-
species infections in our study were equally distributed across 
all age groups with both female and male subjects exposed to 
a similar risk of infection (data not shown), whereas submi-
croscopic infections were more common in older individuals 
(Table  2), suggesting a role for acquired immunity [31]. The 
observation of asymptomatic P. knowlesi infections in our study 
is consistent with recent findings in Malaysia [7] but does not 
necessarily support the occurrence of human-mosquito trans-
mission of P. knowlesi. 
Macaques were present in all sites, and the communities 
shared established risk factors for malaria transmission by 
forest-dwelling Anopheles, thought to be the vector of P. know-
lesi. These data may suggest that acquired immunity per-
mits sustainable chronic infections with this simian parasite. 
Cross-protection among the 4 human Plasmodium species 
may maintain overall parasite density at low levels [31], which 
could also plausibly apply to P. knowlesi, particularly in settings 
where the closely related P. vivax is present. One weakness of 
our study is the lack of a systematic sampling procedure, which 
may have introduced bias; as we had not previously worked in 
these 3 regions, methods were adapted for each site to reflect 
the facilities available and particular local challenges. For South 
Nias, these included frequent sea journeys in small boats. Future 
studies could deploy a more systematic approach and collect 
sufficient data to better explain and characterize asymptomatic 
infections, now that community contacts have been established 
and baseline information is available.
Our study demonstrated the importance of submicrosco-
pic infections of 4 Plasmodium species, including P.  knowlesi, 
to malaria transmission in North Sumatera. There is an urgent 
need for the national malaria program to include in malaria 
guidelines the recommendation that microscopists are trained 
to identify P. knowlesi infection in Indonesian clinics. Molecular 
detection of infection is also needed, to strengthen control and 
elimination programs by accurately defining the true extent of 
the malaria reservoir, so as to achieve the current goal of elimi-
nation [32].
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